Mass spectrometry-based analysis of urinary metabolites of 1,3-Butadiene (BD) in humans and influence of BD-DNA adducts on DNA replication by Kotapati, Srikanth
  
 
 
 
 
Mass Spectrometry-Based Analysis of Urinary Metabolites of 1,3-Butadiene (BD) in 
Humans and Influence of BD-DNA Adducts on DNA Replication 
  
 
 
 
A DISSERTATION  
SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL 
OF THE UNIVERSITY OF MINNESOTA  
BY 
 
 
 
 
Srikanth Kotapati 
 
 
 
 
 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
 
 
Dr. Natalia Y. Tretyakova, Adviser 
 
 
 
 
October 2013 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Srikanth Kotapati October 2013 
 
  i 
Acknowledgements 
 
First and foremost, I would like to express my sincere gratitude to my advisor, Dr. 
Natalia Tretyakova, for her support, guidance, and encouragement over the last five 
years. I am also thankful to Dr. Stephen Hecht, for being my mentor and constant source 
of inspiration and support throughout my graduate studies. I would also like to thank my 
committee members Drs. Rory Remmel, and Mark Distefano for their valuable feedback 
and suggestions over the years. I would also like to acknowledge Dr. Rodney Johnson for 
his support and encouragement. The majority of the work in my thesis would not have 
been possible without the help and support of our collaborators Dr. Loic Le Marchand 
and Dr. Lani Park (University of Hawaii-Honolulu, HI), Dr. Vernon Walker (University 
of Vermont-Burlington, VT), Dr. James Swenberg (University of North Carolina-Chapel 
Hill, NC), Drs. F. Peter Guengerich, Lawrence Marnett, Michael Stone, Matthew Pence, 
Leena Maddukuri, and Ewa Kowal (Vanderbilt University-Nashville, TN). I would also 
like to thank the NIH and the UMN graduate school for financial support. 
I am grateful to all my lab members (current and past) for their valuable 
discussions and suggestions that played a key role in development of this thesis. I am 
especially thankful to Amanda Esades, Dewakar Sangaraju, Susith Wickramaratne, Emily 
Boldry, Amy Grant, Dr. Melissa Goggin and Dr. Uthpala Seneviratne for making 
significant contributions to my thesis. I am also thankful to Dr. Delshanee Kotandeniya, 
Xun Ming, Dr. Bhaskar Malayappan, Arnie Groehler, Chris Seiler, Dr. Teshome 
Gherezghiher and Dr. Jung-Eun Yeo for their helpful insights and technical discussions.  
I am very thankful to Brock Matter for training me in HPLC and MS instrumentation as 
well as for his advice and help during method development and troubleshooting 
throughout my graduate studies. I am also thankful to Dr. Peter Villalta for his help with 
the new LTQ Orbitrap instrumentation. I would also like to thank Steve Carmella for his 
valuable discussions and insights during the HPLC-MS/MS method development.  
Thanks to Bob Carlson for his valuable help in preparing graphics for this thesis and 
other publications. I am also thankful to members of Hecht lab, Murphy lab and Peterson  
  ii 
lab for graciously allowing me to use instrumentation from time to time. I am grateful to 
Tammy Argentine (Waters), Gerald Nagatani (Phenomenex), Martin Cherrier (Biotage) 
and Cullin Bachmeier (Chromtech/Agilent) for their technical assistance during SPE and 
HPLC-MS/MS method development. 
Last but not least, I could not have accomplished this work without the support of 
my family and friends, especially my parents, Peddanna and Rama Devi, and wife Divya. 
I would also like to thank my in-laws, Malleswara Rao and Rama Devi and sister-in-law 
Mounika Alla. Special thanks to all my friends in US and India for their continuous 
support and encouragement.
  iii 
Dedication 
 
In loving memory of my sister, Deepthi (1986-2002)  
 
 
 
  iv 
Abstract 
Cigarette smoking is a known risk factor for the development of lung cancer: 
approximately 1 out of 5 heavy smokers will develop the disease. However, there are 
significant differences in risk of lung cancer among smokers from different ethnic/racial 
groups. African American and Native Hawaiian smokers are at a higher risk of lung 
cancer than European American, Japanese American or Latin American smokers. 
Cigarette smoke has more than 70 known carcinogens. Following metabolic activation to 
electrophilic species, these carcinogens can form covalent DNA adducts, which are 
capable of inducing heritable mutations ultimately resulting in lung cancer. It has been 
hypothesized that the observed ethnic/racial differences in lung cancer risk in smokers are 
due to different frequencies of specific polymorphisms in drug metabolizing genes, 
leading to a different degree of carcinogen bioactivation to DNA-reactive intermediates.  
1,3-Butadiene (BD) is among the most abundant and potent carcinogens present 
in cigarette smoke. BD is metabolically activated primarily by CYP2E1 to form 3,4-
epoxy-1-butene (EB), hydroxymethyl vinylketone (HMVK),  3,4-epoxy-1,2-butanediol 
(EBD), and 1,2,3,4-diepoxybutane (DEB). EB, HMVK, EBD, and DEB have been shown 
to modify DNA bases to form promutagenic adducts. Alternatively, EB, EBD, and DEB 
can undergo detoxification via epoxide hydrolysis (the main pathway in humans) or 
glutathione conjugation and further metabolic conversion into urinary mercapturic acids, 
1-hydroxy 2-(N-acetylcysteinyl)-3-butene (MHBMA), 1,2-dihydroxy-4-(N-acetyl 
cysteinyl)-butane (DHBMA), 1,2,3-trihydroxy-4-(N-acetylcysteinyl)-butane (THBMA), 
and 1,4-bis-(N-acetylcysteinyl)butane-2,3-diol (bis-BDMA), respectively.  
The research presented in this thesis focuses on revealing any ethnic/racial 
differences in metabolism of BD in smokers and examining the ability of BD-DNA 
adducts to cause mutations. In the first part of the thesis, we have identified two novel 
metabolites of BD which have not been previously detected in vivo: 1,2,3-trihydroxy-4-
(N-acetylcysteinyl)-butane (THBMA), and 1,4-bis-(N-acetylcysteinyl)butane-2,3-diol 
(bis-BDMA). To enable their detection in smokers, sensitive and specific HPLC-ESI
-
-
MS/MS methods were developed for both metabolites in human urine. We observed 
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significant amounts of THBMA in samples from smokers, non-smokers and 
occupationally exposed workers. In contrast, bis-BDMA amounts in urine of smokers and 
occupationally exposed workers were below the method’s limit of detection, although it 
was found in urine of F344 rats exposed to 62.5 or 200 ppm BD. Additionally we found 
significant interspecies differences in BD metabolism between laboratory rats and 
humans. DHBMA accounted for only 47% of BD urinary mercapturic acids in rats while 
the corresponding percentage in humans is 93%.  
We further developed a high throughput HPLC-ESI
-
-MS/MS method for the 
quantification of MHBMA and DHBMA in humans and applied this method to quantify 
urinary BD-mercapturic acids metabolites in workers from a BD and styrene butadiene 
rubber (SBR) manufacturing facility and smokers belonging to different ethnic groups in 
two separate multi-ethnic cohort studies. Workers occupationally exposed to BD excreted 
significantly more BD-mercapturic acids than administrative workers at the same plant. 
In a small multi-ethnic study of smokers belonging to European American, Native 
Hawaiian and Japanese American (N = 200 per group), mean urinary MHBMA and 
MHBMA/DHBMA+MHBMA metabolic ratio were highest in European American and 
lowest in Japanese American smokers. Similar results were obtained in the larger study 
(N = 450 per group) composed of European American and African American smokers. 
Urine of European American smokers contained higher concentrations of MHBMA than 
that of African Americans. Genome-wide association study (GWAS) analysis conducted 
for the larger multi-ethnic group has revealed significant associations between single-
nucleotide polymorphisms (SNPs) in chromosome 22 (22564172bp – 22735492 bp, 
nearby genes GSTT1, GSTT2, DDT and MIF) and urinary BD-mercapturic acid levels in 
smokers, providing the first evidence for genetic and ethnic/racial differences in 
metabolism of BD. 
 The second part of my thesis work has focused on evaluating the mutagenic 
ability of three recently discovered BD-dA lesions: N
6
-(2-hydroxy-3-buten-1-yl)-adenine 
(N
6
-HB-dA), N
6
,N
6
-(2,3-dihydroxybutan-1,4-diyl)-2-deoxyadenosine (N6,N6-DHB-dA), 
and 1,N
6
-(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-2-deoxyadenosine (1,N6-
HMHP-dA).  In vitro translesion synthesis experiments were performed on synthetic 
  vi 
oligonucleotides containing each of the three lesions at a site-specific position by gel 
electrophoresis and HPLC-MS/MS. We found that human translesion synthesis (TLS) 
polymerases hPols η, κ, ι and human polymerase were able to bypass (S)-N6-HB-dA in 
an error-free manner because of the conserved Watson-Crick base pairing with dT.  
However, replication past both (R,R)-N
6
,N
6
-DHB-dA and  (R,S)-1,N
6
-HMHP-dA lesions 
by TLS polymerases hPols η and κ was highly error-prone, resulting in A→T, A→C 
mutations and frameshift deletions. This is the first study that identifies (R,R)-N
6
,N
6
-
DHB-dA and  (R,S)-1,N
6
-HMHP-dA as BD-DNA adducts potentially responsible for the 
induction of A→T mutations by BD.  
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acetyl-L-cystein-S-yl)-1-hydroxybut-3-ene + 1-(N-
acetyl-L-cystein-S-yl)-2-hydroxybut-3-ene] 
MS/MS tandem mass spectrometry 
N
6
,N
6
-DHB-dA N
6
,N
6
-(2,3-dihydroxybutan-1,4-diyl)- -
deoxyadenosine 
N
6
-HB-dA N
6
-(2-hydroxy-3-buten-1-yl)-adenine 
N
6
-HEB-dA N
6
-(2-hydroxy-3,4-epoxybut-1-yl) adenine 
NMR nuclear magnetic resonance 
ppm parts per million 
pyr-Val N,N-(2,3-dihydroxy-1,4-butadiyl)-valine 
SBR styrene-butadiene rubber 
SNP single-nucleotide polymorphism 
SPE solid phase extraction 
SRM selected reaction monitoring 
T Thymine 
THBMA trihydroxybutyl mercapturic acid [4-(N-acetyl-L-
cystein-S-yl)-1,2,3-trihydroxybutane] 
  xx 
THB-Val 1,2,3-trihydroxybutyl-valine 
TLS polymerase translesion synthesis polymerase 
U Uracil 
UDG uracil DNA glycosylase 
TOF time of flight 
TSQ triple stage quadrupole 
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I. LITERATURE REVIEW 
1.1 Lung Cancer 
1.1.1 Smoking associated lung cancer 
According to the International Agency for Research on Cancer (IARC), worldwide 
mortality due to cancer in 2008 was 7.6 million. The annual mortality is predicted to 
increase to 13.1 million by 2030 (1). Lung cancer accounts for approximately 14% of all 
cancer deaths worldwide (1) and 27% of all cancer deaths in the US (1). According to the 
American Cancer Society, an estimated 159,480 lung cancer deaths are expected to occur 
in the US in 2013. Approximately 228,190 new cases of lung cancer are expected to be 
diagnosed in the US in 2013 (2).  Cigarette smoking is the major risk factor accounting 
for 87% of lung cancer deaths and 30% of all cancer deaths. Other risk factors include 
exposure to radon, secondhand smoke, asbestos, chromium, cadmium, arsenic, radiation, 
air pollution, diesel exhaust, and paint (2). In 2011, approximately 21.6% of men and 
16.5% of women, a grand total of 43.8 million adults were current cigarette smokers in 
the US (3). According to the study conducted by the Center for Disease Control (CDC) 
regarding tobacco use among US high school students, 28% of male students and 18% of 
female students admitted to have used tobacco in the past month. 5% of adult men and 
less than 1 of adult women used smokeless tobacco in 2011 (3). 
 Cigarette smoke consists of more than 70 known carcinogens, including 
polycyclic aromatic hydrocarbons (PAHs), heterocyclic compounds, N-nitrosamines, 
aromatic amines, heterocyclic aromatic amines, phenolic compounds, volatile 
hydrocarbons, nitrohydrocarbons, metals, inorganic compounds, and other miscellaneous 
compounds (Table 1.1 and Chart 1.1) (4;5). The mechanism of induction of 
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carcinogenesis by cigarette smoke has been a subject of multiple investigations (Figure 
1.1). Many tobacco carcinogens require metabolic activation by cytochrome P450 
monooxygeneses (CYP 450) 1A1, 1A2, 1B1, 2A13, 2E1, and 3A4 to form electrophilic 
metabolites (6). These electrophilic metabolites can be detoxified by glutathione-S-
transferases, epoxide hydrolases and UDP-glucuronosyl transferases (6). If not 
detoxified, the electrophilic metabolites of tobacco carcinogens can react with the 
nucleophilic positions in DNA nucleobases to form DNA adducts (7). These DNA 
adducts may be repaired by alkyltransferases, base excision repair, nucleotide excision 
repair, and mismatch repair (8). If DNA adducts escape repair and persist in vivo, they 
can lead to miscoding during the DNA replication process, leading to permanent 
mutations (Figure 1.1) (7). If these mutations are in critical regions of oncogenes such as 
ras and myc or in tumor-suppressor genes such as p53, they can lead to activation of the 
oncogenes and deactivation of tumor suppressor genes ultimately resulting in 
uncontrolled cellular growth and cancer (Figure 1.1) (5;7).  
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Table 1.1 Known Carcinogens present in cigarette smoke (4) 
Chemical Class No. of carcinogens Examples 
Polycyclic aromatic 
hydrocarbons (PAHs) and 
their heterocyclic analogues 
15 
Benzo[a]pyrene (BaP) 
Dibenz[a,h]anthracene 
N-Nitrosamines 8 
4-(Methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) 
N′-Nitrosonornicotine (NNN) 
Aromatic amines 12 
4-Aminobiphenyl 
2-Naphthylamine 
Aldehydes 2 
Formaldehyde 
Acetaldehyde 
Phenols 2 
Catechol 
Caffeic acid 
Volatile hydrocarbons 3 
Benzene 
1,3-Butadiene 
Isoprene 
Other organics 12 
Ethylene oxide 
Acrylonitrile 
Inorganic compounds 8 
Cadmium 
Polonium-210 
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Chart 1.1 Examples of carcinogens present in cigarette smoke                                        
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Figure 1.1 Proposed mechanism of chemical carcinogenesis induced by cigarette 
smoking (7) 
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1.1.2 Ethnic differences in smoking induced lung cancer risk 
 
While smoking is recognized as a known risk factor for lung cancer, the incidence and 
mortality rates of lung cancer differ among ethnic groups in the United States. Le 
Marchand and co-workers conducted two case-control studies involving 740 lung cancer 
patients and 1616 controls between 1979 and 1985 in Oahu, Hawaii to identify ethnic 
differences in lung cancer risk (9). Among the five ethnic groups included in the study, 
the age adjusted lung cancer incidence rates in males were found to be Hawaiian > 
Caucasian > Chinese > Japanese > Filipino (9). The corresponding lung cancer incidence 
rates in females were Hawaiian > Caucasian > Chinese > Filipino > Japanese (9). Le 
Marchand et al. hypothesized that the observed differences in lung cancer risk might be 
due to differences in diet or metabolic differences in activation and detoxification of 
carcinogens as a result of genetic polymorphisms (9). Hinds and co-workers conducted a 
multi-ethnic cohort study involving 375 cases and 2404 controls in Japanese, Chinese and 
Hawaiian women from Hawaii (10). They found that the trend of lung cancer risk to be 
Hawaiian > Japanese > Chinese women (10). Schwartz et al. conducted similar studies to 
identify ethnic differences in lung cancer risk among African American and European 
Americans (11). The study included 5588 lung cancer cases and 3692 controls (11). They 
found that even after adjustments for smoking habits, African Americans have 2-4 times 
higher risk of lung cancer than European American smokers in the 40-54 age group (11). 
In a similar study conducted by Stellman et al. in men from the United States and Japan, 
it was observed that lung cancer risk was at least 10 times higher in Americans than 
Japanese (12). Stellman and co-workers conducted another study in European American 
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and African American smokers but surprisingly did not find any ethnic differences in 
lung cancer risk among the two groups (13). 
Haiman et al. completed a comprehensive multi-ethnic cohort study involving 
183,813 smokers belonging to African-American, Japanese-American, Latino, Native 
Hawaiian, and European American ethnicity to identify ethnic and racial differences in 
smoking-related lung cancer risk (Table 1.2) (14). In smokers who smoked less than or 
equal to 10 cigarettes/day, the relative risk of lung cancer among African-American, 
Japanese-American, Latino, Native Hawaiian, and European American smokers was 
found to be 1.00, 0.25, 0.21, 0.88 and 0.45, respectively. However, at smoking level 
greater than 30 cigarettes/day the relative risks were 1.00, 0.75, 0.79, 0.95 and 0.82, 
respectively (14). The age-adjusted incidence rates and relative risks of lung cancer 
among different ethnic groups by gender are presented in Table 1.2. The study did not 
find any association between socio-economic status or diet with ethnic differences, but 
concluded that these ethnic differences might be due to differences in metabolism of 
tobacco carcinogens (14). According to the recent statistics from the National Cancer 
Institute, the five year (2006-2010) lung cancer incidence rates among different ethnic 
groups were African American > European American > American Indian > Asian > 
Hispanic in males (Table 1.3) (15). In females the corresponding lung cancer incidence 
rates were European American > African American > American Indian > Asian > 
Hispanic (Table 1.3) (15). 
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Table 1.2 Age-adjusted incidence rates and relative risks of lung cancer among different 
ethnic groups by gender (14) 
 
Variable African 
American 
Native 
Hawaiian 
Latino Japanese 
American 
European 
American 
Men      
No. of Men 11,186 5,803 19,487 24,970 21,012 
Lung Cancer cases 304 103 142 301 285 
Incidence/100,000 263.9 263.9 79.2 121.4 158.3 
Relative Risk 1.00 1.00 0.30 0.46 0.60 
Women      
No. of Women 19,894 7,545 20,992 28,188 24,736 
Lung Cancer cases 299 63 84 129 269 
Incidence/100,000 161.2 129.0 46.7 50.0 133.8 
Relative Risk 1.00 0.80 0.29 0.31 0.83 
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Table 1.3 Lung Cancer incidence rates in US by ethnic groups (2006-2010) (15) 
Race/Ethnicity Male (per 100,000) Female (per 100,000) 
European American 74.5 54.6 
African American 95.8 52.2 
Asian/Pacific Islander 50.7 28.1 
American Indian 51.2 35.7 
Hispanic 40.6 26.3 
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1.2 1,3-butadiene: Overview 
1,3-butadiene (BD) is a colorless and volatile gas generated as a byproduct of ethylene 
production in steam cracking process (16). Global industrial production of BD was 
estimated to be more than 9 million metric tons per year (17). BD is primarily used as a 
monomer in the synthetic rubber industry for the production of styrene-butadiene rubber, 
polybutadiene rubber,  adiponitrile, styrene-butadiene latex, neoprene rubber, 
acrylonitrile-butadiene-styrene resins, and nitrile rubber (16). BD is also used as a 
chemical intermediate in the production of industrial chemicals including Captan and 
Captafol (18).  Workers involved in the production or usage of BD are exposed to the 
chemical by inhalation (18).  However, the general population can also be exposed to BD 
because it is an environmental pollutant present in gasoline, automobile exhaust and 
cigarette smoke (16).  BD is present in relatively high quantities in cigarette smoke (20-
75 µg and 205-360 µg in mainstream and sidestream smoke, respectively per cigarette) 
(19). Additionally, average concentrations of BD in urban air are reported to be 1-10 ppb 
(16). Studies in laboratory rodents have reported that BD induces tumors at multiple sites 
(20;21). Epidemiological studies in workers in the synthetic rubber industry have shown 
an association between BD exposure and increased risk of lymphatic and hemopoietic 
cancer (22-24). BD has the highest cancer risk index among several other carcinogens 
present in tobacco smoke (25). Based on inhalation studies in laboratory animals and 
epidemiological evidence, BD is classified as a “known to be a human carcinogen” by the 
US National Toxicology program (NTP) and “human carcinogen” by the US EPA and 
IARC (26).   
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1.2.1 Metabolism of 1,3-butadiene 
As shown in Scheme 1.1, BD is metabolically activated by cytochrome P450 
monoxygenases CYP 2E1 (major) and CYP 2A6 to form R- and S- enantiomers of 3,4-
epoxy-1-butene (EB) (27;28). EB can undergo a second oxidation by CYP 2E1 to form 1, 
2, 3, 4-diepoxy butane (DEB) (27;29). Alternatively, EB can be detoxified either by 
microsomal epoxide hydrolase (EH) to form 1-butene-3,4-diol (EB-diol) (Scheme 1.1) 
(30) or conjugation with glutathione (via glutathione S-transferase, GSTT1). The 
glutathione conjugate of EB can further undergo metabolic conversion via the 
mercapturic acid pathway and be excreted in urine as 2-(N-acetyl-L-cystein-S-yl)-1-
hydroxybut-3-ene and 1-(N-acetyl-L-cystein-S-yl)-2-hydroxybut-3-ene, together referred 
to as mono hydroxybutyl mercapturic acid (MHBMA) (Scheme 1.1) (31). The other 
detoxification product from EB, EB-diol can either undergo metabolic activation by CYP 
2E1 to form 3,4-epoxy-1,2-butanediol (EBD) or oxidation by alcohol dehydrogenase 
(ADH) to form hydroxymethyl vinyl ketone (HMVK) (Scheme 1.1) (32). HMVK can 
then undergo GSH conjugation and conversion to the mercapturic acid 4-(N-acetyl-l-
cystein-S-yl)-1-hydroxy-2-butanone, which is further reduced by carbonyl reductase to 
form N-acetyl-S-(3,4-dihydroxybutyl)-L-cysteine, also referred to as dihydroxybutyl 
mercapturic acid (DHBMA) (Scheme 1.1) (33). Apart from its formation from EB-diol, 
EBD can also be produced by hydrolysis of one of the epoxide groups of DEB by 
epoxide hydrolase. EBD and DEB can be further detoxified by glutathione conjugation 
and mercapturic acid pathways to be excreted in urine as 4-(N-acetyl-L-cystein-S-yl)-
1,2,3-trihydroxybutane (THBMA) and 1,4-bis-(N-acetyl-L-cystein-S-yl)butane-2,3-diol 
(bis-BDMA), respectively (Scheme 1.1). 
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Scheme 1.1 in vivo metabolism of 1,3-butadiene  
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1.2.2 Toxicity and mutagenicity of 1,3-butadiene 
A long term study in Sprague Dawley rats (N=110 per sex) exposed to 0, 1,000, or 8,000 
ppm of 1,3-butadiene 6 h/day, 5 days/week, for 105 weeks (females) and 111 weeks 
(males) revealed that BD induces tumors at multiple tissue sites including mammary 
gland, brain, Zymbal gland, uterus, pancreas, testis, and thyroid gland (21). The national 
toxicology program (NTP) conducted similar chronic inhalation studies in B6C3F1 mice 
(20). B6C3F1 mice (N=70 per sex) were exposed to 0, 6.25, 20, 62.5, 200 or 200 ppm 
BD 6 h/day, 5 days/week, for 103 weeks. Mice exposed to 6.25-625 ppm BD developed 
lymphocytic lymphoma and tumors of the heart, lung, forestomach, Harderian gland, 
preputial gland, liver, mammary gland, and ovary (20).  
Extensive in vitro and in vivo evidence indicates that the genotoxic effects of BD 
are mainly caused by its DNA-reactive epoxides, EB, DEB and EBD. Among the three 
epoxides, DEB is regarded as the ultimate carcinogenic metabolite of BD because it is 
100-200 fold more mutagenic than EB and EBD.  Studies in TK6 human lymphoblastoid 
cells have shown that DEB is mutagenic in human cells at concentration levels of 1–5 
µM. In comparison, EB and EBD were mutagenic at concentration levels of 100–800 µM 
(34). A comparison of mutational spectra at hprt of TK6 lymphoblasts exposed to DEB 
(4 µM for 24h) and EB (400 µM for 24h) revealed that DEB induced AT→TA 
transversions and partial deletions, while EB induced GC→AT point mutations and 
AT→TA transversions (Table 1.4) (35). BD increased the frequency of AT→GC 
transitions and AT→TA transversions in the spleen and bone marrow in B6C3F1 laci 
transgenic mice exposed to 62.5 ppm, 625 ppm or 1250 ppm of BD for 6 h/day, 5 
days/week for 4 weeks. In addition, GC→AT point mutations were also observed in 
spleen (35). Some studies investigating the mutagenic ability of BD in humans found 
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increased hprt mutation frequencies in blood lymphocytes of exposed workers as 
compared to controls but these results are not consistent. Ma et al. (36) and Liu et al. (37) 
have reported that there was significant increase in frequency of exon deletions in hprt 
gene in workers occupationally exposed to BD. Ma et al. have also observed that BD-
induced AT→TA transversions and frame shift mutations were increased in exposed 
workers (36). In contrast, studies by Hayes et al. (38) and Tates et al. (39) didn’t find 
statistically significant differences in hprt mutant frequencies between exposed and 
control workers.  
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Table 1.4 hprt mutational spectra of EB and DEB in human TK6 cells (35) 
Mutation Class 
No. Mutations (%) 
Control EB (400 μM for 24 h) DEB (4 μM for 24 h) 
GC → AT 10 (23) 15 (30)* 3 (6) 
GC → CG 1 (2) 2 (4) 2 (4) 
GC → TA 3 (7) 2 (4) 2 (4) 
AT → GC 3 (7) 6 (12) 1 (2) 
AT → CG 3 (7) 2 (4) 1 (2) 
AT → TA 2 (5) 12 (24)* 9 (18)* 
Other alterations 1 (2) 12 (24) 40 (59) 
Partial deletions 1 (2) 0 (<2) 7 (14)* 
 
*Statistically significant compared to control 
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1.3 Biomarkers of BD exposure 
Given the high carcinogenicity of BD, it is critical to develop biomarkers of BD 
metabolites for biomonitoring of BD exposure in humans and also to study its in vivo 
effects. DNA adducts, protein adducts, and urinary metabolites have been used as 
biomarkers of exposure to BD, while genetic and chromosomal changes have been 
employed as biomarkers of effect. 
1.3.1 DNA adducts 
The N7-position of guanine, the N3-position of thymidine and the N1-, N3- and N
6
-
positions of adenine are the most common sites of DNA adduct formation by BD and its 
metabolites (40). EB can react with DNA bases to form N7-(2-hydroxy-3-buten-1-
yl)guanine (EB-Gua I), N7-(1-hydroxy-3-buten-2-yl)guanine (EB-Gua II), N1-(2-
hydroxy-3-buten-1-yl)adenine (EB-Ade I) and N1-(1-hydroxy-3-buten-2-yl)adenine (EB-
Ade II) (Chart 1.2) (41-43). Similarly, EBD and DEB can form N7-(2’,3’,4’-
trihydroxybut-1’-yl)guanine (THB-Gua), N6-(2’,3’,4’-trihydroxybut-1’-yl)adenine (N6-
THB-Ade), and N3-(2’,3’,4’-trihydroxybut-1’-yl)adenine (N3-THB-Ade) (Chart 1.2) 
(43;44). DEB is a bis electrophile which can sequentially react with two DNA bases to 
form inter-strand and intra-strand DNA-DNA cross links such as 1,4-bis-(guan-7-yl)-2,3-
butanediol (bis-N7G-BD), 1-(guan-7-yl)-4-(aden-1-yl)-2,3-butanediol (N7G-N1A-BD), 
1-(guan-7-yl)-4-(aden-3-yl)-2,3-butanediol (N7G-N3A-BD), 1-(guan-7-yl)-4-(aden-7-yl)-
2,3-butanediol (N7G-N7A-BD) and 1-(guan-7-yl)-4-(aden-N
6
-yl)-2,3-butanediol (N7G-
N
6
A-BD) cross-links (Chart 1.2) (45-47). Alternatively, DEB can react with two sites on 
the same base to form exocyclic DNA adducts such as 1,N
6
-(2-hydroxy-3-
hydroxymethylpropan-1,3-diyl)-2'-deoxyadenosine (1,N
6
-γ-HMHP-dA) and 1,N6-(1-
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hydroxymethyl-2-hydroxypropan-1,3-diyl)-2'-deoxyadenosine (1,N
6
-α-HMHP-dA)  
(Chart 1.2)  (48-51). Since DNA adducts are responsible for the mutagenicity of BD and 
subsequently carcinogenesis, they can be used as reliable biomarkers of risk. 
Koivisto et al. and Zhao et al. employed 
32
P-post labeling methodology to 
quantify several DNA adducts induced by BD and its metabolites. Koivisto et al. have 
reported the formation of EB-Gua I, EB-Gua II, N
6
-EB-Ade, and THB-Gua in several 
tissues of mice and rats exposed to BD (52-56). Zhao et al. observed significantly higher 
amounts of N1-THB-Ade adducts in human lymphocytes of BD-exposed workers as 
compared to non exposed workers or controls (57;58). Tretyakova et al. detected the 
formation of  EB-Gua I, EB-Gua II and THB-Gua in liver tissues of mice and rats 
exposed to 1250 ppm BD for 10 days by isotope dilution  mass spectrometry (59). Koc et 
al. expanded this study further to construct dose-response curves in liver, lung and kidney 
tissues of mice and rats exposed to 20, 62.5 or 625 ppm of BD (60). THB-Gua adducts 
were also found to be persistent in vivo with half lives of greater than 4 days in laboratory 
animals (61). These three adducts, along with another regio-isomer of THB-Gua, N7-(1-
hydroxymethyl-2,3-dihydroxypropyl)-guanine, were found in liver, lung and testis DNA 
of mice and rats exposed to [2,3-
14
C]-1,3-butadiene by HPLC with on-line UV and 
radioactivity detection methodology (62;63).  
Our laboratory has developed sensitive HPLC-ESI
+
-MS/MS methods for 
quantification of DEB-specific DNA adducts in vivo. Significant levels of racemic bis-
N7G-BD adducts were detected in the liver (3.2 ± 0.4 adducts per 10
6
 dG) and lung (1.8 
± 0.5 adducts per 10
6
 dG) tissues of C57BL/6 mice exposed to 625 ppm BD for 7h/day 
for 5 days (64). N7G-N1A-BD adducts (quantified as N7G-N
6
A-BD following forced 
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Dimroth rearrangement) were also found in liver DNA of B6C3F1 mice exposed to 625 
ppm BD for 2 weeks (65). The levels of bis-N7G-BD, N7G-N1A-BD adducts in 
laboratory mice exposed by inhalation increased linearly with BD exposure (0-625 ppm) 
(66). In contrast, the adduct levels in tissues of rats reached a plateau at 62.5 ppm 
indicating metabolic saturation in this species (66). Tissue distribution studies of bis-
N7G-BD adducts in mice and rats revealed that the highest adduct levels were found in 
liver (66). By a highly sensitive column switching HPLC-ESI
+
-MS/MS method, 1,N
6
-
HMHP-dA  adducts (0.44 ± 0.08 adducts per 10
8
 nucleotides) were detected in liver DNA 
of B6C3F1 mice exposed to 625 ppm BD (67). More recently, an accurate and sensitive 
nanoHPLC-nanoESI
+
-MS/MS method was successfully developed in our laboratory for 
the quantification of bis-N7G-BD adducts in liver tissue of rats exposed to low level BD 
exposure (0-1.5 ppm) (68). 
While the majority of the BD-DNA adducts have been detected and quantified in 
laboratory animals exposed to BD, human data for these DNA adducts is missing. Since 
humans are exposed to low amounts of BD (< 2 ppm), the levels of these adducts will be 
very low, requiring extremely sensitive methods for detection. N7-THBG has been 
recently detected in human lymphocytes in our laboratory by HPLC-HRMS/MS 
methodology on an LTQ Orbitrap Velos instrument (69). BD-DNA adducts, if detected in 
humans, can serve as specific biomarkers; however further research needs to be done. 
 
 
 
 19 
 
 
Chart 1.2 Structures of BD-DNA adducts 
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1.3.2 Hemoglobin adducts 
The electrophilic epoxide metabolites of BD can also react with proteins to form adducts. 
For example, EB, DEB or EBD can react at multiple sites on hemoglobin or serum 
albumin to form adducts (70-72). These adducts can be used as surrogate biomarkers to 
understand BD metabolism in vivo and mechanisms of carcinogenesis (26). Additionally, 
unlike DNA adducts which can be repaired, protein adducts accumulate over lifetime of 
red blood cells, and hemoglobin is more abundant and easily obtained compared to DNA 
for human studies (40). Most of the in vivo work is focused on N-terminal valine adducts 
of hemoglobin as they are the most abundant adducts formed by BD epoxides (73). EB 
can react with N-terminal valine in hemoglobin to form N-(2-hydroxy-3-butenyl)–valine 
(HB-Val) adducts (Scheme 1.2) (74). Similarly, EBD and DEB generate N-(2,3,4-
trihydroxybutyl)–valine (THB-Val) (75) and N,N-(2,3-dihydroxy-1,4-butadiyl)–valine 
(pyr-Val) (Scheme 1.2) (76) adducts, respectively.  All three N-terminal valine adducts 
were quantified in hemoglobin isolated from blood erythrocytes of laboratory animals 
and humans. HB-Val and THB-Val were quantified by a modified Edman degradation, 
followed by derivatization to pentaflurophenyl thiohydantoins and analysis by GC-
MS/MS by stable isotope dilution with labeled internal standards (74;75). Pyr-Val on the 
other hand was quantified as a 7- or 11-mer peptide generated by proteolytic digestion of 
hemoglobin with trypsin, followed by HPLC or immunoaffinity enrichment and stable 
isotope dilution  LC-MS/MS analysis (76;77).  
 Osterman-Golker and co-workers were the first researchers who reported the 
detection of HB-Val and THB-Val in vivo. A linear dose response relationship was 
observed with HB-Val adduct levels and BD exposure in Wistar rats exposed to 0, 250, 
500 or 1000 ppm BD 6 h/day for 2 weeks (74). The mean HB-Val amount in the 1000 
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ppm BD exposure group was 3 nmol/g Hb (74). This study was further extended to the 
other BD-Hb adduct, THB-Val. THB-Val was detected in several strains of mice and rats 
exposed to 0, 2, 10 or 200 ppm BD and also in workers occupationally exposed to BD (1 
ppm). The researchers reported detection of 1-3 pmol HB-Val/g Hb and 10-14 pmol 
THB-Val/g Hb  adducts in blood of occupationally exposed workers (75;78). Tornqvist et 
al. were the first researchers to observe the formation of the DEB-specific hemoglobin 
adduct pyr-Val in mice and rats injected with high concentrations of DEB (76;79).  
Swenberg and co-workers have done pioneering work in detection and 
quantification of BD specific hemoglobin adducts in mice, rats and humans to understand 
inter-species, inter-individual and gender differences in metabolism of BD. Swenberg et 
al. (80) successfully quantified HB-Val and THB-Val in mice and rats B6C3F1 mice and 
Sprague-Dawley rats (1,000 ppm BD for 13 weeks at 6 hours/day, 5 days/week). They 
reported that THB-Val adducts in blood increased with exposure in a time course study in 
B6C3F1 female mice. In the same study, they reported statistically significant differences 
in THB-Val amounts between Chinese workers not occupationally exposed to BD (39 ± 
13 pmol/g Hb) and occupationally exposed workers (88 ± 59 pmol/g Hb) (80). These 
results were subsequently confirmed by another study involving butadiene-polymer 
production workers and controls from China (81).  
Albertini et al. compared the amounts of HB-Val and THB-Val adducts in male 
workers working in administration, monomer production, or polymer production in a BD 
and SBR production facility in the Czech Republic. Statistically significant differences 
were observed in levels of both adducts in the three groups (K-W, P<0.001). The adduct 
levels were found to be in the order of polymer production > monomer production > 
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administration workers (82). This comprehensive study also looked at several other 
biomarkers including urinary metabolites, T-cell mutations, hprt gene mutation 
frequencies, and sister chromatid exchanges (83). This study was later expanded to 
include female workers to understand gender differences in BD metabolism in humans. 
THB-Val adduct levels were found to be significantly higher in males as compared to 
females and the rate of  increase of THB-Val adduct with BD exposure was lower in 
females which led to the observation that females absorb or metabolize less BD than 
males per unit exposure (84;85). There were no significant differences in smoking status 
between males and females and hence these gender differences were due to differences in 
metabolism (85). However, no differences were found in THB-Val adduct levels between 
exposed and control workers in an epidemiological study involving Italian workers 
(86;87).  
Boysen et al. quantified pyr-Val adducts and compared them with HB-Val and 
THB-Val in B6C3F1 mice and F344 rats exposed to 3, 62.5, 1250 ppm BD (6 h/day for 2 
weeks) and found that THB-Val was the major adduct in both species. Also, mice formed 
much higher amounts of pyr-Val as compared to rats (77). A highly sensitive nanoUPLC-
MS/MS method was developed to quantify pyr-Val in mice and rats exposed to 0, 0.5, 1, 
1.5, 6.25, 62.5, 200 or 625 ppm BD. By this method, pyr-Val was detected in lower level 
exposed animals (<1 ppm BD) (88). More recently, Boysen et al. applied the nanoUPLC-
MS/MS method to human samples and found background levels of pyr-Val (0.11 ± 0.07 
pmol/g Hb) in control workers not exposed to BD. As expected, pyr-Val levels were 
much higher  in BD occupationally exposed workers (0.11 ± 0.07 pmol/g Hb) (89). 
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Scheme 1.2 Structures of BD-hemoglobin adducts 
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1.3.3 Urinary bio-markers of exposure to BD 
Quantification of DNA and hemoglobin adducts of BD in humans requires access to 
blood samples. In contrast, urine collection is non-invasive and human urine is readily 
available. Urinary metabolites can be used as biomarkers of exposure to BD as they 
represent the detoxification metabolites of BD epoxides. Furthermore, in human studies 
where the concentrations of DNA adducts are extremely low (<1 per 10
9
 nucleotides) and 
their detection requires ultra-sensitive methodologies, urinary biomarkers are a suitable 
alternative. As discussed above, EB, HMVK, EBD, DEB can be conjugated with 
glutathione and excreted in urine as the corresponding mercapturic acids, MHBMA, 
DHBMA, THBMA and bis-BDMA, respectively (Scheme 1.1). 
 Several studies have focused on quantification of BD-mercapturic acids in vivo. In 
a study by Sabourin et al. (90), Sprague-Dawley rats, B6C3F1 mice, Syrian hamsters, and 
cynomolgus monkeys were exposed to 8000 ppm of 
14
C-BD, and the BD urinary 
metabolites were analyzed. This study revealed that all four species excreted primarily 2-
(N-acetyl-L-cystein-S-yl)-1-hydroxybut-3-ene/1-(N-acetyl-L-cystein-S-yl)-2-hydroxybut-
3-ene (MHBMA or M-II) and N-acetyl-S-(3,4-dihydroxybutyl)-L-cysteine (DHBMA or 
M1) (90). Bechtold et al. observed higher concentration of DHBMA in urine of workers 
exposed to BD (3200 ng/ml) as compared to controls not exposed to BD (320 ng/ml). 
However, MHBMA levels were below the LOD (100 ng/ml) even in exposed workers 
suggesting that it is a relatively minor metabolite of BD in humans (91). Nauhaus et al. 
conducted a comprehensive study of urinary metabolites of BD in laboratory rodents 
exposed to 800 ppm 
13
C-BD. MHBMA and DHBMA together accounted for 87% and 
73% of total urinary metabolites in rats and mice, respectively. Other urinary metabolites 
detected in mouse urine included S-(1-(hydroxymethyl)-2-propenyl)-L-cysteine (4%). N-
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Acetyl-S-(1-hydroxy-3-butenyl)-L-cysteine (4%), N-acetyl-S-(3-hydroxypropyl)-L-
cysteine (5%), N-acetyl-S-(2-carboxyethyl)-L-cysteine (5%) and N-acetyl-S-(1-
(hydroxymethyl)-3,4-dihydroxypropyl)-L-cysteine (5%) (92).  
 4-(N-acetyl-L-cystein-S-yl)-1,2,3-trihydroxybutane (THBMA) and its regio-
isomer  3-(N-acetyl-L-cystein-S-yl)-1,2,4-trihydroxybutane were discovered for the first 
time in the urine of rats and mice exposed to 200 ppm 
14
C-BD for 6 hours by Richardson 
and co-workers (93). Together, these urinary metabolites accounted for 10% of the total 
urinary radioactivity in laboratory animals. The formation of these metabolites was not 
surprising given a previous in vitro observation for the formation of S-(1-
(hydroxymethyl)-2,3-dihydroxypropyl) glutathione and S-(2,3,4-dihydroxybutyl) 
glutathione upon incubation of DEB and 
3
H-GSH in liver and lung cytosol from B6C3F1 
mice and Sprague–Dawley rats and human liver cytosol from six volunteers (94). 
Another interesting observation in that study by Boogaard et al. was the evidence for the 
formation of bis glutathione conjugate of DEB (94). Further, Booth et al. confirmed the 
formation of MHBMA, DHBMA and THBMA at a more relevant BD exposure level (1-
20 ppm) using 
14
C-BD inhalation studies in rats and mice (62). 
 Van Sittert et al. developed a sensitive GC-MS/MS method (LOD: 0.1 ng/ml) for 
the quantification of MHBMA and DHBMA in the urine of workers in the rubber 
industry from the Netherlands or the Czech Republic. Background levels of MHBMA 
and DHBMA in control workers with no known exposure to BD were detected by this 
sensitive method. Overall, the median values of MHBMA and DHBMA in polymer 
workers> monomer workers> controls. The median MHBMA and DHBMA 
concentrations in control workers were 2 and 524 ng/ml, respectively. Although they 
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attempted to quantify THBMA, they were not successful due to high interferences (31). 
This study was later expanded to compare the urinary metabolite levels in humans with 
rat, mice and monkeys exposed to BD. The mean concentrations of MHBMA and 
DHBMA in exposed workers were 39 and 2213 ng/ml, respectively. Additionally, the 
DHBMA/(MHBMA+DHBMA) ratio in humans was determined to be 0.98. In 
comparison, the DHBMA/(MHBMA+DHBMA) ratio in rats and mice were 0.5 and 0.3, 
respectively. The conclusions from this second study were that humans are most efficient 
at hydrolysis of BD epoxides than rats and mice and hence have the least cancer risk 
associated with BD among all the species (95).    
Albertini et al. (83) further expanded the above two studies to find correlations 
between urinary metabolites and other parameters including BD exposures, hemoglobin 
adducts, metabolic genotypes, hprt mutations and cytogenetic end points. MHBMA and 
DHBMA levels generally correlated with BD exposure (Spearman correlation coefficient, 
r>0.5). The correlations between urinary metabolites (MHBMA and DHBMA) and 
hemoglobin adducts (HB-Val and THB-Val) were also positive. No association was 
found between either of the urinary metabolites and CYP2E1, EH, and ADH 
polymorphisms. Also, no significant correlations were observed between urinary 
metabolites and hprt mutations and cytogenetic end points (83). The above study was an 
all-male study and hence, the same researchers conducted another study which included 
both female and male workers to understand the gender differences in metabolism of BD. 
MHBMA and DHBMA along with several other biomarkers were evaluated in that study 
(85). The study found that males excreted significantly higher concentrations of 
MHBMA and DHBMA per unit BD exposure compared to females (85). 
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Urban and co-workers developed a novel stable isotope dilution HPLC-APCI-
MS/MS method for rapid quantification (run time of 10 minutes) of MHBMA and 
DHBMA in urine of smokers and non-smokers (N=10 per group). The analytes present in 
urine samples (5 ml) were enriched by SPE with Strata-X cartridges. It was found that 
MHBMA concentrations in smokers (86.4 ± 14.0 µg/24 hr) were significantly higher than 
non-smokers (12.5 ± 1.0 µg/24 hr) (96). McDonald et al. reported a comprehensively 
validated LC-MS/MS method with turbo spray ion source for the quantification of 
MHBMA and DHBMA in 1 ml of human urine. The LOQ of the method was 1.4 and 4.1 
ng/ml for MHBMA and DHBMA, respectively (Table 1.5) (97). Fustinoni et al. 
conducted similar studies in workers working in an Italian petrochemical company. By 
using a strong anion exchange (SAX) SPE method and HPLC-MS/MS on an ion trap, 
they found that there were no statistically significant differences between control and 
BD-exposed workers with respect to either of the urinary metabolites MHBMA or 
DHBMA (98). Sapkota et al. developed a rapid and sensitive HPLC-ESI-MS/MS method 
for the simultaneous quantification of MHBMA and DHBMA in urine of three general 
population exposure groups: suburban-weekend exposure, urban-weekday exposure and 
toll collectors workday exposure. The LODs of the method were reported to be 0.4 and 
3.7 ng/ml for MHBMA and DHBMA, respectively (Table 1.5). However, there were no 
significant differences in urinary metabolite levels in the three groups (99). Navasumrit et 
al. used LC-APCI-MS/MS to quantify urinary MHBMA and found that temple workers 
exposed to BD from incense smoke had much higher amounts of MHBMA as compared 
to control workers (100). Later, they also observed that MHBMA levels were not 
different among traffic policemen and policemen who worked in an office (101). 
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Schettgen et al. developed a column switching LC-ESI
-
-MS/MS method for the 
simultaneous quantification of urinary biomarkers of 1,3-butadiene (MHBMA, DHBMA) 
and acrylonitrile (CEMA). However, the LOQ of the method for MHBMA was 2 ng/ml 
(Table 1.5) and hence it could not be detected in the majority of the urine samples (80%) 
of the general population exposed passively or actively to cigarette smoke. Smokers 
excreted significantly higher amounts of MHBMA as compared to non-smokers (102). 
Carmella et al. have developed a novel LC-APCI-MS/MS method for simultaneous 
quantification of MHBMA, DHBMA, HPMA (from acrolein), HBMA (from 
crotonaldehyde) and HEMA (from ethylene oxide). They applied this method to look at 
the effect of smoking cessation on the urinary biomarker levels of carcinogens present in 
cigarette smoke. MHBMA levels decreased significantly (>80%) 3 days after smokers 
quit smoking and >95% after 56 days post smoking cessation. DHBMA levels on the 
other hand remained constant after smoking cessation (33). This method was later applied 
to study differences in MHBMA levels between smokers who developed lung cancer 
(cases) and those who remained cancer free (controls) in a Shanghai cohort study. Mean 
MHBMA concentrations were significantly (P<0.001) greater in cases (11.3 pmol/mg Cr) 
as compared to controls (8.3 pmol/mg Cr) (103).  
Ding et al. developed a novel LC-ESI-MS/MS method for simultaneous 
quantification of MHBMA, DHBMA, CEMA, HEMA, HPMA, PMA in urine of smokers 
and non-smokers. The advantages of this method were minimal sample preparation 
(direct injection of diluted urine sample) and high sensitivity (LOD of MHBMA and 
DHBMA were 0.05, 0.14 ng/ml, respectively) (Table 1.5). DHBMA but not MHBMA 
concentrations were significantly higher in smokers than non-smokers, contradictory to 
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earlier reported results. Also, the median concentrations of MHBMA in non-smokers 
(21.3 ng/mg creatinine) were higher than in smokers (10.2 ng/mg creatinine) (104). 
Roethig and co-workers developed two separate HPLC-ESI-MS/MS methods for 
quantification of MHBMA and DHBMA in urine. The sample preparation for MHBMA 
involved SPE enrichment, while DHBMA analysis was performed by direct injection of 
diluted urine (105). Their method was extremely sensitive with LOQs of 0.1 and 10.1 
ng/ml for MHBMA and DHBMA, respectively (Table 1.5). This method was applied to a 
stratified, cross-sectional, multicenter study involving 3,585 adult cigarette smokers and 
1,077 nonsmokers. MHBMA amounts were 12-fold higher in smokers as compared to 
non-smokers. The study also found statistically greater amounts of MHBMA and 
DHBMA in males as compared to females. Higher amounts of BD-mercapturic acids 
were excreted by European-American smokers as compared to African-American 
smokers (105). This method was recently applied to compare the MHBMA levels in 3 
spot urine samples vs 24 hours urine collection. It was found that spot urine samples are a 
good alternative for 24 hour urine sample (106).  
Eckert et al. developed a HILIC-ESI-MS/MS method for the simultaneous 
quantification of six hydroxyalkyl mercapturic acids in human urine including MHBMA 
and DHBMA. The method was relatively less sensitive with LODs of 5 and 4.5 ng/ml for 
MHBMA and DHBMA, respectively (Table 1.5) (107).  This method was slightly 
modified and applied to smokers and non-smokers from Germany. MHBMA couldn’t be 
detected in 90% of the human urine samples (108). More recently, the method was 
further modified to improve the sensitivity of MHBMA analysis (0.5 ng/ml). MHBMA 
was detected in more than 60% of workers with known or unknown exposure to 
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chloroprene; MHBMA and DHBMA concentrations were significantly higher in exposed 
workers as compared to controls (109). Most recently Sterz et al. reported for the first 
time detection of the other regio-isomer of MHBMA, 2-(N-acetyl-L-cystein-S-yl)-1-
hydroxybut-3-ene in human urine with a novel UPLC-HILIC-MS/MS method. Only 100 
µl of the urine was used for analysis without any SPE and the LOD of the method was 
<0.25 ng/ml which highlights the extremely good sensitivity of this method (Table 1.5) 
(110). 
In summary, many research groups developed methods for quantification of 
MHBMA and DHBMA in human urine (Table 1.5). Most of the studies observed higher 
amounts of the urinary metabolites in smokers and exposed workers as compared to non-
smokers or controls. MHBMA is a better biomarker of exposure to BD in the general 
population because of its relatively low background levels in non-smokers. However, to 
our knowledge, no studies have successfully detected or quantified THBMA and bis-
BDMA in the urine of either rodents or humans exposed to BD. Development of 
quantitative methods for these biomarkers is critical in understanding the complex 
mechanisms of carcinogenesis of BD.  
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Table 1.5 Summary of previous HPLC-MS/MS methods for quantification of MHBMA and DHBMA 
Method 
Urine 
volume 
SPE cartridge HPLC column and ionization source 
Run time 
(min) 
LOD(ng/ml) LOQ(ng/ml) 
Urban (96) 
(2003) 
5 ml Strata X 
Synergi Luna  (4.6 X 100 mm, 5 µ); 
APCI 
10 
0.9 (MHBMA) 
 23 (DHBMA) 
2.7 (MHBMA) 
76 (DHBMA) 
McDonald (97) 
(2004) 
1 ml Waters C18 
Phenomenex C18 Aqua;  
Turbo Spray 
7.5 
< 1 (MHBMA) 
< 1 (DHBMA) 
1.4 (MHBMA) 
4.1 (DHBMA) 
Sapkota (99) 
(2006) 
1 ml Oasis HLB 
Alltech custom Mixed mode (C8/anion) 
(2.1 x 100 mm, 7 µ); 
ESI 
6 
0.4 (MHBMA) 
 3.7 (DHBMA) 
NA 
Schettgen (102) 
(2009) 
0.5 ml 
None (column 
switching) 
Trap: LiChrospher RP-8 ADS (4 X 100 
mm, 25 µ) 
Analytical: Luna C8(2) (4.6 X 50 mm, 
3 µ); ESI 
 
25 
1 (MHBMA) 
5 (DHBMA) 
2 (MHBMA) 
10 (DHBMA) 
Carmella (33) 
(2009) 
2 ml Oasis MAX 
Synergi MAX-RP (4.6 X 250 mm, 4 µ); 
APCI 
27 
0.75 (MHBMA) 
3 (DHBMA) 
NA 
Ding (104) 
(2009) 
0.1 ml 
None (Dilution 
and injection) 
Waters Xterra C18 MS column (4.6 
mm × 50 mm, 5 µ); ESI 
12 
0.05 (MHBMA) 
0.14 (DHBMA) 
NA 
Roethig* (105) 
(2009) 
0.5 ml (M) 
0.2 ml (D) 
 
Oasis HLB (M) 
Dilution and 
injection (D) 
Hypersil-Keystone BioBasic AX 
column (150 × 4.6 mm, 5 µ ); ESI 
NA NA 
0.1 (MHBMA) 
10.1 (DHBMA) 
Eckert (107) 
(2010) 
2 ml Isolute ENV+ 
XBridge HILIC (2.1 × 150 mm, 3.5 µ); 
ESI 
22 
5 (MHBMA) 
4.5 (DHBMA) 
NA 
Sterz
#
 (110) 
(2012) 
0.1 ml 
Evaporation and 
dilution 
BEH HILIC column (3 x 150 mm, 1.7 
µ); Turbo spray 
21 
0.05 (1-MHBMA) 
0.24 (2-MHBMA) 
0.15 (1-MHBMA) 
0.72 (2-MHBMA) 
 
*(M): MHBMA, (D):DHBMA. Two separate methods were used for quantification of MHBMA and DHBMA 
# 
1-MHBMA and 2-MHBMA are the two regioisomers of MHBMA 
NA: Not available 
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1.4 Species and gender differences in BD metabolism 
Differences in BD metabolism among different species are well studied. Earlier studies 
reported that mice developed tumors even at 6.25 ppm BD exposure while rats developed 
small number of tumors even at exposures as high as 1000 ppm (20;21). Lung and liver 
tumors were observed at exposure concentrations of 6.25 and 20 ppm BD, respectively in 
female mice. The corresponding exposure levels that induced lung and liver tumors in 
male mice were 62.5 and 200 ppm (26). Also, the in vitro oxidation rates of BD to EB in 
several tissues were higher in mice than rats (27;111). In vitro experiments which 
estimated the Vmax/Km values for the conversion of EB to DEB in mice, rat and human 
liver microsomes revealed that in mice the rates of conversion were 3.5 fold faster than 
rats, and 3-60 fold greater than humans (29;112). Also, the rates of epoxide hydrolase- 
mediated detoxification of EB to EB-diol were higher is humans followed by rats and 
least in mice (27;30). Similarly, the rates of detoxification by GST are higher in rats as 
compared to mice (27).  
Henderson et al. observed that the tissue concentrations of EB were 3-10 fold 
higher in mice than rats and DEB were 30-50 fold higher in mice than rats (113). Blood 
concentrations of EB and DEB were at least 5 fold higher in mice as compared to rats 
(114;115). These researchers also reported that concentrations of DEB in blood, femur, 
lung and fat tissues were greater in female rats as compared to male rats (115). However 
no such gender differences were observed with respect to EB (116). Similar differences 
in EB, DEB concentrations between mice and rats were also obtained by Filser et al. 
(117). These researchers also reported that the blood concentrations of EB-diol were 
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similar in rats and mice and the concentrations of EBD were higher in mice than rats 
(117). 
DHBMA/(DHBMA +MHBMA) ratio is an indication of whether EB is 
metabolized by EH or GST. Bechtold et al. observed that this ratio was 0.20, 0.52 and 
0.98 in mice, rats and humans, respectively (91). Also the ratio of in vivo kinetic rate 
constants for the metabolism of EB by EH or GST were found to be 0.04, 0.08, 1.8 in 
mice, rats, and humans, respectively which clearly showed that the metabolism of BD is 
different among the three species (91). Henderson et al. reported similar results for 
DHBMA/(DHBMA +MHBMA) ratio among mice, rats and humans (113). MHBMA and 
DHBMA concentrations in male control and male exposed workers were significantly 
higher than female control and female exposed workers, respectively (85). Also, the 
MHBMA/(MHBMA+DHBMA) ratio was significantly higher in male exposed workers 
as compared to female exposed workers.  
Comparison of the levels of BD-hemoglobin adducts between B6C3F1 mice and 
F344 rats showed 4-10 fold higher concentrations of HB-Val and pyr-Val in mice as 
compared to rats at 0-62.5 ppm BD exposure. The ratio of THB-Val to total BD-
hemoglobin adduct formation in rodents were 2-6 while in humans that ratio was >500 
(26;73). Interestingly, THB-Val adduct levels were significantly higher in male control 
and male exposed workers than female control and female exposed workers, respectively 
(84). Among mice, rats and humans exposed to 1 ppm BD, HB-Val and pyr-Val adducts 
were the highest in mice. Also, % THB-Val was highest in humans (99.6%) proving that 
metabolism of BD is different among the three species (Table 1.6) (26;89). The 
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concentrations of pyr-Val are much higher in mice compared to rats or humans (Table 
1.6) which suggest that mice produce higher concentrations of DEB. bis-N7G-BD adduct 
levels in several tissues were also higher in mice as compared to rats exposed to the same 
concentration of BD (Table 1.7) (66). Additionally, female mice were observed to have 
significantly higher levels of bis-N7G-BD adducts as compared to their male 
counterparts. These gender differences were not observed in rats. In the same study, 
N7G-N
6
A-BD adducts were found to be significantly higher in mice as compared to rats 
(66). THB-Gua adducts were also significantly higher in liver, lung and kidney tissues of 
mice as compared to rats exposed to 625 ppm BD (60). 
In summary, significant inter-species and gender differences in metabolism of BD 
have been observed. Among the species examined, laboratory mice convert a relatively 
high fraction of BD to DEB, followed by rats and humans. Since DEB is the most 
genotoxic metabolite of BD believed to be responsible for its adverse health effects, this 
may suggest that mice are most susceptible to BD associated cancer while humans are 
least susceptible. Although gender differences in BD hemoglobin adduct formation were 
observed at relatively high exposure of BD in rodents, there is less evidence for such 
differences at low BD exposures (88). These differences in BD metabolism makes BD 
risk assessment complex. 
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Table 1.6 Comparison of BD-hemoglobin adducts (pmol/g globin) in mice, rats and 
humans exposed to ~1 ppm BD 
 
 HB-Val pyr-Val THB-Val 
B6C3F1 Mice 21.5 ± 4.0 66.8 ± 5.9 525 ± 307 
F344 Rats 1.6 ± 0.5 1.4 ± 0.2 29 ± 3 
Human Workers 2.2 ± 1.4 0.3 ± 0.2 716 ± 426 
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Table 1.7 Differences in bis-N7G-BD adduct levels (per 10
7
 nucleotides) between female 
B6C3F1 mice and female F344 rats exposed to 625 ppm BD  (66) 
 
Tissue (N=4) B6C3F1 mice F344 rats 
Liver 3.95 ± 0.89 0.36 ± 0.23 
Lung 1.35 ± 0.12 0.30 ± 0.01 
Kidney 1.10 ± 0.13 0.14 ± 0.05 
Brain 0.38 ± 0.15 0.24 ± 0.06 
Thymus 1.15 ± 0.26 0.21 ± 0.06 
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1.5 Mutagenicity of BD-DNA adducts 
1.5.1 Translesion synthesis polymerases 
The DNA damage induced by endogenous or exogenous factors can be repaired by one of 
the several mechanisms including direct reversal, base excision repair (BER), nucleotide 
excision repair (NER), mismatch repair (MMS), and double-strand break (DSB) repair 
(118;119). Some of the adducts either escape repair (120) or can be temporarily tolerated 
by specialized cellular mechanisms (121). These adducts block DNA replication since 
they cannot be accommodated in the active site of replicative DNA polymerases (122).  
The cellular mechanisms that can tolerate these lesions include translesion synthesis by a 
specialized group of polymerases called the translesion synthesis (TLS) polymerases 
(122). The major TLS polymerases in mammalian cells are hPol η, hPol ι, hPol κ, Rev1 
from the Y family and hPol ζ from the B family (121;122). The Y family polymerases 
have a thumb, palm and finger domains similar to the replicative polymerases (A and B 
family) and play the same roles in DNA replication (123;124). However, the thumb and 
finger domains are significantly smaller in the Y-family polymerases as compared to the 
replicative polymerases (124). As a result of this, the active site in the palm domain of the 
Y-family polymerases is more open and solvent accessible (123). The presence of an 
open and larger active site enables Y-family polymerases to accommodate bulky lesions 
(121).  
The Y family polymerases also have a unique and conserved domain which 
extends from the finger domain called the little finger (LF) domain (125) or polymerase-
associate domain (PAD) (126). This LF domain is responsible for making additional 
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contacts with DNA (121). Another important difference between the Y-family 
polymerases and the replicative polymerases is the conformational change of finger 
domain in the latter during the replication process (123). When a regular Watson-crick 
base pairing is being formed in the replicative polymerases, a conformational change 
(induced fit) in the finger domain allows the base pair to be placed in a closed active site 
(123). However, when the replicative polymerases encounter a damaged DNA adduct, 
such a conformational change doesn’t occur thereby leading to reduced catalytic rate 
(123). On the other hand, Y family polymerases don’t adopt an “induced fit” mode of 
replication as their active site is open and “preformed” and hence can catalyze base 
pairing opposite a DNA lesion (123). Another important difference is the lack of intrinsic 
3’ to 5’exonuclease domain responsible for proofreading in the Y family polymerases as 
compared to the replicative polymerases (127). 
The human replicative polymerases belonging to the A and B families have high 
replication fidelity since they have proofreading activity and replicate via an “induced fit” 
model. The error rates for replicative polymerase are one incorrect nucleotide for every 
10
6
 to 10
8
 bases replicated (121;128). In contrast, the Y family polymerases have 
extremely low fidelity with very high error rates ranging from one incorrect nucleotide 
for every 10 to 10,000 bases (121). Since the replication by TLS polymerases is highly 
error-prone, they can be potentially mutagenic (121). The mechanism of translesion 
synthesis involves multiple “polymerase switching” events (Figure 1.2) (129). When the 
DNA replication machinery encounters a DNA adduct, the replicative polymerase is 
blocked and the replication is stalled (Figure 1.2) (122). The replicative polymerase is 
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then switched with a TLS polymerase which can incorporate a correct or incorrect 
nucleotide opposite the lesion and carries out replication past it (Figure 1.2) (130). Once 
the lesion is bypassed by the TLS polymerase, another “polymerase switching” event 
occurs and the regular replicative polymerase is recruited to carry out further DNA 
synthesis (Figure 1.2) (130).  
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Figure 1.2 Mechanism of translesion synthesis (129) 
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1.5.2 DNA sequencing by tandem mass spectrometry  
Tandem mass spectrometry (MS/MS) has been extensively used in sequencing 
native (unmodified) oligonucleotides. Initial efforts in this area employed fast atom 
bombardment (FAB) (131;132) and plasma desorption (PD) (133;134) coupled with 
single stage mass spectrometry to achieve “bi-directional” sequencing of 
oligonucleotides. These techniques resulted in the cleavage of phosphodiester bonds, 
thereby leading to the formation of fragment ions (5'-P and 3'-P sequence ions) which can 
be used to determine the sequence (131). However, matrix interferences and surface 
fragmentation interfered with accurate sequencing by FAB-MS, a problem solved by 
employing tandem mass spectrometry (135). Cerny et al. were among the first to 
sequence a short oligonucleotide (less than 6 bases in length) by fast atom bombardment 
(FAB) coupled with tandem mass spectrometry (FAB-MS/MS) (135;136).  FAB-MS/MS 
sequencing of oligonucleotides soon fell out of favor due to its high detection limit (10 
nmol for oligonucleotides of MW>1200) (137). Instead, MALDI-MS methods using a 
variety of matrices have been developed and successfully applied to oligonucleotide 
sequencing (138-141). The use of a delayed extraction (DE) methodology (142) has 
improved the resolution of MALDI-MS, while post source decay (PSD) (137;143;144) 
provided useful fragmentation information during oligonucleotide sequencing. Recently, 
the use of 1,5-diaminonapthalene as a matrix has been reported to improve in-source 
dissociation (ISD) of oligonucleotides during MALDI-MS (145). More spectral fragment 
ions have been observed with this technique which is useful for accurate sequencing 
(145).  
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McLuckey et al. (146) employed ESI-MS/MS to determine the sequence of short 
oligonucleotides (4-8 nucleotides in length) and proposed a comprehensive nomenclature 
for fragment ions, which is analogous to the nomenclature of peptide fragments (Figure 
1.3). Under most CID conditions, the phosphodiester bond can be cleaved at four 
different positions, giving rise to several types of 5'-terminus containing fragments (a, b, 
c, and d) and several types of 3'-terminus group containing fragments (w, x, y, and z) 
(Figure 1.3) (146). Each of these ions is assigned a numerical subscript (an, zn etc.), where 
n represents the cleavage position from the respective termini (Figure 1.3). In addition, 
“a” series of ions that underwent the neutral loss of a DNA base are commonly observed 
due to the facile cleavage of N-glycosydic bonds. The corresponding ions are designated 
as an-Bn, where upper case B denotes the cleaved base, and subscript n stands for the 
position of the base from the 5' terminus. Finally, d and w series ions can lose water 
molecules to form ions with the same m/z as fragment ions c (d-H2O) and x (w-H2O), 
respectively. Structurally modified oligomers exhibit similar fragmentation patterns, and 
the characteristic mass shifts observed for modification-containing fragments can be used 
to determine the positions of structurally altered bases within the sequence (147).  
Negative ion ESI-MS/MS is especially suitable to oligonucleotide sequencing due 
to its high sensitivity and the production of multiply charged ions (146;148-152). 
However, CID spectra of oligonucleotides can be quite complex, especially for longer 
oligonucleotides (> 10-mers), making data interpretation challenging (150;152;153). 
Manual interpretation of this data can be cumbersome, but can be facilitated by 
computational interpretation. Several useful computer algorithms have been developed in 
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the last 10 years for interpreting the MS/MS spectra. McCloskey and coworkers 
developed a program called Mongo oligo mass calculator (154). When the user inputs a 
known oligonucleotide sequence, the program can perform multiple functionalities 
including molecular mass calculations, predicting electrospray series, potential MS/MS 
fragments obtained by collision-induced dissociation (CID), and fragments of enzymatic 
digests by endonuclease and exonuclease. Simple oligonucleotide sequencer (SOS) was 
the first automated sequencing algorithm launched in 2002 by Rozenski and McCloskey 
(155). This algorithm could be successfully used for de novo sequencing of 
oligonucleotides 20 bases long or less but can’t be used for base or sugar modified 
oligonucleotides of greater than 10 bases (155). The program identifies the 5′ (a–B-ions)- 
and 3′ (w-ions)-end ion series and extends the series by addition of masses of one of the 
four bases to derive different combinations of m/z values which will be compared with 
the experimental spectra (155).  
Oberascher et al. started with comparative sequencing algorithm (COMPAS) 
(156) for sequencing oligonucleotides and later developed a global de novo sequencing 
algorithm that starts with a known nucleotide composition and generates a theoretical 
mass spectra by extending it with different base combinations leading to increased run 
times (157). More recently, Oberascher et al. improved their previous global de novo 
sequencing algorithm by usage of simulated annealing for stochastic optimization (158). 
Briefly, the nucleotide composition of a given oligonucleotide is determined from 
accurate molecular mass measurements to yield an initial sequence. The algorithm 
predicts the fragmentation spectra for this reference sequence and compares it with the 
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experimental fragmentation spectra and a parameter called fitness (FS) which measures 
the difference between the predicted and observed m/z (158). If the FS value is smaller, a 
simulated annealing algorithm is applied wherein two bases of the initially predicted 
oligonucleotide sequence are randomly changed and again the FS value is calculated. If 
the FS value is greater than the first iteration, the new sequence will become the reference 
sequence and this process continues until the optimal sequence is predicted.  
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Figure 1.3 CID fragmentation of DNA oligonucleotides (159) 
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1.5.3 Primer extension studies  
Mass spectrometry along with gel electrophoresis is an important tool employed in 
studying the mutagenic ability of structurally defined DNA adducts in vitro (160-164). 
These in vitro translesion synthesis experiments are generally performed by annealing a 
DNA template strand containing a site specific DNA adduct to a complementary DNA 
strand (primer). The length of the primer strand is shorter than the template, so that the 3' 
terminus of the primer is positioned prior to the lesion (162;164). The template-primer 
duplexes are incubated in the presence of a TLS polymerase and all four dNTPs allowing 
for primer extension. The primer extension products have been traditionally visualized by 
gel electrophoresis using a 
32
P-end labeled primer (165-167). However, the exact 
sequence of primer extension products cannot be determined by gel electrophoresis, and 
multiple time consuming experiments involving individual dNTPs must be conducted to 
evaluate each incorporation step (164). More importantly, gel electrophoresis fails to 
detect deletion products occurring  when a polymerase skips the modified base, resulting 
in frameshift mutations. HPLC-ESI-MS/MS can be used to accurately sequence primer 
extension products in a single experiment, without the use of radioactivity (164).  
 Because of size limitations for sequencing oligonucleotides by MS/MS, Zang et al 
have developed a methodology in which the primer is engineered to contain a uracil 
residue close to its 3' terminus (Scheme 1.3) (164). Following primer extension, the 
extension products are cleaved with uracil DNA glycosylase (UDG) and hot piperidine 
(95 
0
C) to generate shorter oligonucleotides which can be readily sequenced by tandem 
mass spectrometry (Scheme 1.3).  
 47 
 
For the specific template-primer complex shown in Scheme 1.3, 7-mer products 
are generated when the primer extension is complete. Depending on the specific base 
incorporated opposite the adduct (X) and assuming the enzyme does not make any 
additional errors while copying beyond the adduct, the sequence of the extension product 
can be any of the following: 5'p-TCAATGA-3', 5'p-TCGATGA-3', 5'p-TCCATGA-3', or 
5'p-TCTATGA-3'. The preliminary identity of the product can be obtained by 
determining the m/z values of the observed oligonucleotide products with full scan 
HPLC-ESI
- 
MS. MS/MS spectra of each product are then obtained on an ion trap or triple 
quadrupole, and are compared to the predicted spectra (Mongo Oligo Mass Calculator 
v2.06).  
 The methodology developed by Zang et al. has been successfully used in 
translesion synthesis studies of several important DNA adducts including 1,N
2
-etheno 
guanine (160;164), malondialdehyde-deoxyguanosine (M1-dG) (162;168), 7-8-dihydro-
8-oxodeoxyguanosine (169;170), O
6
-benzylguanine (171;172), O
6
-methylguanine 
(172;173), O
6
-[4-oxo-4-(3-pyridyl)butyl]guanine (O
6
-Pob-G) (172), N
2
-alkyl guanine 
adducts (174), C8- and N
2
-deoxyguanosine adducts of the dietary mutagen 2-amino-3-
methylimidazo[4,5-f]quinolone (163), N
6
-deoxyadenosine-BPDE adducts (175), 2,6-
diamino-4-hydroxy-N
5
-(methyl)-formamidopyrimidine (MeFapy-dGuo) (176), and 7-(2-
oxoheptyl)-1,N
2
-etheno-2′-deoxyguanosine (161).  
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Scheme 1.3 Workflow of primer extension studies using HPLC-MS/MS (159) 
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1.5.4 In vitro and in vivo translesion synthesis past BD-DNA adducts 
As already discussed in the previous sections, EB induces GC→AT point mutations and 
AT→TA transversions while DEB induces AT→TA transversions and partial deletions 
(35). Lloyd et al. investigated the mutagenic potential of four BD-DNA adducts, R and S 
stereoisomers of N
6
-(1-hydroxy-3-buten-2-yl)- 2′-deoxyadenosine (N6-HB-dA II) (formed 
from EB) and (R,R) and (S,S) stereoisomers of N
6
-THB-dA adduct (formed from DEB) 
(177). These adducts were site-specifically incorporated onto an 11-mer oligonucleotide 
strand representing human N-ras codon 61. These 11 mer oligonucleotide strands were 
further ligated into a single stranded vector M13mp7L2 (in vivo studies) or 85-mer 
oligonucleotide strands (in-vitro studies).  In vitro translesion synthesis experiments were 
conducted on 85-mer oligonucleotide strands containing one of the four lesions annealed 
to one of the three γ32P-labeled -5, -2 or +5 primers. The duplexes were then added to the 
appropriate buffer and further incubated in the presence of E.Coli DNA polymerases and 
dNTPs for specified time points (177). The reaction mixture was quenched and products 
were separated on 15% sequencing gel and visualized by autoradiography (177). None of 
the lesions affected DNA replication and were bypassed by E.Coli DNA polymerases as 
evident by the extension of all three primers (177). For in vivo studies, M13mp7L2 vector 
containing the modified adducts were transfected into E.Coli. R and S stereoisomers of 
N
6
-(1-hydroxy-3-buten-2-yl)-2′-deoxyadenosine were not mutagenic (Chart 1.3) but the 
N
6
-THB-dA adducts induced mutations albeit at low frequency. (R,R) N
6
-THB-dA 
adducts induced A→G mutations (0.14%), while their stereoisomers (S,S) N6-THB-dA 
induced A→T mutations (0.25%) (Chart 1.3) (177).  
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Similar in vitro and in vivo experiments were also performed by Lloyd et al. to 
understand the mutagenic ability of R and S stereoisomers of N
2
-(1-hydroxy-3-buten-2-
yl)- 2′-deoxyguanosine and (R,R) and (S,S) stereoisomers of the N2-THB-dG adduct 
(178). All four N
2
-dG adducts primarily blocked DNA replication by E.Coli polymerases 
and were weakly mutagenic (1%) as they induced G→T, G→A and G→ C mutations 
(Chart 1.3) (178). In contrast, the N1-deoxyinosine adducts (formed from EB) were 
highly mutagenic (179). It was observed that the (S)- N
6
-(1-hydroxy-3-buten-2-yl)- 2′-
deoxyinosine adducts induced A→G (80%), A→C (10%) and A→T (8%) mutations 
(Chart 1.3) (179). (R)- N
6
-(1-hydroxy-3-buten-2-yl)-2′-deoxyinosine adducts also induced 
the same mutations but with frequencies of 48, 7 and 4%, respectively (179). N3-(2-
hydroxy-3-buten-1-yl)-deoxyuridine adducts formed from alkylytation of Cytosine by EB 
followed by deamination, were reported to be highly mutagenic (97%) in vivo (180). 
These adducts induced C→T > C→A > C→G mutations (Chart 1.3) (180).  
Lloyd et al. also performed studies with intrastrand 1,4-bis-N
2
-guanine-2,3-
butanediol (N
2
G-N
2
G) cross-links formed from DEB (181). It was found that these intra 
strand cross links mostly blocked DNA replication in vitro and in vivo (Chart 1.3). 
However, it was also reported that N
2
G-N
2
G cross links induced a small frequency of 
G→A transitions, G→T and G→C transversion mutations. Interestingly, the S,S 
steroisomer was observed to be more mutagenic than the R,R stereoisomer (181). 
Additional studies with N
6
,N
6
-deoxyadenosine intrastrand cross-links formed from DEB 
revealed that they induced A→G > A→C > A→T mutations (Chart 1.3) (179). The 
mutation frequency was higher for R,R (54%) as compared to S,S stereoisomer (20%) 
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(179). While significant research has been conducted to understand the mutagenic ability 
of several BD-DNA adducts, the identity of the specific BD-DNA adduct responsible for 
primarily A→T mutations still needs to be established. 
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          Non-Mutagenic 
      
Weakly mutagenic (A→G, 
A→T) 
 
 
        Strongly blocking 
 
Strongly blocking 
 
 
Highly mutagenic (A→G, 
A→C, A→T) 
 
Highly mutagenic (C→T, 
C→A, C→G) 
 
              Strongly blocking 
 
 
Highly mutagenic (A→G, A→C, A→T) 
Chart 1.3 Mutations induced by BD-DNA adducts 
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1.5.5 Potentially mutagenic BD-dA adducts  
EB can alkylate the exocylic N
6
 position of adenine to form two different adducts, N
6
-(2-
hydroxy-3-buten-1-yl)-2′-deoxyadenosine (N6-HB-dA I) and N6-(1-hydroxy-3-buten-2-
yl)-2′-deoxyadenosine (N6-HB-dA II) (Scheme 1.4) (182). It is also hypothesized that N6-
HB-dA adducts can be formed by Dimroth rearrangement of N1-EB-dA adducts (42). 
Koivisto and co-workers observed N
6
-HB-dA adducts upon treatment of calf thymus 
DNA with EB (52). Additionally a linear dose response relationship was observed 
between N
6
-HB-dA adducts and BD exposure in lung DNA of mice and rats exposed to 
BD (52). Koivisto and coworkers also determined the relative percentages of in vivo 
formation of the two regioisomers N
6
-HB-dA I and N
6
-HB-dA II to be 31 and 69%, 
respectively (183). While the N
6
-HB-dA II was found to be non mutagenic in in vitro and 
in vivo translesion synthesis experiments (177), the mutagenic ability of N
6
-HB-dA I was 
not previously determined (184).  
 Our laboratory has recently discovered two novel exocyclic BD-dA adducts 
formed by alkylation of the exocylic N
6
 position of adenine by DEB (48). DEB reacts 
with the exocyclic amine group of adenine to form N
6
-2-hydroxy-3,4-epoxybut-1-yl-dA 
(N
6
-HEB-dA) lesions (Scheme 1.4) (48). The epoxy group in the N
6
-HEB-dA is highly 
electrophilic and can undergo nucleophilic attack by another site in the same lesion to 
form fused ring structures such as N
6
,N
6
-(2,3-dihydroxybutan-1,4-diyl)-2′-
deoxyadenosine (N
6
,N
6
-DHB-dA) and 1,N
6
-(2-hydroxy-3-hydroxymethylpropan-1,3-
diyl)-2′-deoxyadenosine (1,N6-γ-HMHP-dA) (Scheme 1.4) (48). Another BD-dA 
exocyclic adduct, 1,N
6
-(1-hydroxymethyl-2-hydroxypropan-1,3-diyl)-2′-deoxyadenosine 
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(1,N
6
-α-HMHP-dA) can be formed by the alkylation of the N-1 position of adenine to 
form N1-(2-hydroxy-3,4-epoxybut-1-yl)-adenine adducts followed by spontaneous 
cyclization (48). 1,N
6
-α-HMHP-dA and 1,N6-γ-HMHP-dA adducts can interconvert under 
physiological conditions with the former adduct being thermodynamically stable 
(Scheme 1.4) (48). N
6
,N
6
-DHB-dA adducts were found in smaller quantities upon 
treatment of calf thymus DNA with 200 fold excess DEB but they were not detected in 
vivo (48). 1,N
6
-α-HMHP-dA and 1,N6-γ-HMHP-dA adducts were found in significant 
quantities in vitro and in liver DNA of mice exposed to BD (48). A linear dose response 
relationship was observed between 1,N
6
-HMHP-dA adducts in mouse liver DNA and BD 
exposure (67). Additionally, it was found that the in vivo half life of 1,N
6
-HMHP-dA 
adducts in mouse liver and kidney tissues was 38-42 days (185). N
6
,N
6
-DHB-dA and 
1,N
6
-HMHP-dA cannot form the regular Watson Crick base pairing with dT as the N
6
 
position is blocked and therefore can be promutagenic (48). Since 1,N
6
-HMHP-dA 
adducts persist in vivo and are not repaired, and based on structural similarity to 1,N
6
-
etheno-dA and 1,N
6
-ethano-dA, they were hypothesized to be potentially mutagenic  
(186). Studies focusing on determining the mutagenic ability of N
6
,N
6
-DHB-dA and 1,N
6
-
HMHP-dA will be interesting. 
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Scheme 1.4 Mechanism of formation of exocyclic BD-dA adducts from EB and DEB 
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1.6 Summary and thesis goals 
BD is a high volume industrial chemical used as a monomer in the production of rubber 
and plastics. The general population is exposed to BD because of its presence in cigarette 
smoke and automobile exhaust. Based on studies in laboratory animals and 
epidemiological studies in workers in the rubber industry, BD is classified as a known 
human carcinogen.  BD is metabolically activated to EB, HMVK, EBD and DEB 
(Scheme 1.1). These electrophilic metabolites can be detoxified by glutathione 
conjugation and further metabolic conversion into urinary mercapturic acids: MHBMA, 
DHBMA, THBMA and bis-BDMA, respectively (Scheme 1.1). These BD-urinary 
metabolites can be used as biomarkers of exposure to BD in human biomonitoring 
studies. MHBMA and DHBMA have been previously detected in urine of rats exposed to 
BD, workers occupationally exposed to BD and smokers. However, neither THBMA 
(formed from EBD, the most abundant BD epoxide) nor bis-BDMA (formed from DEB, 
the most genotoxic BD epoxide) has been detected before. Hence the initial goals of this 
thesis work were to develop HPLC-MS/MS methods for the quantification of these two 
novel urinary metabolites of BD in vivo.  
 It is also known that there are significant ethnic/racial differences in susceptibility 
to smoking associated lung cancer (Tables 1.2 and 1.3). It has been hypothesized that 
these differences might be due to genetic polymorphisms contributing to differences in 
metabolic activation and deactivation of carcinogens. Since BD is one of the most 
abundant and potent carcinogens present in cigarette smoke, it will be interesting to study 
whether there are any differences in metabolism of BD. Our second goal of this thesis 
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work was to develop a high throughput HPLC-MS/MS method for quantification of 
MHBMA and DHBMA in human urine and apply this method to urine samples of 
smokers belonging to two different multi-ethnic cohort studies to identify ethnic 
differences in BD metabolism. 
EB and DEB induce a large number of A→T mutations. However, the identity of 
the BD-dA lesions responsible for these mutations remains to be established. The 
mutagenic ability of N
6
-HB-dA formed from EB, N
6
,N
6
-DHB-dA and 1,N
6
-HMHP-dA 
formed from DEB (Scheme 1.4) has not been evaluated before. Hence the final goal of 
this research was to conduct in vitro translesion synthesis studies on synthetic 
oligonucleotide strands containing these lesions at a site-specific position in the presence 
of human TLS polymerases.  
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II. QUANTITATIVE ANALYSIS OF TRIHYDROXYBUTYL MERCAPTURIC 
ACID, A URINARY METABOLITE OF 1,3-BUTADIENE, IN HUMANS 
Reprinted with permission from: Srikanth Kotapati, Brock A. Matter, Amy L. Grant, and Natalia 
Y. Tretyakova. Chem. Res. Toxicol. (2011) 24, 1516-1526. 
© 2011 American Chemical Society 
2.1 Introduction 
1,3-Butadiene (BD) is a colorless gas with a gasoline-like odor that is widely used 
in the polymer industry for the production of rubber and plastics (18). BD is a multi-site 
carcinogen in laboratory animals, capable of inducing lymphocytic lymphoma and 
neoplasms of the heart, forestomach, Harderian gland, mammary gland, ovary, liver, and 
the lung (16).  Based on epidemiological evidence for an increased risk of leukemia in 
occupationally exposed workers (23;24;187), BD is classified as a “known human 
carcinogen” in the Ninth Report on Carcinogens (2000) by the US National Toxicology 
Program (18) and is categorized as a “human carcinogen” by the US EPA and IARC (26).  
BD is also present in automobile exhaust, urban air, and is abundant in cigarette smoke 
(16-75 µg in main- stream smoke and 205-361 µg in side-stream smoke) (19), leading to 
widespread exposure of the general population. Toxicological risk analysis suggests that 
BD has the highest cancer risk index among all tobacco constituents (25), necessitating 
further studies of its mechanism of action.  
The genotoxic effects of BD are attributed to its epoxide metabolites (16;188). 
Cytochrome P450 monooxygenases P450 2E1 and P450 2A6 catalyze the initial 
epoxidation of BD to yield (R)- and (S)-3,4-epoxy-1-butene (EB) (Scheme 1.1) (27;28). 
EB can be hydrolyzed to 1-butene-3,4-diol (EB-diol) (30), which can be further oxidized 
to form 3,4-epoxy-1,2-butanediol (EBD) (189) or can undergo further metabolism to 
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hydroxymethyl vinylketone (HMVK) (32). Alternatively, EB can be subject to second 
oxidation catalyzed by cytochrome P450 2E1 and 3A to yield S,S, R,R, and meso-
diepoxybutane (DEB) (27;29). 
All three epoxides of BD, e.g. EB, DEB, and EBD, are direct-acting mutagens, 
with DEB exhibiting the most potent genotoxicity (34;188). If not detoxified by epoxide 
hydrolysis or glutathione conjugation, they can react with nucleophilic sites in DNA and 
proteins to form covalent adducts (41;44;47;190). DNA adducts induced by BD exposure 
include N-7-(2-hydroxy-3-buten-1-yl)guanine, N-7-(1-hydroxy-3-buten-2-yl)guanine, N-
7-(2,3,4-trihydroxy-3-buten-2-yl)guanine (191), 1,4-bis-(guan-7-yl)-2,3,-butanediol (bis-
N7G-BD) (46;64), 1-(guan-7-yl)-4-(aden-1-yl)-2,3-butanediol (N7G-N1A-BD), 1-(guan-
7-yl)-4-(aden-3-yl)-2,3-butanediol(N7G-N3A-BD), and 1-(guan-7-yl)-4-(aden-7-yl)-2,3-
butanediol (N7G-N7A-BD) (46). Several BD-induced hemoglobin adducts have been 
identified, e.g. N-(2-hydroxy-3-buten-1-yl)-valine (HB-Val), 1,2,3-trihydroxybutyl-valine 
(THB-Val), and N,N-(2,3-dihydroxy-1,4-butadiyl)-valine (pyr-Val) (80;84). DEB also 
induces DNA-protein cross-links that are hypothesized to interfere with DNA replication, 
transcription, and repair (192;193). 
BD is a potent carcinogen in mice (20), but is only a weak carcinogen in rats, 
requiring 300-fold higher concentrations to achieve the same tumor numbers (21). This 
can be explained by more efficient metabolic activation of butadiene to EB, DEB, and 
EBD, and an inefficient detoxification of butadiene epoxides in the mouse 
(113;194;195). Indeed, the concentrations of butadiene-induced DNA and protein 
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adducts are greater in tissues of mice than in rats exposed to the same butadiene 
concentration (60;66;77;196;197). 
BD metabolites are excreted in urine as mercapturic acids. Glutathione conjugates 
of EB are processed via the mercapturic acid pathway to yield 2-(N-acetyl-L-cystein-S-
yl)-1-hydroxybut-3-ene and 1-(N-acetyl-L-cystein-S-yl)-2-hydroxybut-3-ene, collectively 
called MHBMA (Scheme 1.1) (31;95). HMVK undergoes glutathione conjugation 
followed by reduction and is excreted as  4-(N-acetyl-L-cystein-S-yl)-1,2-
dihydroxybutane (DHBMA) (32;33). EBD undergoes similar glutathione conjugation and 
metabolic conversion to form another mercapturic acid, 4-(N-acetyl-L-cystein-S-yl)-
1,2,3-trihydroxybutane (THBMA) (31;93). N-acetylcysteine conjugates of EB (MHBMA 
in Scheme 1.1), HMVK (DHBMA), and EBD (THBMA) can serve as useful indicators of 
BD exposure and genotoxicity in smokers and occupationally exposed individuals, 
allowing for human bio-monitoring and risk assessment from BD exposure 
(31;33;95;99;105). 
 While MHBMA and DHBMA have been found in smokers and non-smokers, to 
our knowledge, THBMA has not been previously detected in humans. THBMA has been 
found in urine of rats and mice exposed to 200 ppm of radiolabeled 
14
C-1,3-BD for 6 
hours. THBMA accounted for about 4.1% and 6.7% of the total BD dose in the rat and in 
mice, respectively (93). Van Sittert et al. (31) have attempted to quantify the amounts of 
THBMA in human urine by a GC-NECI-MS/MS method. In their approach, THBMA 
was isolated from smoker’s urine (1 mL) by strong anion exchange SPE and derivatized 
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with pentafluorobenzyl bromide, followed by GC-NECI-MS/MS analysis. However, 
THBMA could not be quantified due to high interferences from sample matrix (31). 
The goal of the present study was to develop a sensitive, accurate and reliable 
isotope dilution HPLC-ESI
-
-MS/MS method for quantification of THBMA in human 
urine and evaluate its potential as a biomarker of exposure to BD in cigarette smoke and 
its metabolism to DNA-reactive species.  The novel method was employed to determine 
the concentrations of THBMA in urine of current smokers and non-smokers and to 
analyze the effects of smoking cessation on THBMA levels. 
2.2 Materials and Methods 
Materials. HPLC-MS grade acetic acid, methanol, acetonitrile, and d,l DEB were 
purchased from Sigma Aldrich (St. Louis, MO). HPLC grade acetonitrile and methanol 
were obtained from Fisher Scientific (Pittsburgh, PA). THBMA and its deuterated 
analog, d3-THBMA, were synthesized in our laboratory as described below. d3-N-acetyl- 
L- cysteine was purchased from Toronto Research Chemicals (Ontario, Canada). Isolute 
ENV+ 50 mg/1 mL SPE cartridges were purchased from Biotage (Charlotte, NC). All 
other materials and solvents were from Sigma-Aldrich (St. Louis, MO) 
Synthesis of 4-(N-acetyl-L-cystein-S-yl)-1,2,3-trihydroxybutane (THBMA) 
and its deuterated analogue (d3-THBMA). THBMA and d3-THBMA were prepared as 
shown in Scheme 2.1. N-acetyl-L-cysteine (338 mg, 2 mmol) was dissolved in 1 mL of 
water. Racemic  DEB (155 µL, 2 mmol) was added, followed by mixing and incubation 
at 65°C for 72 h. THBMA was isolated by semi-preparative HPLC. HPLC purification 
was performed on an Agilent 1100 HPLC system equipped with a DAD UV detector 
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(Agilent Technologies, Santa Clara, CA) on an Agilent Eclipse XDB C18 column (10 
mm x 250 mm; 5 µm). The buffer system consisted of 5 mM N, N, dimethylhexylamine 
adjusted to pH 9.2 with acetic acid (A) and 25:56.25:18.75 5 mM N, N, 
dimethylhexylamine (pH 9.2):methanol:acetonitrile. The flow rate was 3 mL/min, and the 
solvent composition was changed linearly from 1 to 13% (B) in the first 12 min. The 
gradient was ramped up to 50% (B) in the next 2 minutes and held at that composition for 
3 minutes. The solvent composition was brought back to the initial composition of 1% 
(B) in the next three minutes and equilibrated at those conditions for 12 minutes. 
THBMA eluted as a broad peak at 14 minutes.  
HPLC fractions containing THBMA were collected, concentrated under vacuum, 
and re-purified with the same column and solvent system with a slower gradient. For the 
second round of purification, the flow rate was 3 mL/min, and the solvent composition 
was linearly changed from 8 to 30% (B) in 20 minutes. The system was brought back to 
8% (B) in 1 min and equilibrated at these conditions for 11 min. Under these conditions, 
THBMA eluted at 10.5 min. HPLC peaks corresponding to THBMA were collected and 
concentrated under vacuum (estimated reaction yield, 1%). d3-THBMA was synthesized 
analogously starting with N-acetyl- d3- L- cysteine (Scheme 2.1). The isotopic purity of 
d3-THBMA as determined by HPLC-ESI-MS/MS was 99.7%. 
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Scheme 2.1 Synthesis of THBMA and d3-THBMA 
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THBMA and d3-THBMA (Scheme 2.1) were structurally characterized by high 
resolution tandem mass spectrometry on Waters Acquity UPLC/Synapt G2 QTOF mass 
spectrometer and NMR. The HPLC conditions for accurate mass measurements included 
a Waters Acquity UPLC HSS T3 column (2.1 x 100, 1.8µ) eluted at a flow rate of 0.4 
ml/min using 97:3 0.1% formic acid in water: 0.1% formic in ACN as the mobile phase. 
The sample was introduced into the mass spectrometer using “Lockspray” dual 
electrospray ion source (leucine-enkephalin as calibrant) and analyzed in the negative 
ionization mode with a m/z scan range of 50-1500. MS/MS fragmentation patterns were 
as follows: THBMA (ESI
-
-MS : 266.0698 [M-H]
-
 , MS/MS: 137.0348, 128.0423 and 
119.0233); d3-THBMA (ESI
-
-MS : 269.0882 [M-H]
-
 , MS/MS: 137.0342, 131.0602, 
119.0228) (Figure 2.1). 
1
H NMR of THBMA: δ 7.9 (1H, s, cys-NH), 4.2 (1H, m, αC-
cys), 3.5-3.3 (4H, m, OCH2, OCH), 2.9-2.5 (4H, m, SCH2), 1.8 (3H, s, COCH3) (Figure 
2.2).  
THBMA stock solution concentrations were determined by proton NMR. Toluene 
(1.12 µmol) was added to THBMA standard dissolved in DMSO (Figure 2.2). The ratio 
of 
1
H NMR integrations corresponding to aromatic protons of toluene (5H, 7.2 ppm) and 
a C-H proton of THBMA (1H, 4.2 ppm) was used to determine THBMA concentration 
(Figure 2.2). d3-THBMA concentrations were determined by capillary HPLC-UV using 
THBMA as an external standard and confirmed by HPLC-ESI-MS/MS analysis of 
solutions spiked with known amounts of unlabeled THBMA. 
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Figure 2.1 UPLC-ESI
-
-TOF-MS/MS spectra of THBMA and d3-THBMA (B) 
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Figure 2.2 
1
H NMR spectrum of THBMA  
 
Toluene* was added as an internal standard for quantification. (Residual N, N- 
dimethylhexylamine
#
 from HPLC purification is observed). 
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Sample Preparation. Solid phase extraction (SPE) was performed using Isolute 
ENV+ cartridges (1 mL / 50 mg) obtained from Biotage (Charlotte, NC, USA). Human 
urine (100 μL) was mixed with 100 μL of 50 mM ammonium formate buffer (pH 2.5), 10 
μL of formic acid (98%), and 60 ng of d3-THBMA. Samples were vortexed repeatedly 
and centrifuged at 13,000 rpm for 15 minutes. The supernatant was loaded onto SPE 
cartridges pre-conditioned with methanol and 0.3% formic acid (3 ml each). The 
cartridges were sequentially washed with 1.5 mL of 0.3% formic acid and 0.75 mL of 5% 
aqueous methanol containing 0.3% formic acid and allowed to dry completely under 
vacuum for 20 minutes. THBMA and d3-THBMA were eluted with 1.2 mL of 2% formic 
acid in methanol, dried under vacuum, and reconstituted with 20 μL of 0.2% acetic acid 
for HPLC-ESI-MS/MS analysis. 
Liquid chromatography-Tandem Mass spectrometry. HPLC-ESI
-
-MS/MS 
analysis was conducted on an Agilent 1100 HPLC system (Agilent Technologies, Santa 
Clara, CA) coupled with a Thermo-Finnigan TSQ Quantum Discovery mass spectrometer 
(Thermo Scientific Corp., Waltham, MA). A SIELC Primesep B2 column (5 μm, 2.1 x 50 
mm) was equipped with a guard column of the same packing (5 μm, 2.1 x 10 mm). The 
column was maintained at 50° C and eluted with a gradient of 0.2% acetic acid (A) and 
acetonitrile (B) at a flow rate of 150 µl/min. The solvent composition was maintained at 
1% B for the first six minutes and then increased to 50% B in the next three minutes. The 
column was eluted with 50% B for three more minutes, and the solvent composition was 
brought back to the initial conditions of 1% B in the next three minutes. The column was 
equilibrated at 1% B for 10 minutes before a new injection was made. Under these 
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conditions, THBMA and d3-THBMA eluted at 5.12 and 5.18 minutes, respectively. The 
total HPLC-ESI
-
-MS/MS run time was 25 minutes.  
The mass spectrometer was operated in the ESI
-
 mode, and typical MS settings 
were as follows:  spray voltage, - 3500 V; sheath gas pressure, 50 psi; capillary 
temperature, 250° C; collision energy, 16; source CID, -9 V; collision gas pressure, 1.0 
mTorr; Q1 (FWHM), 0.4; Q3 (FWHM), 0.7; scan width , 0.4 m/z; and scan time, 0.4 s. 
The mass spectrometer settings were optimized upon direct infusion of authentic 
standards and may vary slightly between analyses. Quantification of THBMA was 
performed in the selected reaction monitoring (SRM) mode by isotope dilution with d3-
THBMA. The SRM transitions used for quantitation were: m/z 266.1 → 137.1 (THBMA) 
and m/z 269.1 → 137.1 (d3-THBMA).  An additional SRM transition (m/z 266.1 → 128.1 
for THBMA and 269.1→131.1 for d3-THBMA) was used to confirm the identity of the 
THBMA peak.  
 Calibration curves were constructed by injecting standard solutions containing 
fixed amount of d3-THBMA (25 ng) and varying amounts of THBMA (0.05, 0.25, 0.5, 1, 
1.5, 2.5, 5 and 12.5 ng), in triplicate (on column). Regression analyses were conducted to 
determine the correlation between the theoretical molar ratio and the HPLC-ESI
-
-MS/MS 
response ratio (ratio of THBMA and d3-THBMA peak areas). 
Method Validation. Eight validation standards were prepared by spiking non-
smoker urine (100 μL) with increasing amounts of THBMA (0.1, 0.5, 1, 2, 3, 5, 10 and 
25 ng) and a fixed amount of d3-THBMA (50 ng), in triplicate. These samples were 
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processed by SPE and analyzed by HPLC-ESI
-
-MS/MS as described above. Regression 
analysis was conducted to compare the measured and the theoretical THBMA amounts. 
Determination of LOD/LOQ. Artificial urine (100 μL) was spiked with 100, 50, 
25 or 10 pg of THBMA and 60 ng of d3-THBMA, and the samples were processed by 
SPE and analyzed by HPLC-ESI
-
-MS/MS as described above. The limit of quantification 
(LOQ) was estimated as the amount of analyte which gave the signal to noise ratio (S/N) 
greater than 10 (Thermo Xcalibur, ICIS algorithm) and % CV < 15%.  Limit of Detection 
(LOD) was determined as the amount of analyte which produced the signal to noise ratio 
> 3. 
Precision and Accuracy. To determine the intraday and interday precision and 
accuracy of the new method, artificial urine (100 μL) was spiked with 1, 3, or 6 ng of 
THBMA and 60 ng of d3-THBMA. The samples were subjected to SPE as described 
above and analyzed by HPLC-ESI
-
-MS/MS three times per day on three consecutive 
days.   
Extraction Recovery. Extraction recovery was determined by analyzing blank 
urine samples spiked with 2 ng of THBMA prior to SPE and 60 ng of internal standard 
post-extraction (n = 3) and the same urine sample spiked with both the analyte and the 
internal standard post SPE (n = 3).   
Freeze-thaw stability. Stock solutions containing either 5 ng/ml or 30 ng/ml of 
THBMA were analyzed before and after three freeze-thaw cycles. The solutions were 
stored at - 20
0
 C for 23 hours and thawed for 1 hour at room temperature, after which a 
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fixed amount of internal standard (60 ng) was added, and the mixture was analyzed by 
HPLC-ESI
-
-MS/MS using standard methods. This procedure was repeated for 3 days. 
A similar procedure was used to assess analyte stability in urine. Blank human urine 
sample (1 ml) was spiked with 5 ng or 30 ng of THBMA standard. The spiked urine 
samples were stored at -20
0
 C for 23 hours and thawed for 1 hour at room temperature. 
Three 100 μL aliquots from each of the tubes were drawn and following the addition of 
d3-THBMA internal standard and SPE cleanup, HPLC-ESI
-
-MS/MS was used to quantify 
THBMA. The procedure was repeated for 3 consecutive days.  
Matrix effects. Urine samples from a confirmed non-smoker and a confirmed 
smoker (100 μl each) were processed by SPE and spiked with THBMA (2 ng) and d3-
THBMA (60 ng), followed by HPLC-ESI
-
-MS/MS analysis. HPLC-ESI
-
-MS/MS peak 
areas were compared for spiked samples and pure standard mixtures containing 2 ng of 
THBMA and 60 ng of internal standard to identify any potential analyte suppression by 
the biological matrix. 
Human Urine Samples. Urine samples from confirmed smokers (N = 27) and 
non-smokers (N = 19) were obtained from the University of Minnesota Tobacco 
Research Programs and stored at - 20° C. Urine samples (100 μL) were processed by SPE 
and analyzed by HPLC-ESI
-
-MS/MS methods as described above. THBMA amounts 
were normalized to creatinine, which was determined with the VITROS CREA kit and 
VITROS 350 system (Ortho-clinical Diagnostics, Rochester, New York). 
Smoking cessation samples were obtained from the previously described study.
40
 
In brief, 5 smokers from Minneapolis were asked to continue smoking for 2 weeks 
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(baseline) and 24 hour urine samples were collected 14 and 7 days prior to smoking 
cessation. Following a two-week baseline period, the smokers were asked to quit 
smoking. Urine samples were collected on days 3, 28 and 56 post smoking cessation and 
analyzed by HPLC-ESI
-
-MS/MS as described above.  
Statistical Analysis. Method calibration and validation curves were constructed 
in Microsoft Excel. Linear regression analysis was performed and residual plots were 
constructed to determine the homogeneity of the error. An unpaired t test was compiled 
to look at the differences in levels of THBMA between smokers and non-smokers. A p-
value < 0.01 was considered statistically significant. 
2.3 Results 
2.3.1 Synthesis and structural characterization of THBMA 
Authentic THBMA and its deuterated internal standard (d3-THBMA) were 
synthesized by reacting N-acetyl-L- cysteine and d3-N-acetyl-L-cysteine, respectively, 
with commercial d,l DEB (Scheme 2.1). Although multiple stereoisomers of THBMA are 
possible, they were not resolved by our HPLC methods, and both standards were isolated 
as racemic mixtures. 
The structural identities of THBMA and d3-THBMA were confirmed by high 
resolution mass spectrometry, tandem mass spectrometry, and proton NMR spectroscopy 
(Figures 2.1, 2.2). Accurate masses of THBMA and d3-THBMA as determined by Q-
TOF MS (m/z 266.0698 and 269.0882; M-H) (Figures 2.1A, 2.1C) were consistent with 
the theoretical values (m/z 266.0698 and 269.0887, respectively). Tandem mass 
spectrometry analysis of THBMA (m/z 266.0827 (M-H)
-
) generated product ions at 
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137.0348 (2,3,4-trihydroxybutane-1-thiolate formed following the C-S bond cleavage), 
128.0423 (2-acetamidoacrylate, the other fragment formed as a result of C-S bond 
cleavage) and 119.0233 (the loss of water from 2,3,4-trihydroxybutane-1-thiolate) 
(Figure 2.1B). The corresponding ions for d3-THBMA were observed at m/z 269.0997 
(M-H)
-
, 137.0342, 131.0602 and 119.0228 (Figure 2.1D) and were consistent with 
theoretical values. The isotopic purity of d3-THBMA standard was 99.7%. 
2.3.2 SPE Method Development for THBMA 
THBMA is a highly polar metabolite that is not well retained on reverse phase 
HPLC stationary phases, complicating SPE method development. Due to the presence of 
a carboxylic acid functionality in its structure (pKa = 3.5), THBMA can potentially be 
retained via the anion exchange mechanism. Several types of SPE packing have been 
tested for solid phase extraction of THBMA from human urine, including reversed phase 
(Strata X, Bond Elut C18), weak anion exchange (Strata X-AW), strong anion exchange 
(Isolute SAX, Baker SAX, Agilent SAX), and mixed mode reversed phase/anion 
exchange (Oasis MAX, Oasis HLB), but the recoveries were insufficient (below 5%). 
The best results were achieved with ENV+ cartridges (Biotage), which are packed with a 
stationary phase composed of highly cross-linked hydroxylated polystyrene 
divinylbenzene copolymer. Since analyte retention on this packing is primarily due to 
hydrophobic interactions between the analyte and the stationary phase, samples were 
loaded under acidic conditions (formic acid) to neutralize the carboxylate group of 
THBMA, resulting in stronger binding of the analyte to the stationary phase. ENV+ 
cartridges have been previously employed by Eckert et al. for solid phase extraction of 
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six hydroxylalkyl mercapturic acids, including MHBMA and DHBMA, from human 
urine (107). The published method (107) was modified to enable the isolation of 
THBMA, which has a greater polarity than the other two BD-mercapturic acids due to the 
presence of an additional hydroxyl group (Scheme 1.1). Small SPE cartridges (1 mL, 50 
mg) were employed for processing 100 μL urine samples. Our optimized SPE method has 
an estimated recovery of 54.5% (Table 2.1). 
2.3.3 HPLC-ESI-MS/MS Method Development  
 As discussed above, the ESI
-
 MS/MS spectrum of THBMA is characterized by 
the main product ion at m/z 137.0348 corresponding to C-S bond cleavage and the 
formation of trihydroxybutyl thiolate anion (Figure 2.1A). The second most abundant 
fragment (m/z 128.0423) corresponds to other half of the molecule following C-S bond 
cleavage and negative charge retention on the carboxylate functionality. The d3-THBMA 
internal standard produces analogous fragments at m/z 137.0342 and 131.0602 (Figure 
2.1B). Similar fragments are observed with a triple quadrupole mass spectrometer (results 
not shown). Our selected reaction monitoring method is therefore based on the transitions 
266.1 → 137.1 (THBMA) and 269.1 → 137.1 (d3-THBMA). The secondary 
fragmentation pathway 266.1 → 128.1 (THBMA) and 269.1 → 131.1 (d3-THBMA) was 
used for confirmation purposes (see below). 
HPLC-ESI-MS/MS method development for THBMA was complicated by its 
poor retention on standard HPLC columns and ESI
-
 signal suppression due to the 
presence of other polar compounds in human urine samples. Our initial method employed 
a capillary Thermo Hypercarb column. Although excellent sensitivity was achieved for 
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pure standards, this method was not robust when analyzing multiple urine samples due to 
a sample-dependent retention time shift, complicating peak identification (results not 
shown). Therefore, a different HPLC method was sought.  
Multiple HPLC columns were evaluated, including Thermo BetaMax Acid (2.1 x 
50 mm), Waters Xterra MS C18 (4.6 x 50 mm), and Synergi Hydro RP (2.1 x 100 mm). 
The best results were achieved with the Primesep B2 column (SIELC), a mixed mode 
column containing C12 alkyl chains and weak anion exchange groups. Various solvent 
combinations, flow rates, and temperatures were evaluated in an effort to achieve good 
analyte retention, baseline resolution of the THBMA peaks from matrix components, and 
improved HPLC peak shape.   Solvent composition consisting of 0.2% acetic acid (A) 
and acetonitrile (B) proved to be very efficient, and a temperature of 50° C was necessary 
to successfully resolve THBMA from the interfering matrix peaks (see below). THBMA 
was eluted at 1% of acetonitrile. This is not uncommon as many of the researchers 
including Boettcher et al. (198) reported the use of low percentages of organic solvents to 
achieve efficient separation of polar metabolites. Under our optimized conditions, 
THBMA and d3-THBMA have a similar retention time (5.0-5.2 min) and are resolved 
from the impurities present in human urine (see below). The total HPLC-ESI
-
-MS/MS 
run time is 25 minutes to allow for efficient column cleaning and equilibration prior to 
the next injection. 
2.3.4 Method Validation 
Calibration curves covering a broad THBMA concentration range were 
constructed by analyzing standard solutions containing fixed amounts of d3-THBMA (50 
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ng) and increasing amounts of THBMA (0.1-25 ng) (8 points) and plotting the ratios of 
the observed HPLC-ESI-MS/MS peak areas against the theoretical THBMA/ d3-THBMA 
molar ratios. A linear curve with a slope of 1 and an R
2
 value > 0.99 was obtained (Figure 
2.3). The LOQ value for pure THBMA standard was less than 1 pg (on column). 
The HPLC-ESI
-
-MS/MS method was validated by analyzing non-smoker urine 
(100 μL) spiked with known amounts of THBMA (8 concentrations, 0.1-25 ng) and d3-
THBMA (50 ng). Spiked samples were processed by SPE and analyzed by HPLC-ESI
-
-
MS/MS as described above. The results were plotted as the amount of THBMA spiked 
versus the amount measured by HPLC-ESI
-
-MS/MS. The resulting method validation 
curve (Figure 2.4) has a slope of 0.98 and an R
2
 > 0.99, confirming that THBMA can be 
accurately quantified in human urine. The y-intercept of the validation curve is 1.54, 
corresponding to ~15.4 ng/mL of THBMA present in non-smoker urine (see below). 
Linear regression analysis (199) showed that the error was homogenous 
(homoscedasticity), and hence no weighing factor was applied for plotting the validation 
curve. 
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Figure 2.3 Standard curve for HPLC-ESI
-
-MS/MS analysis of THBMA 
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Figure 2.4 Method validation curve for THBMA spiked in non-smoker urine 
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2.3.5 Linearity, limits of detection, and extraction recovery 
The linearity of the HPLC-ESI
-
-MS/MS method for THBMA has been 
demonstrated over a broad range of concentrations (1 to 250 ng/ml) (Figure 2.4). To 
determine the sensitivity of the method, artificial urine (100 μL) was spiked with 10-100 
pg of THBMA. Artificial urine was used due to the presence of THBMA in urine of both 
smokers and non-smokers (see above). The spiked samples were processed by standard 
methods and analyzed by HPLC- ESI
-
-MS/MS. Based on the signal to noise ratio > 10 
and % CV < 15%, the LOQ was found to be 1 ng/mL urine (Table 2.1). The LOD for the 
HPLC- ESI
-
-MS/MS assay was estimated to be as 0.1 ng/mL urine (S/N > 3). The 
optimized extraction recovery was determined to be ~ 54.5% due to the polar nature of 
the analyte (Table 2.1). 
2.3.6 Precision and Accuracy 
The precision and accuracy of our HPLC-ESI
-
-MS/MS assay were determined 
using artificial urine (100 μL) spiked with 1, 3, or 6 ng of THBMA. The samples were 
analyzed in triplicate on three consecutive days. The mean accuracy for THBMA was 85-
115% at all the three concentration levels, while the intra-day and inter-day precision was 
< 15%. The precision and accuracy data for THBMA are reported in Table 2.2 
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Table 2.1 Analytical detection limits and extraction recovery for HPLC-ESI
-
-MS/MS 
analysis of THBMA 
Analyte 
Range 
(ng/mL) 
LOD 
(ng/mL) 
LOQ 
(ng/mL) 
Extraction 
Recovery (%) 
THBMA 1.0-250 < 0.1 1.0 54.5 
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Table 2.2 Precision and accuracy data for HPLC-ESI
-
-MS/MS analysis of THBMA 
Concentration 
(ng/ml) 
Intraday 
Precision 
RSD (%) 
Interday 
Precision 
RSD (%) 
Accuracy (%) 
10 4.58 4.87 101.73 ± 4.75 
30 6.55 7.85 106.67 ± 6.16 
60 0.88 1.63 102.42 ± 1.67 
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2.3.7 Freeze-thaw Stability and matrix effects 
Stability experiments determined that THBMA concentrations were essentially 
unchanged upon several freeze-thaw cycles, both in stock solutions and in spiked human 
urine. Analyte losses were < 3% over three freeze-thaw cycles at concentration levels of 
5 ng/ml and 30 ng/ml.  
A direct comparison of HPLC-ESI
-
-MS/MS peak areas corresponding to pure 
THBMA in buffer and THBMA mixed with SPE-processed human urine (smoker or non-
smoker, 100 µl) revealed no significant signal suppression by the matrix, with peak areas 
remaining within 5% of the original value. 
2.3.8 Quantification of THBMA in urine from smokers and nonsmokers 
To determine the relationship between smoking and urinary THBMA 
concentrations, urine samples from 27 confirmed smokers and 19 non-smokers (100 μL) 
were analyzed. Representative HPLC-ESI
-
-MS/MS extracted ion chromatograms are 
shown in Figure 2.5 Interestingly, the HPLC-ESI-MS/MS retention time of THBMA was 
reproducibly 0.05-0.06 minutes shorter than that of the d3-internal standard. This is 
unusual since the non-deuterated compound is expected to have the same retention time 
as its non-deuterated analog or elute slightly later due to stronger van der Waals 
interactions between the C-H bonds and the stationary phase as compared to the C-D 
bonds (200). To confirm that the peak of interest indeed corresponded to THBMA, 
sample was spiked with 6 ng/mL of authentic THBMA and re-analyzed. HPLC-ESI-
MS/MS analysis confirmed that authentic THBMA co-eluted with the peak observed in 
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human samples, which was accompanied by proportional increase in the HPLC-ESI-
MS/MS peak area corresponding to concentration increase by 6 ng/mL. 
To obtain additional evidence for the presence of THBMA in human urine, the 
same sample was re-analyzed on a different HPLC column, Primesep D (2.1 x 100 mm) 
using a pH gradient method comprising of 0.5% acetic acid and 15 mM ammonium 
acetate in methanol. Similar results were obtained, with THBMA peak eluting 0.05 min 
before its deuterated standard. The calculated amounts of THBMA were the same for the 
sample analyzed by two different HPLC-ESI-MS/MS methods.  
Finally, a sample obtained from a larger volume of urine (500 μL) was analyzed 
in the product ion scan mode to reveal additional MS/MS fragments. These experiments 
revealed that the THBMA peak present in human samples produced fragment ions at m/z 
137.1, 128.1, and 119.1, which are consistent with the structure of THBMA (Figure 2.1). 
SRM analysis with two transitions (266.1→137.1 and 266.1→128.1) revealed HPLC-
ESI-MS/MS peaks in both ion channels. THBMA amounts calculated with the two SRM 
transitions were identical, further confirming the identity of the peak observed in human 
urine sample.  
The new method was then employed to determine the effects of smoking on 
urinary THBMA concentrations. A box plot showing the creatinine-corrected THBMA 
concentrations in urine of non-smokers (N = 19) and smokers (N = 27) is shown in 
Figure 2.6. Smokers contained significantly higher concentrations of THBMA than non-
smokers (21.6 ± 10.2 versus 13.7 ± 7.9 ng THBMA/mg creatinine; p < 0.01 using 
unpaired two-sample t-test). Importantly, THBMA concentration varied widely within 
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each group (11.3 to 47.2 ng/mg creatinine in smokers, and 2.9 -31.0 ng/mg creatinine in 
non-smokers), revealing significant inter-individual differences. 
The presence of THBMA in samples from non-smokers suggests that sources 
other than smoking contribute to its formation in human urine. For example, 
environmental exposures to BD from automobile exhaust and urban air may contribute to 
THBMA formation. Furthermore, the metabolic precursor of THBMA, EB-diol, has been 
hypothesized to form endogenously as a product of catabolism of carbohydrates (87).  
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Figure 2.5 HPLC-ESI
-
-MS/MS analysis of THBMA in urine of a smoker and non-
smoker 
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Figure 2.6 Comparison of THBMA concentrations (ng/mg creatinine) between smokers 
and non-smokers 
*boxes represent 25th and 50th percentiles and lines represent the minimum and 
maximum concentrations. 
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2.3.9 Smoking cessation study 
To investigate the effect of smoking on THBMA concentrations in human urine, 
samples were obtained from five individuals participating in a smoking cessation study.  
Five urine samples from each smoker were considered:  the first two represented baseline 
values (-14
th
 day and –7th day) prior to smoking cessation, and an additional three 
samples were obtained following termination of smoking (3, 28, and 56 days post 
cessation). Urine samples (100 µl) were processed by SPE and analyzed by HPLC-ESI
-
-
MS/MS as described above. THBMA concentrations measured post smoking cessation 
were normalized to the baseline value to reveal any changes in urinary THBMA levels 
following the termination of smoking (Figure 2.7).  As shown in Figure 2.7, the mean 
urinary THBMA levels decreased by 25-50% following smoking cessation, confirming 
that a significant portion of human exposure to BD can be attributed to exposure to 
cigarette smoke. 
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Figure 2.7 Percent reduction in urinary THBMA concentrations in smokers after 
smoking cessation 
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2.4 Discussion 
A recognized critical step in BD-mediated carcinogenesis is the chemical 
modification of DNA by its epoxy metabolites to form covalent nucleobase adducts 
(41;44;47;190). Because of the requirement for metabolic activation of BD to DNA-
reactive epoxides, enzymes that are involved in the formation and detoxification of 
butadiene epoxides largely determine the individual sensitivity to BD-mediated 
mutagenesis and carcinogenesis. Therefore, quantitative analysis of butadiene metabolites 
in human samples may provide important information in regard to BD exposure and 
metabolic activation in a given individual.  
Several laboratories previously quantified MHBMA and DHBMA (Scheme 1.1 
and Table 1.5) in human urine by liquid chromatography-tandem mass spectrometry 
(33;96-99;104) 
 
and gas chromatography-tandem mass spectrometry techniques (31;95). 
The concentrations of MHBMA have been reported as 1 -132 ng/mL (smokers) and 1-
73.4 ng/mL (non-smokers), while the corresponding values for  DHBMA are 16-1,959 
ng/mL (smokers) and 20-1000 (non-smokers) (33;96-99;104). Following smoking 
cessation, the levels of MHBMA in human urine decreased from 66.1 ± 69.4 nmol/24 h 
(baseline) to 3.66 ± 2.41 nmol/24 h (56 days post cessation); while  the concentrations of 
DHBMA dropped from 1038 ± 514 nmol/24 h (baseline) to 662 ± 248 nmol/24 h (56 
days post cessation) (33). In contrast, little is known about THBMA excretion in urine of 
smokers and non-smokers,  despite the fact that it is produced from EBD, the most 
abundant epoxide metabolite of BD in humans (26). 
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Scheme 2.2 Work flow for HPLC-ESI
-
-MS/MS analysis of THBMA in human urine 
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In the present study, a highly sensitive and specific HPLC-ESI
-
-MS/MS method 
was developed for quantitative analyses of THBMA in human urine (LOQ, 1 ng/mL). 
Our methodology (Scheme 2.2) incorporates isotope dilution with d3-THBMA, sample 
processing via SPE on ENV+ cartridges, and HPLC-ESI
-
-MS/MS analysis using a 
Primesep B2 column. The new method is reproducible (Table 2.2) and reasonably fast, 
with an average analysis time of 25 minutes. We also found out that the analyte 
concentrations in urine are essentially unchanged upon multiple freeze-thaw cycles.  
Several laboratories previously employed ENV+ solid phase extraction for 
isolation of mercapturic acids from human urine (107;198;201-203). However, lower 
SPE recoveries have been reported as analyte polarity increased (107;198;201-203). 
While percent recoveries for SPE of MHBMA and DHBMA using ENV+ cartridges have 
been reported as 81 and 67%, respectively (107), THBMA is significantly more polar 
than MHBMA and DHBMA due to the presence of an additional hydroxyl group in its 
structure (Scheme 1.1). To maximize THBMA recovery from small urine samples (100 
μL), samples were loaded onto ENV+ cartridges (50 mg) under acidic conditions and 
eluted with 2% formic acid in methanol following several washing steps to remove 
impurities. We found that THBMA recovery decreased and interferences increased when 
stronger solvents such as acetonitrile were employed. 
Our HPLC-ESI-MS/MS method development for THBMA was complicated by 
its high polarity, leading to poor analyte retention on typical reverse phase HPLC 
columns. Previous researchers have employed reversed phase HPLC with polar 
embedded groups to improve the retention of mercapturic acids and took advantage of 
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reduced-length bonded phase chains (C8 and C12) to prevent stationary phase collapse 
under highly aqueous conditions required for their separation. For example, Carmella et 
al. utilized Synergi MAX-RP column with a C12 bonded phase for the analysis of a series 
of mercapturic acids including MHBMA and DHBMA in human urine (33). Boettcher et 
al. (198) and Schettgen et al. (102) used a Luna C8(2) column for the analysis of BD 
mercapturic acids. Eckert et al. employed hydrophilic interaction liquid chromatography 
(HILIC) for analyses of various mercapturic acids (107). We have selected a mixed mode 
Primesep B2 column with C12 bonded phase length and embedded basic ion pairing 
groups, which in our hands provided the best separation of THBMA from other sample 
components (Figure 2.5).   
The optimized HPLC-ESI
-
-MS/MS method was applied to quantify THBMA in 
urine samples from 27 smokers and 19 non-smokers (Figure 2.6). We found that 
THBMA concentrations in urine of smokers (30.7 ng/mL) were significantly greater than 
in samples from non-smokers (16.3 ng/mL, ~ 45% difference, p < 0.001). This difference 
was less pronounced when THBMA amounts were normalized to urinary creatinine 
(36%) due to the higher creatinine levels in urine of smokers as compared to non-
smokers. However, the differences between creatinine-adjusted concentrations of 
THBMA in smokers and non-smokers were still statistically significant (p < 0.01).  
To our knowledge, THBMA had not been previously quantified in human urine. 
However, the corresponding N-terminal valine hemoglobin adducts, THB-Val, have been 
quantified in humans (80;84). Most recently, Vacek et al. (84) compared the levels of 
BD-hemoglobin adducts in males and females with different smoking status. The mean 
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concentrations of THB-Val adducts in male smokers were reported as 501.9 pmol/g 
hemoglobin (N = 7) and 179.1 pmol/g hemoglobin in male non-smokers (N = 15). THB-
Val concentrations in smoking females were 189.2 pmol/g hemoglobin (N = 6) as 
compared 180.2 pmol/g hemoglobin in non-smoking females (N = 19) (84). Since both 
THBMA and THB-Val are produced from the same metabolite of BD (EBD, Scheme 
1.1), these results are consistent with our data (Figure 2.6), which reveal that both 
smokers and non-smokers excrete significant amounts of THBMA.  
The urinary concentrations of THBMA observed in the present study are 2-3 fold 
higher than the published concentrations of MHBMA in smokers and 20-30 fold lower 
than previously observed concentrations of DHBMA. For example, Urban et al. (96) 
reported that the mean MHBMA levels in smokers were 86.4 µg/24 h (N = 10) while the 
corresponding levels in non-smokers were 12.5 µg/ 24 h (N = 10). DHBMA levels in 
smokers and non-smokers were 644 and 459 µg/ 24h (N = 10), respectively (96). Several 
studies, including the most recent one by Carmella et al. (33) concluded that MHBMA is 
a better biomarker of exposure to BD as compared to DHBMA. Existence of alternate 
source of exposure to the precursors to DHBMA other than BD has been speculated (33). 
Similar to THBMA, MHBMA and DHBMA are present in significant levels in the urine 
of non-smokers, which may be a result of background exposure to BD due to passive 
smoking and environmental exposure to BD (102).  
Richardson et al. previously employed HPLC with radioflow detection to analyze 
THBMA in urine of rats and mice exposed to radiolabeled 
14
C-1,3-butadiene (200 ppm of 
for 6 hours) (93). Their analyses revealed 2 peaks corresponding to THBMA. The main 
 93 
 
peak was identified as 4-(N-acetyl-L-cystein-S-yl)-1,2,3-trihydroxybutane based on co-
chromatography with a synthetic standard. The authors inferred that the second peak was 
the other regioisomer of THBMA, 3-(N-acetyl-L-cystein-S-yl)-1,2,4-trihydroxybutane, 
which would form via glutathione conjugation to an internal carbon of EBD (93). 
However, synthetic standard for 3-(N-acetyl-L-cystein-S-yl)-1,2,4-trihydroxybutane was 
not available to validate this result (93). An attempt to synthesize all possible isomers of 
THBMA yielded only the diastereoisomers of 4-(N-acetyl-L-cystein-S-yl)-1,2,3-
trihydroxybutane, but no 3-(N-acetyl-L-cystein-S-yl)-1,2,4-trihydroxybutane (204). In the 
current study, only 4-(N-acetyl-L-cystein-S-yl)-1,2,3-trihydroxybutane was observed 
both in reactions of N-acetylcysteine with d,l DEB and in human samples. However, it is 
possible that our HPLC-MS methods cannot resolve the THBMA regioisomers, therefore 
the potential formation of 3-(N-acetyl-L-cystein-S-yl)-1,2,4-trihydroxybutane cannot be 
excluded. 
In summary, we have successfully developed and validated a sensitive and 
reproducible HPLC-ESI
-
-MS/MS method for quantification of THBMA in human urine. 
Our results provide evidence for the presence of THBMA in urine of smokers and non-
smokers, with smokers excreting significantly higher concentrations of this metabolite. 
Smoking cessation results indicated that a significant portion of THBMA found in human 
urine is due to exposure of BD in cigarette smoke. However, the presence of any other 
endogenous and exogenous sources of THBMA in humans requires further investigation. 
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III. DISCOVERY OF A DEB SPECIFIC BIOMARKER, BIS-BDMA AND 
INTERSPECIES DIFFERENCES IN METABOLISM OF BUTADIENE TO ITS 
ULTIMATE CARCINOGENIC SPECIES 
3.1 Introduction 
1,3-butadiene (BD) is a high volume industrial chemical extensively used in the 
production of synthetic rubber, resins, and polymers (16;18). BD is also an 
environmental chemical present in automobile exhaust, automotive fuel, forest fires, and 
cigarette smoke (16;18). C57BL/6 x C3H F1 mice exposed to relatively low doses of BD 
(6.25-200 ppm) by inhalation developed lymphocytic lymphoma and tumors of the heart, 
lung, forestomach, Harderian gland, preputial gland, liver, mammary gland, and ovary 
(20). Sprague-Dawley rats exposed to 1000 - 8000 ppm BD exhibited neoplasms in the 
mammary gland, brain, Zymbal gland, uterus, pancreas, testis, and thyroid gland (21). 
Occupational exposure of humans to BD is associated with an increased risk of leukemia, 
lymphatic, and hematopoietic cancer (23;24). Based on the above evidence, BD has been 
classified as a known human carcinogen in the Twelfth Annual Report on Carcinogens 
published by the National Toxicology Program (2011) (18).  
 Although the exact mechanisms of BD-mediated cancer are unknown, metabolic 
activation of BD to DNA-reactive intermediates is required for its genotoxic and 
carcinogenic activity (26). BD is initially metabolized by CYP 2E1 to (R,S)-3,4-epoxy-1-
butene (EB), which can be further oxidized to form 1,2,3,4-diepoxybutane (DEB) 
(Scheme 1.1) or hydrolyzed by EH to 1-butene-3,4-diol (EB-diol) (16). EB-diol can in 
turn undergo another CYP 2E1-mediated oxidation to 3,4-epoxy-1,2-butanediol (EBD) 
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(16) or alcohol dehydrogenase-mediated conversion to hydroxymethyl vinyl ketone 
(HMVK)(32) (Scheme 1.1). While all the three BD-derived epoxides are mutagenic (16), 
DEB is 30-fold more genotoxic than EB and 100-fold more mutagenic than EB-diol (34), 
probably due to its bifunctional nature that enables DEB to cross-link cellular 
biomolecules. Epoxide hydrolase-mediated hydrolysis appears to be the predominant 
pathway of metabolic deactivation of EB, DEB, and EBD in rats and humans (30).  
If not inactivated, BD-derived electrophilic metabolites can modify DNA 
nucleobases to give a wide range of adducts, including N-7-(2-hydroxy-3-buten-1-
yl)guanine (HB-Gua I), N-7-(1-hydroxy-3-buten-2-yl)guanine (HB-Gua II), and N-7-
(2,3,4-trihydroxy-3-buten-2-yl)guanine (THB-G) (Chart 1.2) (26). DNA alkylation by 
DEB initially produces 2-hydroxy-3,4-epoxybut-1-yl monoadducts (205), which can 
further react with another nucleophilic site to form exocyclic deoxyadenosine lesions 
such as 1, N
6
-(2-hydroxy-3,4-epoxybut-1-yl)-2'-deoxyadenosine (67;185), DNA-DNA 
cross links (46;47;64;68) (Chart 1.2), and DNA-protein cross links (192;193). 
Previous studies in laboratory animals have revealed significant species and 
gender differences in susceptibility to BD, which have been attributed to profound 
differences in metabolism. Specifically, laboratory mice developed tumors at ~ 200-fold 
lower BD concentrations than rats, supposedly a result of higher BD 
bioactivation/detoxification ratio in the mouse (21). Epoxide hydrolase-mediated 
hydrolysis of DEB was more efficient in human liver microsomes than in rat microsomes, 
while no hydrolysis was detected in mouse microsomes (30). Female mice were more 
susceptible to BD-mediated cancer than males exposed at the same conditions and 
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exhibited greater numbers of DNA-DNA cross-links (66). In contrast, hemoglobin adduct 
measurements in BD-exposed Czech workers suggested that females absorbed or 
metabolized BD to a lesser extent than males (84). If present, any interspecies and gender 
differences in metabolism of BD are critically important for human cancer risk 
assessment. 
Urinary metabolites can provide a sensitive, non-invasive measure of carcinogen 
metabolism to their ultimate tumorigenic species. As shown in Scheme 1.1, EB, EB-diol, 
and HMVK are excreted in urine as MHBMA, THBMA, and DHBMA, respectively 
(Scheme 1.1) (33;82;96;97;105;107;206). By analogy, DEB is expected to react with 
two molecules of glutathione and be excreted in urine as the corresponding bis-
mercapturic acid, 1,4-bis-(N-acetyl-L-cystein-S-yl)butane-2,3-diol (bis-BDMA, Scheme 
1.1). However, to our knowledge, such conjugates had not been previously detected. We 
hypothesized that bis-BDMA, if formed in vivo, can serve as a non-invasive biomarker of 
BD metabolism to its ultimate carcinogenic species, DEB. To test this hypothesis, we 
prepared synthetic bis-BDMA and developed an accurate isotope dilution HPLC-ESI
-
-
MS/MS method for its analysis in vivo. The new methodology was used to quantify bis-
BDMA and other BD-mercapturic acids (MHBMA, DHBMA, and THBMA) in urine of 
F344 rats exposed to 0-200 ppm BD, workers occupationally exposed to BD, and 
confirmed smokers. We also quantified DEB-induced DNA-DNA cross-links in liver 
tissues of the same BD-treated rats. Our results reveal pronounced interspecies and 
gender differences in the metabolic pathways of BD in rats and humans. 
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3.2 Materials and Methods 
Materials. N-acetyl-L-cysteine and HPLC-MS grade formic acid were purchased 
from Sigma Aldrich (St. Louis, MO). HPLC-MS grade acetonitrile was obtained from 
Fisher Scientific (Pittsburgh, PA). Isolute ENV+ 50 mg/1 mL SPE cartridges were 
purchased from Biotage (Charlotte, NC). R, R-Diepoxybutane was synthesized as 
reported previously (47). MHBMA, DHBMA, 
2
H6-MHBMA, 
2
H7-DHBMA, and
 2
H3-N-
acetyl-L-cysteine were obtained from Toronto Research Chemicals (Ontario, Canada). 
THBMA and 
2
H3-THBMA standards were available from a previous study (Chapter II) 
(206). Bis-BDMA and 
2
H6-bis-BDMA were synthesized in our laboratory as described 
below.  
Synthesis of 1,4-bis-(N-acetyl-L-cystein-S-yl)butane-2,3-diol (bis-BDMA) and 
its deuterated analogue (
2
H6-bis-BDMA). N-acetyl-L-cysteine (280 mg, 1.70 mmol) 
was dissolved in 8 mL of water, and the pH was adjusted to 10 with 1N NaOH. R, R-
Diepoxybutane (47) (75 mg, 0.85 mmol) was added, and the reaction mixture was stirred 
at room temperature for 4 hours. At the end of the reaction, sodium ions were removed by 
the addition of Bio-Rad AG 50W-X8 cation exchange resin, followed by filtration. Bis-
BDMA was isolated by semi preparative HPLC on an Agilent 1100 HPLC system 
interfaced to a DAD UV detector (Agilent Technologies, Santa Clara, CA). HPLC 
separation was achieved with a Synergi HydroRP column (250 mm × 10.00 mm; 4 µ) 
(Phenomenex, Torrance, CA) by isocratic elution with 6% acetonitrile in 0.1% 
trifluoroacetic acid/water. Under these conditions, bis-BDMA eluted as sharp peak at 
19.6 min. HPLC fractions containing bis-BDMA (19.0-20.2 min) were manually 
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collected and concentrated under vacuum to yield a white powder. 
2
H6-bis-BDMA was 
similarly synthesized starting with 
2
H3-N-acetyl-L-cysteine. 
 Bis-BDMA and 
2
H6-bis-BDMA were structurally characterized by NMR and high 
resolution mass spectrometry. 
1
H NMR of bis-BDMA (Figure 3.1): δ 8.3 (2H, s, cys-
NH), 4.4 (2H, m, αC-cys), 3.7 (2H, s, internal OH), 3.6 (2H, m, CHOH), 3.0-2.8 (4H, m, 
βC-cys), 2.7-2.5 (4H, m, SCH2), 1.9 (6H, s, COCH3). HRMS results (Figure 3.2): bis-
BDMA (ESI
-
-MS : 411.0905 [M-H]
-
 , MS/MS: 282.0468, 153.0042, and 128.0348); 
2
H6-
bis-BDMA (ESI
-
-MS : 417.1275 [M-H]
-
 , MS/MS: 285.0668, 153.0045, and 131.0544). 
Stock solutions of bis-BDMA and 
2
H6-bis-BDMA were prepared in water and stored at -
20 °C. 
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Figure 3.1 
1
H NMR spectra of bis-BDMA 
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Figure 3.2 UPLC-ESI
-
-TOF-MS/MS spectrum of bis-BDMA (A) and 
2
H6-bis-BDMA 
(B) 
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Animals and treatment. Male and female F344 rats (aged 27-29 days) were 
purchased from Charles River Breeding Laboratories (Raleigh, NC) and housed in cages 
with animal chow and water in temperature (72 ± 4°F) and humidity (50 ± 10%) 
controlled rooms with a 12-h light/dark cycle (NIH Publication 86-23, 1985) at the 
Environmental Exposure and Inhalation Health facility (EEIH, at the University of Texas 
Medical Branch at Galveston). After a 7 day acclimation period, the animals were 
randomly separated into air-control and exposure groups by weight. All procedures 
involving the use of animals were approved by the Institutional Animal Care and Use 
Committee. Rats were exposed whole-body to nominal 62.5 ppm or 200 ppm BD in air 
for 2 weeks (6 h/day, 5 days/week) in Hinnar exposure chambers. Rats in the third 
chamber received filtered air only as a control group. Stock BD (99+ %; from Air Gas 
Southwest, Texas City, Texas) was metered with a mass flow valve and diluted with 
HEPA filtered room air and then pumped into the exposure chambers. Fresh animal chow 
and water were provided to the rats during the exposure period. Following exposures, the 
left-over food and water were discarded, and animals were returned to their appropriate 
housing box until the next exposure. Monitoring of exposure atmosphere was achieved 
using a Shimadzu GC-17A gas chromatograph equipped with a DB-1 column and a FID 
detector.  
Groups of female and male rats (N = 4 per exposure level and sex) were randomly 
selected and transferred from exposure chambers into metabolic cages at the end of a 6 h 
exposure period on days 7 or 8 of BD exposure. Rats were held in metabolic cages, with 
access to food and water, until the next exposure period, when they were returned to 
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Hinnar exposure chambers. Urine excreted by individual rats during overnight housing in 
metabolic cages was placed in Eppendorf tubes, snap frozen, and stored at – 80 °C. At the 
end of the final exposure period, animals were euthanized via cardiac puncture. Liver and 
lung tissues were collected and immediately flash frozen in liquid nitrogen and stored at -
80 °C. Frozen rat urine samples and liver tissues were shipped on dry ice to the 
University of Minnesota, where they were stored at -80
 
°C until analysis. A total of 24 rat 
urine samples (N = 8 per exposure level; exposed to 0, 62.5ppm, 200 ppm BD for 2 
weeks) were analyzed. 
Human subjects. The formation of bis-BDMA was investigated in urine samples 
of smokers and occupationally exposed individuals. For occupational exposure study, 72 
subjects working in a BD production facility were included. Of these, 40 were controls 
(administrative workers) and 32 were BD production workers. BD exposures in workers 
were determined by personal monitoring tubes for 8 h work shifts on 10 separate 
occasions over a 4-month interval for each study subject. Ambient air samples were also 
analyzed for BD concentrations. Details of the occupational exposure study have been 
reported previously (85). The experimental protocol was approved by the Institutional 
Review Boards at Regional Institute of Hygiene of Central Bohemia and the University 
of Vermont. Archived urine samples were shipped to the University of Minnesota on dry 
ice and stored at – 80 °C.  
Smoker urine samples (N = 36) were obtained from the University of Minnesota 
Tobacco Research Programs and University of Hawaii Cancer Center and stored at – 80 
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°C. Smoking status was confirmed by cotinine analysis. These samples were blinded 
since they are part of an ongoing large epidemiological study. 
 Quantitation of bis-BDMA. Urine samples (100 μL) were vortexed and diluted 
with 100 μL of 50 mM ammonium formate buffer (pH 2.5) and 10 μL of formic acid. 
2
H6-bis-BDMA (internal standard, 60 ng) was added, and the samples were mixed and 
centrifuged at 13,000 rpm for 15 minutes. The supernatant was loaded onto Isolute ENV+ 
cartridges (1 mL/50 mg) pre-conditioned with methanol (3 ml) and 0.3% formic acid (3 
ml). The cartridges were then washed with 1.5 mL of 0.3% formic acid, followed by 0.75 
mL of 5% methanol in 0.3% formic acid, and allowed to dry completely under vacuum 
for 20 minutes. Bis-BDMA and its internal standard were eluted with 1.2 mL of 2% 
formic acid in methanol. SPE eluates were dried under vacuum and reconstituted with 30 
μL of water. Typically, 3 μL of this solution was injected onto the HPLC column for 
HPLC-ESI
-
-MS/MS analysis. 
HPLC-ESI
-
-MS/MS analysis of bis-BDMA was conducted with an Agilent 1100 
HPLC system (Agilent Technologies, Santa Clara, CA) coupled to a Thermo-Finnigan 
TSQ Quantum Discovery mass spectrometer (Thermo Scientific Corp., Waltham, MA). 
HPLC separations were carried out on a SIELC Primesep D column (2.1 x 100 mm, 5 μm 
particle size) equipped with a guard column (Primesep D; 2.1 x 10 mm). The column was 
maintained at 50 °C and eluted with a gradient of water (Solvent A) and 1% formic acid 
in 50% acetonitrile (Solvent B), at a flow rate of 200 µl/min. Gradient program was as 
follows (Time, % of solvent B): 0-8 min, 40 to 48% B; 8-10 min, 48 to 75% B; 10-13 
min, isocratic at 75% B; 13-15 min, 75 to 40% B; 15-25 min, finally maintained at 40% 
 104 
 
B. The flow was directed into the MS detector only during 4.5-10 min of the 
chromatographic run.  
The TSQ Vantage triple quadrupole instrument (Thermo Scientific), was operated 
in the negative electrospray ionization (ESI
-
) mode. Typical MS parameters were as 
follows: spray voltage, - 3500 V; sheath gas pressure, 50 psi; capillary temperature, 250° 
C; collision energy, 16; source CID, -9 V; collision gas pressure, 1.0 mTorr; Q1(FWHM), 
0.4; Q3 (FWHM), 0.7; scan width , 0.4 m/z; and scan time, 0.4 s. The MS parameters we 
optimized by direct infusion of authentic standards and may differ between runs. The 
mass spectrometer was operated in the selected reaction monitoring (SRM) mode. The 
SRM transitions used for quantification of bis-BDMA were: m/z 411.1 → 282.1 (bis-
BDMA) and m/z 417.1 → 285.1 (2H6-bis-BDMA). For confirmation purposes, additional 
SRM transitions were also monitored (m/z 411.1 → 153.1, 411.1 → 128.1 for bis-BDMA 
and m/z 417.1 → 153.1, 417.1 → 131.1 for 2H6-bis-BDMA).  
HPLC-ESI-MS/MS Method validation for bis-BDMA. The standard curves for 
HPLC-ESI-MS/MS analysis of bis-BDMA were constructed by analyzing standard 
solutions containing 0.05-160 ng of bis-BDMA and 6 ng of 
2
H6-bis-BDMA, in triplicate. 
The amounts of bis-BDMA observed were calculated by comparing the peak area ratios 
between the analyte and the internal standard. Regression analyses were conducted to 
determine the correlation between the expected and experimentally observed bis-BDMA 
amounts. Method calibration curves were constructed by spiking control rat urine 
samples (100 µl) with 0.5 - 1600 ng of bis-BDMA and 60 ng of 
2
H6-bis-BDMA in 
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triplicate, followed by SPE and HPLC-ESI-MS/MS analysis. The observed bis-BDMA 
amounts were plotted against the theoretical values (ng/ml). 
The limit of detection (LOD) and the limit of quantification (LOQ) of the HPLC-
ESI-MS/MS method for bis-BDMA were determined by addition of 10-500 pg of bis-
BDMA and 60 ng of 
2
H6-bis-BDMA to 100 µl of control rat urine. These fortified urine 
samples were processed by SPE and analyzed by the validated HPLC-ESI-MS/MS 
method as described below. The lowest concentration of bis-BDMA which gave a S/N > 
10 and % CV < 15% was reported as the LOQ, while the lowest concentration of bis-
BDMA which gave S/N > 3 was reported as the LOD.  
In order to determine the precision and accuracy of the analytical method, control 
rat urine (100 μL) was spiked with 100 ng of bis-BDMA and 60 ng of 2H6-bis-BDMA, 
followed by SPE and analysis by HPLC-ESI
-
-MS/MS three times per day on three 
consecutive days. The relative standard deviations between these measurements were 
calculated and reported as intra-day and inter-day precision, while the accuracy range 
was determined from the equation (100 x Cm)/Cs by comparing each of the nine 
concentration measurements (Cm) to the actual concentration spiked (Cs). 
Extraction recovery of the SPE method was determined from the equation: Rb/Ra 
x 100% where Rb is the relative response ratio calculated from HPLC-ESI
-
-MS/MS peak 
areas of analyte and the internal standard obtained upon analyzing control rat urine 
samples spiked with 100 ng of analyte prior to SPE and 60 ng of internal standard post-
extraction (n = 3) and Ra is the corresponding relative response ratio obtained from the 
analysis of same control rat urine sample spiked with same amounts of analyte and the 
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internal standard mentioned above post SPE (n = 3).  Analyte signal suppression in the 
presence of urine matrix was evaluated from the equation (100-(100 x Am)/As) where Am 
is the peak area of the analyte or internal standard obtained by SPE and HPLC-ESI
-
-
MS/MS analysis of control rat urine spiked with 100 ng of analyte and 60 ng of internal 
standard and As is the corresponding peak area of the analyte or internal standard 
obtained by HPLC-ESI-MS/MS analysis of a pure standard mix containing 100 ng of 
analyte and 60 ng of internal standard. 
 Quantitative analysis of MHBMA, DHBMA and THBMA. Urine samples (200 
μL) were spiked with 60 ng of each 2H6-MHBMA and 
2
H7-DHBMA and processed by 
SPE on Waters HLB cartridges. The SPE eluates were dried, reconstituted in 30 μL of 
0.1% formic acid, and analyzed by HPLC-ESI
-
-MS/MS with a Pursuit 3 Diphenyl (2.1 x 
150 mm, 3 µm) column eluted with a gradient of 0.1% formic acid and acetonitrile 
(Kotapati and Tretyakova, manuscript in preparation). For THBMA analysis, urine 
aliquots (100 μL) were spiked with 2H3-THBMA and processed by Isolute ENV+ SPE as 
described previously (206). The gradient program was modified as follows (Time, % of 
solvent B): 0-6 min, 15 to 21% B; 8-10 min, 21 to 75% B; 10-13 min, isocratic at 75% B; 
13-15 min, 75 to 15% B; 15-25 min, finally maintained at 15% B.  
Determination of bis-N7G-BD in rat liver DNA. NanoHPLC-NSI
+
-MS/MS 
methodology developed in our laboratory (68) was used to quantify DEB-induced bis-
N7G-BD crosslinks in liver DNA of rats exposed to 0, 62.5 or 200 ppm BD by 
inhalation. In brief, DNA was extracted with NucleoBond AXG500 anion exchange 
cartridges (Machery-Nagel, Düren, Germany). DNA concentrations and purity were 
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determined by HPLC-UV analysis of dG in enzymatic digests. DNA (100 µg) was spiked 
with 50 fmol of racemic 
15
N10-bis-N7G-BD (internal standard) and subjected to neutral 
thermal hydrolysis at 70 
°
C for 1 hour to release N7-guanine adducts as free bases. 
Partially depurinated DNA was removed by ultrafiltration. Bis-N7G-BD and its internal 
standard were enriched by offline HPLC and reconstituted in 0.01% aqueous acetic acid. 
Samples (8 µl) were injected onto a trap column (Symmetry C18 nanoAcquity, 0.18 × 20 
mm, Waters Corp., Millford, MA) connected to a manually packed Zorbax SB-C18 nano 
HPLC column (75 μm x 200 mm, 5μ), which was eluted with 0.01% acetic acid in 1:1 
methanol:acetonitrile at a flow rate of 0.4 µl/min. Bis-N7G-BD adducts were quantified 
by isotope dilution HPLC-ESI
+
-MS/MS. The SRM transitions for bis-N7G-BD and 
15
N10-bis-N7G-BD were m/z 389.1 [M + H]
+
 → m/z 238.1 [M + H − Gua]+) and m/z 
399.1 [
15
N10-M+H]
+
 → m/z 243.1 [M + H − [15N5]Gua]
+
, respectively. Accurate 
quantitation of bis-N7G-BD was achieved by comparing the areas of nanoHPLC-NSI
+
-
MS/MS peaks corresponding to the analyte and its internal standard using standard 
curves (68). 
3.3 Results 
3.3.1 Development of HPLC-MS/MS methodology for bis-BDMA 
It has been proposed that susceptibility of a given organism towards BD-induced cancer 
can be determined from the extent of metabolic activation of BD to its ultimate 
carcinogenic metabolite, DEB (113). In support of this notion, we have previously 
observed that DNA of laboratory mice (more sensitive species) contained 5-10-fold 
greater numbers of DEB-specific bis-N7G-BD adducts than rats (less sensitive species) 
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exposed at the same conditions (66). However, human tissue and blood samples are not 
readily available. We therefore examined the feasibility of using urinary bis-BDMA as a 
novel, non-invasive biomarker of BD bioactivation to DEB.  
Authentic standards of bis-BDMA and its deuterated analogue were prepared by 
reacting DEB with N-acetyl-L-cysteine and 
2
H3-N-acetyl-L-cysteine, respectively. Both 
standards were characterized by high resolution mass spectrometry and proton NMR 
(Figures 3.1 and 3.2) and were used for the development of a sensitive and specific 
isotope dilution HPLC-ESI-MS/MS method for bis-BDMA in urine. In our approach, bis-
BDMA is isolated by solid phase extraction (SPE) and quantified by negative ion HPLC-
ESI-MS/MS using isotope dilution with the corresponding deuterated internal standard 
(
2
H6-bis-BDMA).  
Our HPLC-MS/MS method for bis-BDMA is based on selected reaction 
monitoring of MS/MS transitions corresponding to C-S bond cleavage (m/z 411 → 281.1 
for the analyte and m/z 417 → 285.1 for the deuterated internal standard, respectively, see 
Figure 3.2). Analysis of standard solutions containing a fixed amount of 
2
H6-bis-BDMA 
internal standard and increasing amounts of bis-BDMA confirmed that HPLC-ESI
-
-
MS/MS responses were linear between 0.05-160 ng of bis-BDMA (on column) (Figure 
3.3 A). Further method validation was conducted by spiking control rat urine sample (100 
µl) with 60 ng of 
2
H6-bis-BDMA and 0.5-1600 ng of bis-BDMA, followed by SPE and 
HPLC-ESI
-
-MS/MS analysis (Figure 3.3 B). Excellent correlation between the measured 
and expected concentrations of bis-BDMA was observed (Figure 3.3 B) (R
2
 = 0.9999). 
The limit of detection (LOD) and the limit of quantification (LOQ) for bis-BDMA in 
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urine were determined to be 1 and 5 ng/ml, respectively (Table 3.1). The intra-day and 
inter-day precision (% RSD) determined by repeated analysis of bis-BDMA (100 ng) 
spiked into control rat urine sample (100 µl) were 0.88 and 1.17%, respectively. 
Comparison of analyte or internal standard peak areas in buffer and analyte/internal 
standard spiked into control urine matrix (post SPE) revealed very moderate (< 2%) 
signal suppression of the analyte by the sample matrix. Method accuracy was observed to 
be 96.2-100.5%. Complete HPLC-ESI
-
-MS/MS method validation parameters are 
compiled in Table 3.1.  
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Figure 3.3 Standard and method validation curves for bis-BDMA  
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Table 3.1 Validation parameters for HPLC-ESI
-
-MS/MS analysis of bis-BDMA 
 
Range 
(ng/ml) 
LOD 
(ng/ml) 
LOQ 
(ng/ml) 
Intra-day 
precision (%) 
Inter-day 
Precision (%) 
Accuracy 
(%) 
Extraction 
Recovery (%) 
 
5-16,000 
 
1.0 
 
5.0 
 
0.88 
 
1.17 
 
98.04 
 
46 
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3.3.2 Quantification of BD-mercapturic acids in urine of F344 rats exposed to BD by 
inhalation  
The new HPLC-ESI-MS/MS methodology described above was used to quantify bis-
BDMA in urine of male and female F344 rats (N = 4 per exposure level and sex) treated 
with 0, 62.5, or 200 ppm BD by inhalation for 2 weeks (6 h/day, 5 days/week). Other 
BD-mercapturic acids were also determined in the same samples. No bis-BDMA was 
detected in urine of control rats exposed to air (Figure 3.4 A), and a concentration-
dependent increase in bis-BDMA amounts was observed in animals exposed to 62.5 ppm 
and 200 ppm BD (Figures 3.4 B and 3.5 A). The identity of bis-BDMA observed in rat 
urine was further confirmed by examining two additional MS/MS transitions and by re-
analyzing the samples on a different HPLC column (Synergi Hydro-RP). Mean urinary 
concentration of bis-BDMA following exposure to 200 ppm BD was 4.8 ± 2.9 µg/ml 
urine, while the concentrations of MHBMA, DHBMA and THBMA in the same samples 
were 77.9 ± 37.8 µg/ml, 209.5 ± 85.1 µg/ml, and 150.3 ± 59.9 µg/ml, respectively 
(Figures 3.5 B-D). Urinary BD-mercapturic acid concentrations correlated with BD 
exposure, with 2-3 fold higher amounts observed in 200 ppm BD exposure group as 
compared to 62.5 ppm exposure group (Figure 3.5). Urine of unexposed rats contained 
background levels of MHBMA (68.5 ± 17.1 ng/ml), DHBMA (3192.7 ± 533.2 ng/ml) 
and THBMA (561.7 ± 81.7 ng/ml), but no bis-BDMA. This is consistent with previous 
studies that have revealed the presence of these metabolites in unexposed animals and 
human subjects due to an unidentified endogenous source (96;97;206).  
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Urinary bis-BDMA concentrations tended to be 2-3 fold higher in female rats as 
compared to the male animals exposed under the same conditions but the difference was 
only marginally significant (Figure 3.5A, p = 0.06). In contrast, female rats excreted 
slightly lower levels of MHBMA, DHBMA and THBMA as compared to males, although 
these differences were not statistically significant (p > 0.3, Figures 3.5B-D). These results 
suggest that the metabolic pathways of BD are distinct in female vs male animals, 
supposedly a result of hormonal effects on xenobiotic metabolizing enzymes. 
The relative concentrations of the four BD-mercapturic acids in urine of BD-
exposed rats were DHBMA (47%) > THBMA (37%) > MHBMA (15%) > bis-BDMA (1 
%) (Figure 3.6A). These results are consistent with previous studies that examined BD-
induced hemoglobin adducts in blood of rats exposed by inhalation (88). Similar 
DHBMA/THBMA/MHBMA/ bis-BDMA metabolic ratios were observed in animals 
treated with 62.5 and 200 ppm BD, but the contribution of bis-BDMA were consistently 
higher in females (1.6-2%) as compared to males (0.6 %). 
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Figure 3.4 HPLC-ESI
-
-MS/MS analysis of bis-BDMA in urine of control (A) and BD 
exposed (B) F344 rats 
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Figure 3.5 Dose response relationships for bis-BDMA, MHBMA, DHBMA and 
THBMA in urine of F344 rats exposed to 0-200 ppm BD  
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Figure 3.6 Inter-species differences in BD metabolism between rats and humans 
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3.3.3 Quantification of BD-mercapturic acids in urine of smokers and 
occupationally exposed workers 
To examine the possibility of DEB and bis-BDMA formation in humans, two populations 
chronically exposed to BD were examined: smokers and occupationally exposed 
individuals. Workers at a BD polymer production plants (N = 32) were exposed to 0.1 - 2 
ppm BD, while the corresponding controls (office workers, N = 40) were exposed to < 
0.02 ppm BD. Current smokers (N = 36) were exposed to BD due to its presence in 
cigarette smoke (~ 46 μg/ cigarette in main-stream smoke and 283 μg/cigarette in side-
stream smoke). For comparison, the other three urinary BD-mercapturic acids (MHBMA, 
DHBMA and THBMA) were also analyzed. The high sensitivity and specificity of our 
HPLC-ESI-MS/MS method has enabled us to use small volumes of urine (100-200 µl) 
for these analyses. Bis-BDMA concentrations in both groups were below the limit of 
detection of our method (1 ng/ml) (Figure 3.7A); it was not detectable even when a more 
sensitive capillary HPLC-ESI-MS/MS method was employed (LOD, 0.1 ng/ml), (Figure 
3.7B) or when larger urine samples were analyzed (up to 1 ml). Relative contributions of 
MHBMA, DHBMA, THBMA and bis-BDMA to the total urinary BD- mercapturic acids 
excreted by smokers were 2, 93, 5 and <0.1%, respectively (Figure 3.6B). DHBMA was 
the major BD metabolite excreted in human urine (93%), followed by THBMA and 
MHBMA. These results are consistent with previous studies in liver microsomes and 
hemoglobin adduct measurements that suggested that BD metabolism to DEB is less 
efficient in humans than in rats and mice (26;89). These results indicate that the 
metabolic pathways of BD in humans are distinct from those in laboratory mice and rats. 
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Figure 3.7 HPLC-ESI
-
-MS/MS analysis of bis-BDMA in human urine using narrow bore 
(A) and capillary (B) HPLC methods 
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3.3.4 Dose response studies of DEB-derived bis-N7G-BD adducts in rat liver DNA 
In order to examine the correlation between urinary metabolite and DNA-bound DEB, 
DEB-specific bis-N7G-BD adducts were quantified in liver DNA of laboratory rats 
exposed to BD by inhalation. Ultra-sensitive nanoHPLC-nanoESI
+
-MS/MS methodology 
recently reported by our group was employed (68). In brief, DNA was spiked with 
15
N10- 
bis-N7G-BD internal standard and subjected to neutral thermal hydrolysis to release bis-
N7G-BD as a free base conjugates, which were enriched by off-line HPLC (68). As 
expected, no bis-N7G-BD was detected in control animals (Figure 3.8A), while BD-
exposed animals contained significant amounts of the cross-link (Figure 3.8B). 
Interestingly, dose-response relationships for bis-N7G-BD adducts in rat liver were not 
linear, with highest levels of the cross-links observed following exposure to 62.5 ppm BD 
(1.4 adducts/10
8
 nucleotides) (Figure 3.8C). As was the case with bis-BDMA, female rats 
had higher numbers of bis-N7G-BD adducts (1.6 adducts/10
8
 nucleotides) as compared to 
males (1.2 adducts/10
8
 nucleotides) at 62.5 ppm BD exposure, but this difference was not 
statistically significant (Figure 3.8). 
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Figure 3.8 nanoHPLC-NSI
+
-MS/MS analysis of bis-N7G-BD in liver DNA of control 
(A) and BD exposed (B) F344 rats and dose-response relationship (C) 
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3.4 Discussion 
A potent human and animal carcinogen, BD is metabolically activated to four 
electrophilic species: EB, HMVK, EBD, and DEB (Scheme 1.1) (16;32). Among these, 
DEB displays the greatest genotoxicity in vitro and has been hypothesized to be the 
ultimate carcinogenic metabolite of BD (16). DEB is 50-fold more effective at inducing 
sister chromatid exchanges and chromosomal aberrations in human lymphocytes than EB 
(207;208) in vitro and is two orders of magnitude more mutagenic than EB and EBD in 
TK6 lymphoblasts (Table 1.4) (34). More efficient DEB formation from BD in laboratory 
mice is thought to be responsible for their increased sensitivity to BD-induced lung and 
liver cancer as compared to laboratory rats (66;196). Previous studies of DEB formation 
in humans are limited, although experiments with human liver microsomes suggest that 
any DEB produced in humans is rapidly detoxified via epoxide hydrolase-catalyzed 
hydrolysis (29). 
Urinary mercapturic acids are commonly used as biomarkers of exposure to 
carcinogens and as a measure of their metabolic activation to DNA-reactive intermediates 
(209). In the present work, bis-BDMA was employed as a novel urinary biomarker for 
DEB formation form BD. To our knowledge, bis-BDMA has not been previously 
reported in vivo, although Boogaard et al. detected the formation of a conjugation product 
of DEB with two molecules of glutathione following in vitro incubation of DEB with 
radiolabeled glutathione in human liver cytosolic tissue fractions (94). Analogous bis-
glutathione conjugates have been also reported for other bis-electrophiles such as 
hexachloro-1,3-butadiene (210), vinyledene chloride (211), and 1,2-dibromoethane (212). 
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Such conjugates are formed via consecutive reactions of the two electrophilic groups with 
two molecules of glutathione. While the first reaction is catalyzed by glutathione S-
transferases, the second conjugation step may be either spontaneous or enzymatic (212). 
The resulting bis-glutathion-S-yl conjugates undergo further processing by 
glutamyltransferases, cysteinyl-glycinases, and acetylases in the kidney (mercapturic acid 
pathway) and are excreted in urine as the corresponding bis-N-acetylcysteine conjugates.  
The availability of specific urinary biomarkers for DEB, EB, HMVK, and EBD 
(bis-BDMA, MHBMA, DHBMA, and THBMA, respectively, Scheme 1.1), has enabled 
us to evaluate the formation of all four electrophilic metabolites of BD in vivo (BD-
exposed rats and humans exposed to BD in the workplace or via smoking). While 
MHBMA, DHBMA, and THBMA were observed in both species, bis-BDMA was 
detected only in BD-treated rats, but not in BD-exposed humans. Furthermore, the 
metabolic ratios differed dramatically between the two species. In humans, DHBMA 
accounted for 93% of total urinary BD-mercapturic acids (Figure 3.6B), while the other 
three BD-mercapturic acids were much less abundant, with THBMA at 5%, MHBMA at 
2%, and bis-BDMA at < 0.1% (Figure 3.6B). In contrast, in the rat, DHBMA accounted 
for only 47% of metabolites, closely followed by THBMA (37%). In the latter species, 
MHBMA comprised for 15% and bis-BDMA for 1% of BD-mercapturic acids excreted 
(Figure 3.6A). Although in the present study, humans were exposed to lower 
concentrations of BD that rats, the sensitivity of our HPLC-ESI-MS/MS methodology 
(LOD, 0.1 ng/ml urine for the capillary method) should have been more than sufficient to 
detect bis-BDMA if it was produced in human urine similar to rats. By comparison, EB, 
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EBD, and DEB in blood of rats exposed to 62.5 ppm or 200 ppm BD followed a similar 
order EB-diol (DHBMA) > EBD (THBMA) > EB (MHBMA) > DEB (bis-BDMA). 
Furthermore, the relative abundance of the corresponding hemoglobin adducts in blood of 
BD-exposed rats was THB-Val (from EBD) > HB-Val (from EB) > pyr-Val (from DEB) 
(26). Overall, results from these studies are consistent with significant interspecies 
differences in BD metabolism between humans and laboratory rats, which are commonly 
used as a model organism for human risk assessment from exposure to BD.  
Background amounts of MHBMA (68.5 ± 17.1 ng/ml), DHBMA (3192.7 ± 533.2 
ng/ml) and THBMA (561.7 ± 81.7 ng/ml) were observed in urine of control animals 
exposed to filtered air only. This finding is consistent with a previous report by Mcdonald 
et al. who detected MHBMA and DHBMA in urine of control F344 rats (10 and 1,500 
ng/ml, respectively) (97). Georgieva et al. also observed significant background levels of 
the corresponding hemoglobin adducts (HB-Val and THB-Val) in F344 control rats 
(73;88), suggesting that there is a significant endogenous source of these metabolites in 
mammals. In our recent paper (206), we observed significant amounts of THBMA in 
urine of non-smokers (16.3 ng/ml), although smokers excreted higher amounts of this 
metabolite (30.7 ng/ml). In contrast, DEB-specific biomarker adducts bis-N7G-BD 
(Figure 3.8) and pyr-Val were not detected in control animals (73;88).  
Our results reveal that female F344 rats excrete higher concentrations of DEB-
specific metabolite than males (Figure 3.5A). Consistent with this observation, liver DNA 
of female animals contained higher concentrations of DEB-specific bis-N7G-BD cross-
links as compared to males (Figure 3.8C). We have previously reported that bis-N7G-BD 
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formation was influenced by gender in a larger study that examined dose-dependent DNA 
adduct formation in BD-exposed mice and rats (66). Furthermore, Boysen et al. reported 
that the concentrations of DEB-specific hemoglobin adducts (pyr-Val) were 2-4 fold 
higher in female rats as compared to males following exposure to 1000 ppm BD (77), 
although no gender differences were observed following 200 ppm BD exposure (66;88). 
Increased formation of DEB in females may be responsible for their enhanced 
susceptibility towards BD-induced cancer as revealed in animal inhalation studies (20). 
Therefore, future studies are needed to evaluate gender differences in metabolism of BD. 
To evaluate the correlation between urinary metabolites of DEB and the amounts 
of diepoxide bound to genomic DNA, DEB-specific DNA-DNA cross-links (bis-N7G-
BD) were quantified in liver DNA of the same BD-exposed rats (Figure 3.8). Unlike 
linear curve observed for bis-BDMA, bis-N7G-BD followed a more complex dose-
response relationship, with the highest adduct numbers observed at a medium exposure 
levels (62.5 ppm BD, see Figure 3.8C).  
It has been previously hypothesized that the metabolic activation of EB to DEB in 
the rat is saturated at high BD concentrations (> 62.5 ppm)(66;213). Our data for urinary 
bis-BDMA in the same animals is not consistent with this hypothesis, since bis-BDMA 
amounts continue to increase following inhalation exposure to 62.5 and 200 ppm BD 
(Figure 3.5A).  
An alternative explanation for bis-N7G-BD adduct levels decrease in the high 
exposure group includes the induction of DNA damage response and oxidative stress 
pathways. These cellular stress responses could include cell cycle arrest, senescence, and 
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cell death (214;215). Such dose-related apoptosis is expected to reduce measurable DNA 
adduct levels by removing affected cells from the population. In addition, cell cycle arrest 
induced by BD-DNA damage could induce DNA repair by influencing the levels of gene 
expression (216). Indeed, Rusyn et al. have observed significant epigenetic changes in 
rats exposed to BD (217). For example, such changes could involve the p53 gene that 
codes for a transcription factor for the DNA damage response pathway and mediates 
apoptosis in DEB-exposed cells (218). These possibilities should be investigated in 
further studies. 
In summary, the current study for the first time establishes bis-BDMA as a novel 
urinary biomarker of BD bioactivation to DEB in the rat. Unlike other BD-mercapturic 
acids, bis-BDMA is not present in urine of unexposed animals, suggesting that it is a 
specific biomarker of exposure to BD. Furthermore, since bis-BDMA was detected in rats 
exposed to BD by inhalation, but not in occupationally exposed workers or smokers, 
humans appear to be less efficient than rats in respect to metabolizing BD to DEB, 
revealing interspecies differences in metabolism of BD that may be relevant to human 
risk assessment.  
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IV. DEVELOPMENT OF A HIGH THROUGHPUT HPLC-ESI--MS/MS 
METHOD FOR QUANTIFICATION OF URINARY METABOLITES OF BD IN 
HUMANS AND DISCOVERY OF ETHNIC/RACIAL DIFFERENCES IN 
METABOLISM OF BD 
4.1 Introduction 
1,3-butadiene (BD) is a high volume industrial chemical widely used as a monomer in the 
production of synthetic rubber and plastics (18). BD is also an intermediate for the 
manufacture of other industrial chemicals (18). The primary sources of exposure of 
general population to BD include automobile exhaust, forest fires, urban air, and cigarette 
smoke (18). Among these, cigarette smoke contains relatively high quantities of BD (16-
75 μg/cigarette in main-stream smoke and 205-361 μg/cigarette in side- stream smoke 
(19). Inhalation studies in laboratory mice and rats have shown that BD induces tumors in 
multiple tissues including lung, heart, liver and mammary gland (20;21). Epidemiological 
studies in rubber industry and BD production workers have revealed a strong association 
between BD exposure and the development of leukemia, lymphatic, and hematopoietic 
cancers (22-24). Based on this evidence, BD has been classified as a human carcinogen 
by the National Toxicology Program, EPA and IARC (18;26). 
  BD requires metabolic activation to electrophilic epoxides for its mutagenic 
activity (16;206). CYP2E1 and CYP2A6 monoxygenase-mediated oxidation of BD 
produces (R)- and (S)-3,4-epoxy-1-butene (EB), which can be hydrolyzed to 3,4-epoxy-
1,2-butanediol (EBD). EB can undergo further oxidation to 1,2,3,4-diepoxybutane (DEB) 
or epoxide hydrolysis and oxidation to hydroxymethyl vinylketone (HMVK) (Scheme 
1.1) (27;29;32). If not detoxified by epoxide hydrolase (EH) or glutathione S-transferase 
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(GST), BD-derived epoxides EB, EBD and DEB can alkylate DNA to form mutagenic 
covalent DNA adducts (16;26;30). The glutathione conjugates of EB, HMVK, EBD and 
DEB are further modified by γ-glutamyltranspeptidase, cysteinylglycine dipeptidase, and 
cysteine S-conjugate N-acetyltransferase (110), and are ultimately excreted in urine as 2-
(N-acetyl-L-cystein-S-yl)-1-hydroxybut-3-ene/1-(N-acetyl-L-cystein-S-yl)-2-hydroxybut-
3-ene (MHBMA), 4-(N-acetyl-L-cystein-S-yl)-1,2-dihydroxybutane (DHBMA), 4-(N-
acetyl-L-cystein-S-yl)-1,2,3-trihydroxybutane (THBMA), and  1,4-bis-(N-acetyl-L-
cystein-S-yl)butane-2,3-diol (bis-BDMA), respectively (Scheme 1.1) (31;110;206). 
  Because they are derived from toxic and carcinogenic metabolites of BD, urinary 
mercapturic acids are useful biomarkers of BD exposure and bioactivation (82;85;99). 
Among the four BD mercapturic acids, MHBMA is regarded as a specific biomarker of 
BD exposure because urinary MHBMA concentrations decrease by more than 90% upon 
smoking cessation (33). In contrast, DHBMA and THBMA were present in urine of both 
smokers and non-smokers, suggesting that they are at least partially formed from an 
unknown endogenous source (33;96;206). bis-BDMA, a specific biomarker of DEB, is 
not detectable in urine of smokers and workers occupationally exposed to BD, probably 
because of the inefficient formation of DEB in humans (Chapter III). The 
MHBMA/(MHBMA+DHBMA) metabolic ratio has been previously used as relative 
measure of BD activation because it reflects the portion of EB that is not detoxified via 
epoxide hydrolysis and is available for binding to biomolecules (85;96). Several mass 
spectrometry-based methods have been developed for quantification of MHBMA and 
DHBMA in human urine (31;33;96;97;99;102;104;105;107). However, many of these 
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methods (Table 1.5) require a large sample volume (> 1 ml) and are not amenable to high 
throughput analyses.  
  As discussed in section 1.1.2, there are significant differences in lung cancer risk 
among ethnic groups (9;14). Haiman et al. reported the lung cancer risk among five 
different ethnic groups as: African American > Native Hawaiian > European American > 
Japanese American > Latin American smokers (14). It has been proposed that these 
differences in risk are because of differences in metabolic activation and detoxification of 
tobacco carcinogens (9;14). Hence, it is important to determine whether there are 
differences in metabolism of BD in smokers belonging to different ethnic groups. Ethnic 
differences in BD metabolism would manifest in variation of MHBMA, DHBMA 
concentrations and their metabolic ratio among different ethnic/racial groups. 
  In the present study, a sensitive HPLC-ESI
-
-MS/MS method for simultaneous 
quantification of MHBMA and DHBMA in human urine was developed. The method 
requires only 150-200 µl of urine and employs a 96 well plate high throughput SPE 
cleanup amenable for processing multiple samples at the same time. The new method has 
high sensitivity, with LOQ values of 0.5 and 10 ng/ml for MHBMA and DHBMA, 
respectively. The intra-day and inter-day precision (%RSD) was < 5% for both analytes, 
confirming the reproducibility of our method. This method was applied to urine samples 
from workers employed at a BD and styrene-butadiene rubber manufacturing facility in 
Czech Republic (85). THBMA concentrations were also determined in the same urine 
samples by a previously published method by our laboratory (206). We found that the 
concentrations of MHBMA, DHBMA, and THBMA were significantly higher in  
 129 
 
workers occupationally exposed to BD as compared to the controls, suggesting that BD-
mercapturic acids can be used as sensitive biomarkers of BD exposure and bioactivation. 
Furthermore, the concentrations of MHBMA and DHBMA were also determined in 
smokers belonging to different ethnic groups in two separate multi-ethnic cohort studies. 
Significant differences in MHBMA concentrations were observed, suggesting that the 
metabolism of BD is different among ethnic/racial groups. 
4.2 Materials and Methods 
  Materials. MHBMA, DHBMA, 
2
H6-MHBMA and 
2
H7-DHBMA were purchased 
from Toronto Research Chemicals (Toronto, Canada). THBMA and 
2
H3-THBMA were 
synthesized in our laboratory as described previously (206). HPLC grade methanol, LC-
MS grade formic acid and acetonitrile were obtained from Fisher Scientific (Pittsburgh, 
PA). All other reagents and chemicals were obtained from Sigma Aldrich (St. Louis, 
MO). Oasis HLB SPE 96 well plates (30 mg) were purchased from Waters Corporation 
(Milford, MA) and Isolute ENV+ 96 well plates (50 mg) were obtained from Biotage 
(Charlotte, NC).  
  Sample preparation. Urine samples (200 µl) were diluted with 200 µl of water 
and acidified with 20 µl of 1 N hydrochloric acid. 
2
H6-MHBMA and 
2
H7-DHBMA 
internal standards (60 ng each) were added, and the spiked samples were vortexed and 
centrifuged. The supernatant was loaded onto an Oasis HLB 96 well plate (30 mg) pre-
conditioned with 1 ml methanol and 1 ml of water. The SPE wells were washed with 1 ml 
of 5% methanol. MHBMA, DHBMA, 
2
H6-MHBMA and 
2
H7-DHBMA were eluted into a 
96 well elution plate with 75% methanol. The eluates were completely dried under 
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vacuum and reconstituted with 30 µl of 0.1% formic acid for analysis by HPLC-ESI
-
-
MS/MS methodology as described below. 
  For analysis of THBMA, 100 µl aliquots of human urine were processed by 
Isolute ENV+ 96 well plate (50 mg) by the SPE methodology described previously (206). 
Briefly, 100 µl aliquots of urine were acidified with 100 µl of 50 mM ammonium formate 
buffer (pH 2.5) and 10 μL of formic acid. 2H3-THBMA internal standard (60 ng) was 
added to the acidified sample, followed by thorough mixing by vortexing. The samples 
were centrifugated, and the supernatants were loaded onto an Isolute ENV+ 96 well plate 
pre-conditioned with 3 ml each of methanol and 0.3% formic acid. The well plates were 
washed with 1.5 mL of 0.3% formic acid and further with 0.75 mL of 5% aqueous 
methanol containing 0.3% formic acid. The well plates were dried completely under 
vacuum, and the analyte and its internal standard were eluted with 1.2 ml of 2% formic 
acid in methanol into a 96 well elution plate. The elution plate was dried under vacuum, 
and the eluates were reconstituted in 30 µl of water. THBMA concentrations were 
determined by isotope dilution HPLC-ESI
-
-MS/MS as described below. 
 HPLC-ESI
-
-MS/MS method for quantification of MHBMA and DHBMA. 
The HPLC-ESI
-
-MS/MS system consisted of an Agilent 1100 HPLC system (Agilent 
Technologies, Santa Clara, CA) equipped with a 96 well plate autosampler and interfaced 
to Thermo TSQ Vantage mass spectrometer (Thermo Scientific Corp., Waltham, MA). 
Samples (10 µl) were injected onto an Agilent Pursuit 3 Diphenyl column (2.0 x 150 mm, 
3 µm) connected to an Agilent Metaguard Pursuit 3 DP guard column. The column was 
eluted with a gradient of aqueous 0.1% formic acid (A) and 0.1% formic acid in 
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acetonitrile (B) at a flow rate of 150 µl/min and 5
 0
C. The analytes were resolved with the 
following linear gradient program (time, % of solvent B): 0-12 min, 3 to 9% B; 12-14 
min, 9 to 50% B; 14-16 min, isocratic at 50% B; 16-18 min, 50 to 3% B; 18-30 min, 
conditioning at 3% B.  
  The mass spectrometer was operated in the ESI
-
 mode, at the following MS 
settings: spray voltage, -3000 V; sheath gas pressure, 65 psi; capillary temperature, 250
 
0
C; collision energy, 14 (MHBMA), 24 (DHBMA); S-lens, 75; source CID, 8 V; collision 
gas pressure, 1.1 mTorr; Q1 (fwhm), 0.4; Q3 (fwhm), 0.7; scan width, 0.4 m/z; and scan 
time, 0.3 s. MHBMA and DHBMA were quantified in the SRM mode by comparing the 
peak area of analytes with their corresponding internal standards (
2
H6-MHBMA and 
2
H7-
DHBMA, respectively). The SRM transitions used were m/z 238.1 → 109.1 (2H6-
MHBMA), 232.1 → 103.1 (MHBMA), 257.1 → 78.1 (2H7-DHBMA) and 250.1 → 75.1 
(DHBMA). 
 HPLC-ESI
-
-MS/MS method for quantification of THBMA. THBMA was 
quantified by the HPLC-ESI
-
-MS/MS methodology previously reported by our laboratory 
(Chapter III).  Samples (10 µl) were injected onto a SIELC Primesep D column (2.1 x 
100 mm, 5 μm particle size) connected to a guard column (Primesep D; 2.1 x 10 mm). 
The HPLC-MS system consisted of Agilent 1100 HPLC system (Agilent Technologies, 
Santa Clara, CA) interfaced to a Thermo-Finnigan TSQ Quantum Discovery mass 
spectrometer (Thermo Scientific Corp., Waltham, MA). The column was eluted with a 
gradient of water (A) and 49.5:49.5:1 water: ACN: formic acid (B) as reported previously 
(Section 3.2) THBMA concentrations were determined by isotope dilution with the 
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corresponding internal standard (
2
H3-THBMA). The mass spectrometer was operated in 
the selected reaction monitoring (SRM) mode by monitoring the transitions m/z 269.1 → 
137.1 (
2
H3-THBMA) and 266.1 → 137.1 (THBMA). 
  Calibration Curves. Non-smoker urine samples (200 µl) were spiked with 9 
different amounts of MHBMA (0.1–40 ng), DHBMA (2.0–1000 ng) and 60 ng each of 
2
H6-MHBMA and 
2
H7-DHBMA, in triplicate. The samples were processed by Oasis HLB 
96 well plate (30 mg) SPE method and the analyte concentrations were determined by the 
new HPLC-ESI
-
-MS/MS method described above. Calibration curves were constructed 
separately for MHBMA and DHBMA to determine the correlation between the 
analyte/internal standard amount ratio and the corresponding MS peak area ratios. 
  LOD and LOQ determination. Synthetic urine (200 µl) was spiked with 
MHBMA (20–100 pg) and DHBMA (0.2–2.0 ng) and 60 ng each of 2H6-MHBMA and 
2
H7-DHBMA (internal standards for quantitation). These spiked samples were subjected 
to SPE enrichment on Oasis HLB 96 well plates (30 mg) and subsequently analyzed by 
HPLC-ESI
-
-MS/MS as described above. Analyte amounts at which the signal-to-noise 
ratio (S/N) was greater than 10 and % CV < 15% was designated as the method’s limit of 
quantification (LOQ). Similarly, the lowest analyte amount at which the signal-to-noise 
ratio (S/N) was greater than 3 was defined as the limit of detection (LOD). 
  Intra-day and Inter-day Precision. Nine 200 µL urine aliquots from a 
confirmed smoker were processed by SPE as described above. The reconstituted SPE 
eluates were pooled into a single sample, and the pooled sample was injected three times 
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per day on three consecutive days. Intra-day and Inter-day precision were determined by 
calculating the relative standard deviations (%RSD) between these 9 measurements. 
  Method Accuracy. Aliquots of non-smoker urine (N = 5) were spiked with 10 
ng/ml of MHBMA, 250 ng/ml of DHBMA and 60 ng each of 
2
H6-MHBMA and 
2
H7-
DHBMA. The aliquots were processed by SPE and subsequently analyzed by HPLC-
MS/MS as described above. Background concentrations of MHBMA and DHBMA in the 
non-smoker urine sample were determined by analyzing 200 µl aliquots of the non-
spiked nonsmoker urine by HPLC-MS/MS in triplicate and subtracted from the observed 
concentration for determination of method accuracy. 
   Analyte Recovery. Three aliquots of non-smoker urine (200 µl each) were spiked 
with MHBMA (10 ng/ml), DHBMA (250 ng/ml), and 60 ng each of 
2
H6-MHBMA and 
2
H7-DHBMA, followed by SPE as described above. Three additional urine aliquots from 
the same sample were processed by the same method as above, with the exception that 
2
H6-MHBMA and 
2
H7-DHBMA internal standards were added following SPE 
purification. All six samples were analyzed by HPLC-ESI-MS/MS as described above, 
and SPE recoveries of MHBMA and DHBMA were determined by comparing the 
relative (analyte/internal standard) response ratios between the two sets of samples. 
  Quantification of BD urinary metabolites in workers in a BD production 
facility. Urine samples from 72 workers were obtained from workers employed at a BD 
monomer and SBR production facility near Prague, Czech Republic (83;85). Out of 72 
subjects, 40 were administrative workers (21 male and 19 female) not occupationally 
exposed to BD (< 0.03 mg/m
3
) while 32 were workers in the production unit (16 male 
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and 16 female; BD exposure, 0.05-1.5 mg/m
3
). Complete details of the study population 
have been published previously (83;85). The present study was conducted in a blind 
fashion, e.g. subject information was not revealed until the urinary BD mercapturic acid 
concentrations of all the subjects were determined. After the analyses were completed, 
the information about BD exposure, age, gender, protein biomarkers, mutation 
frequencies, and smoking status of each subject were made available. 
  Quantification of MHBMA and DHBMA in smokers belonging to different 
ethnic groups. The newly developed HPLC-MS/MS method for MHBMA and DHBMA 
quantification (described above) was employed to study inter-ethnic/racial differences in 
BD metabolism in two different multi-ethnic cohort studies (blinded). The first study 
(Study # 1) involved smokers belonging to three different ethnic groups: Native 
Hawaiians, European Americans and Japanese American (N = 200 per group). 
Additionally, thirty-five blind duplicates were included for quality control measures. 
Study # 2 included smokers of European American and African American ethnicity (N = 
450 per group). MHBMA and DHBMA concentrations were determined for all the 
smoker urine samples in both studies and metabolic ratios were calculated later. 
  Statistical Analysis. Multiple regression analyses were conducted to determine 
the associations between urinary BD-mercapturic acids and gender, BD exposure, and 
smoking status. Additionally, Pearson partial correlation coefficients were computed to 
determine the correlation between MHBMA, DHBMA, THBMA, THB-Val, pyr-Val and 
hprt mutation frequencies. A two-way ANOVA test was also performed to identify any 
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differences in urinary MHBMA, DHBMA, THBMA concentrations between the control 
and occupationally exposed groups. 
  For the multi-ethnic cohort studies, MHBMA and DHBMA concentrations were 
normalized to urinary creatinine to account for differing dilution. To examine 
ethnic/racial differences in study # 1, least square means were computed for each 
ethnic/racial group using multi variable linear regression model. For the study # 2, a 
Wilcoxon non-paramateric test was performed and p-values were calculated to observe 
any differences in urinary MHBMA, DHBMA, and their metabolic ratio between the 
European American and African American smokers. Additionally, genome wide 
association study (GWAS) was also completed to identify any correlation between the 
genetic polymorphisms and BD urinary metabolites. 
 
4.3 Results 
4.3.1 SPE and HPLC-MS/MS method development for MHBMA and DHBMA 
  While multiple methods exist in the literature for quantitative analysis of BD-
mercapturic acids (MHBMA and DHBMA) in human urine (Table 1.5) 
(33;96;97;99;102;104;105;107), most of them require large sample sizes and are not 
amenable for high throughput analyses. The goal of the present study was to develop an 
HPLC-ESI-MS/MS method for MHBMA/DHBMA that is sensitive enough to quantify 
urinary BD-mercapturic acids in small volumes of human urine (< 200 µl) and that could 
be applied to large numbers of samples typical for molecular epidemiology studies. 
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Because urinary concentrations of MHBMA in smokers are 50-100 fold lower than that 
of DHBMA based on previous reports (102;105),  our method development efforts have 
focused on maximizing analyte recovery for MHBMA.  We chose solid phase extraction 
(SPE) for analyte cleanup step because of its ability to remove the bulk of interferences 
from urine with minimal analyte losses. Multiple SPE stationary phases have been tested, 
including reversed phase, anion exchange, weak anion exchange, and mixed modes. 
Among these, Oasis HLB (Waters Corporation, Milford, MA) which is a hydrophilic-
lipophilic balanced stationary phase with high reversed-phase retention provided the 
highest MHBMA recoveries and therefore was chosen for final SPE method 
development. Our SPE method for MHBMA and DHBMA is based on the previously 
published procedure (99), which was modified by incorporating an additional 5% 
methanol wash (to remove additional interferences) and a final elution step with 75% 
methanol to maximize analyte recoveries of MHBMA and DHBMA. SPE recoveries for 
MHBMA and DHBMA by our method were determined to be 92 and 18%, respectively. 
Low recovery for DHBMA did not interfere with the analysis due to the use of an 
isotopically labeled internal standard and because of the relatively high concentrations of 
DHBMA in human urine (33;105). 
  HPLC-ESI-MS/MS method development for MHBMA and DHBMA was 
complicated by their poor retention on reverse phase columns. Both BD-mercapturic 
acids are highly polar metabolites with hydroxyl and carboxylic acid functionalities in 
their structure (Scheme 1.1). Furthermore, MHBMA is a mixture of four isomers 
(Scheme 4.1), which complicates its HPLC separation. Multiple HPLC stationary phases 
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were evaluated in an attempt to find a stationary phase that makes it possible to resolve 
MHBMA and 
2
H6-MHBMA isomers from any co-eluting interferences present in the 
human urine matrix.  
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Scheme 4.1 Structures of the four isomers of MHBMA 
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  In the initial stages of method development, we attempted to employ capillary 
HPLC columns (0.5 mm i.d.) for improved HPLC-ESI-MS/MS sensitivity. Despite 
promising results for pure standards, poor results were obtained for actual urine samples 
due to the complexity and the variability of human urine matrix, which has led to sample-
dependent retention time shifts. To minimize retention time shifts, we turned our 
attention to narrow bore (2.1 mm i.d.) columns. The use of ion pairing reagents such as 
N,N-dimethyl hexylamine and triethylamine increased analyte retention, but required 
longer equilibration times and resulted in a severe ion suppression for subsequent users. 
Therefore, we focused on specialized HPLC phases capable of retaining polar analytes in 
the absence of ion pairing agents. 
  While good analyte retention in the absence of ion-pairing agents was achieved on 
a number of columns, including Synergi MAX-RP (Phenomenex), Luna C18 
(Phenomenex), Xterra MS-C18 (Waters), Primesep B2 (Sielc), Primesep D (Sielc), 
Zorbax SB-C18 (Agilent) and Hypersil Gold (Thermo), these columns were unable to 
resolve MHBMA from a co-eluting interference present in most human urine samples. 
The best results in terms of analyte retention and separation from the matrix was achieved 
with an Agilent Pursuit Diphenyl column (2.1 x 150 mm, 3 µ) (Agilent Technologies). In 
order to maximize analyte retention, the carboxylate group of the analyte (pKa ~4.5) was 
protonated by employing acidic mobile phase (0.1% formic acid, pH ~2.5). While higher 
sensitivity was achieved with 0.5% acetic acid, MHBMA separation from a co-eluting 
peak was not satisfactory with this mobile phase. A linear gradient of acetonitrile in 0.1% 
aqueous formic acid has afforded good HPLC resolution and MS sensitivity for 
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MHBMA. The HPLC column was maintained at 5 °C to maximize the separation of 
MHBMA analyte peaks from an interfering matrix peak.  
  For HPLC-ESI-MS/MS detection of MHBMA/DHBMA, the best sensitivity was 
achieved in the negative ion mode. The major ESI
-
 MS/MS fragmentation pathway for 
MHBMA and DHBMA corresponds to the cleavage of the C-S bond. Therefore, the main 
MS/MS transitions of MHBMA and DHBMA and their deuterated analogs used as 
internal standards are 238.1 → 109.1 (2H6-MHBMA), 232.1 → 103.1 (MHBMA), 257.1 
→ 128.1 (2H7-DHBMA) and 250.1 → 121.1 (DHBMA). Because of a co-eluting peak in 
the major SRM transition for DHBMA and 
2
H7-DHBMA (results not shown), an 
alternative MS/MS transition was selected for quantification of this analyte: 257.1 → 
78.1 (
2
H7-DHBMA) and 250.1 → 75.1 (DHBMA).  As shown in Figure 4.1 for a 
representative sample from a BD-exposed worker, MHBMA isomers elute as two HPLC-
ESI
-
-MS/MS peaks at 13.2 and 14.1 min (Figure 4.1A, second panel), while the 
corresponding isomers of 
2
H6-MHBMA internal standard elute at 12.8 and 13.8 min, 
respectively (Figure 4.1A, top panel). The first peak contains (R) and (S) 2-MHBMA as 
well as one of the stereoisomers of 1-MHBMA, while the second peak corresponds to the 
other stereoisomer of 1-MHBMA. In the same samples, DHBMA signal is observed at 8-
8.2 min, while 
2
H7-DHBMA internal standard elutes slightly earlier at 7.9-8.1 min 
(Figure 4.1, bottom panels). THMBA was analyzed by a similar HPLC-ESI
-
-MS/MS 
approach as described previously (Chapter 4, Figure 4.2). Our optimized methodology for 
quantification of BD-mercapturic acids in human urine is summarized in Scheme 4.2. 
 
 141 
 
 
Figure 4.1 Representative traces for HPLC-ESI
-
-MS/MS analysis of MHBMA and 
DHBMA in urine of a BD-exposed worker and a control worker 
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Figure 4.2 Representative traces for HPLC-ESI
-
-MS/MS analysis of THBMA in urine of 
a BD-exposed worker and a control worker 
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Scheme 4.2 Workflow for quantification of MHBMA, DHBMA and THBMA in human 
urine 
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4.3.2 Method Validation 
  The new HPLC-ESI
-
-MS/MS method for MHBMA and DHBMA was validated 
by analyzing non-smoker urine spiked with increasing concentrations of MHBMA and 
DHBMA and constant amount of the corresponding internal standards. As shown in 
Figure 4.3, linear correlation curves were obtained for both analytes (R
2 
> 0.9998). The 
HPLC-ESI
-
-MS/MS method was linear between 0.5-200 ng/ml for MHBMA and 10-
5000 ng/ml for DHBMA (Table 4.1). The y-intercepts in the correlation curves were 
above zero (Figure 4.3) due to background concentrations of MHBMA and DHBMA in 
non-smoker urine (MHBMA, 3.8 ng/ml; DHBMA, 229 ng/ml). The LOD and LOQ 
values for MHBMA were 0.2 and 0.5 ng/ml, respectively, while the corresponding values 
for DHBMA were 5 and 10 ng/ml (Table 4.1). The LOD and LOQ values for DHBMA 
were higher because minor SRM transitions were chosen for quantification of this analyte 
(see above). However, this did not prevent accurate analysis of DHBMA due to relatively 
high concentrations of this analyte in human urine. Intra-day and inter-day precision was 
determined by repeated analysis of a smoker urine sample (three times per day on three 
consecutive days). The calculated % RSD values for both analytes were below 5% (Table 
4.1), demonstrating the reproducibility of our HPLC-ESI
-
-MS/MS method. The accuracy 
of the HPLC-ESI
-
-MS/MS method for MHBMA and DHBMA was determined by 
spiking known amounts of each analyte (MHBMA, 10 ng/ml and DHBMA, 250 ng/ml) 
into a non-smoker urine sample. We found that the accuracy range for MHBMA was 
100.5 ± 5.1, while the corresponding value for DHBMA was 102.7 ± 3.2. Complete 
validation parameters for both analytes are presented in Table 4.1. 
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Figure 4.3 Method validation curves for MHBMA and DHBMA spiked into non-smoker 
urine (200 µl). 
 
 
 
 
 
 
 
 146 
 
Table 4.1  HPLC-ESI
-
-MS/MS method validation parameters for quantification of 
MHBMA and DHBMA in human urine. 
Analyte 
Range 
(ng/ml) 
LOD 
(ng/ml) 
LOQ 
(ng/ml) 
Precision (% RSD) Accuracy 
(%) 
Recovery 
(%) 
intra-day inter-day 
MHBMA 0.5-200 0.2 0.5 4.1 4.5 100.5 ± 5.1 92 
DHBMA 10.0-5000 5 10 2.4 3.0 102.7 ± 3.2 18 
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4.3.3 Urinary BD concentrations in occupationally exposed workers and the 
corresponding controls. 
  In order to test the applicability of the new method to human bio-monitoring, the 
concentrations of MHBMA, DHBMA and THBMA were determined in after-work urine 
samples of 72 workers in a BD and SBR production facility in Czech Republic. Among 
72 workers, 40 were administrative workers (21 male and 19 female) with minimal 
exposure to BD (<0.03 mg/m
3
) and 32 were workers in BD production unit (16 male and 
16 female, 0.05-1.5 mg/m
3). Each worker’s individual exposure to BD was monitored 
separately during their work shifts with diffusive solid sorbent tubes (85). This procedure 
was repeated on 10 different days over a 4-month interval, and the average BD exposure 
concentrations were determined. Average BD exposure concentration was 0.007 ± 0.005 
mg/m
3
 in control workers and 0.55 ± 0.50 mg/m
3 
in exposed workers.  
  Urinary BD-mercapturic acids (MHBMA, DHBMA and THBMA) were detected 
in both control and exposed groups, but their concentrations were significantly greater in 
samples from occupationally exposed individuals as compared to controls (Figures 4.1, 
4.2 and Table 4.2). For example, as demonstrated in Figure 4.1, HPLC-ESI
-
-MS/MS peak 
areas corresponding to MHBMA and DHBMA were much higher in exposed workers 
(Figure 4.1A) than in controls (Figure 4.1B). Similarly higher concentrations of THBMA 
were found in exposed workers as compared to controls (compare Figures 4.2A and 
4.2B). A summary of urinary concentrations of MHBMA, DHBMA and THBMA and 
their metabolic ratio in control and exposed workers are given in Table 4.2.  
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Table 4.2  Mean urinary MHBMA, DHBMA, THBMA concentrations and metabolic ratios in exposed and control workers by sex 
 
 
 
 
 
 
 
 
*Values in parenthesis (    ) are per unit dose of BD 
a
Male exposed significantly greater than male controls (Two way ANOVA test, p-value <0.01) 
b
Male controls significantly greater than Female controls (Two way ANOVA test, p-value <0.01) 
c
Male exposed significantly greater than Female exposed (Two way ANOVA test, p-value <0.01) 
d
Female exposed significantly greater than Female controls (Two way ANOVA test, p-value <0.05) 
e
Male exposed significantly greater than Female exposed (Two way ANOVA test, p-value <0.01) 
   Concentrations (ng/ml)  
 N BD exposure 
(mg/m
3
) 
 MHBMA* DHBMA* THBMA* Metabolic Ratio* 
Males       
Controls 21 0.007 ± 0.005
a
 9.9 ± 11.2
a,b
 1480.6 ± 968.5
a,b
 57.1 ± 33.5
a,b
 0.007 ± 0.008
a
 
Exposed 16 0.68 ± 0.41
a,c
 95.9 ± 111.4
a,c 
(176.5 ± 228.3)
e
 
3136.1 ± 2560.3
a,c 
(5922.7 ± 4737.5) 
139.3 ± 104.7
a,c 
(254.1 ± 152.1) 
0.027 ± 0.026
a 
(0.07 ± 0.10) 
       
Females       
Controls 19 0.007 ± 0.005
d
 3.1 ± 4.8
b,d
 561.2 ± 531.5
b
 24.2 ± 16.6
b
 0.006 ± 0.007
d
 
Exposed 16 0.32 ± 0.34
c,d
 8.3 ± 8.1
c,d 
(44.3 ± 45.4)
e
 
716.1 ± 830.7
c 
(3251.3 ± 2907.5) 
47.4 ± 70.9
c 
(232.2 ± 243.2) 
0.017 ± 0.012
d 
(0.11 ± 0.14) 
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  Mean MHBMA concentrations in urine of BD-exposed female workers (8.3 ± 8.1 
ng/ml) were significantly higher than those in control female workers (3.1 ± 4.8 ng/ml) (p 
< 0.05) (Table 4.2). An even greater difference was seen in male workers, with mean 
MHBMA concentrations of 95.9 ± 111.4 ng/ml (exposed) and 9.9 ± 11.2 ng/ml (controls) 
(p = 0.001). Interestingly, urinary MHBMA concentrations in males were significantly 
greater than in females for both groups (p < 0.05 for controls and p = 0.005 for 
occupationally exposed). This difference remained when the metabolite values were 
normalized to BD exposure concentrations (Table 4.2, numbers in parentheses). Taken 
together, these results indicate that occupational exposure to BD is reflected in 
significantly increased levels of MHBMA in human urine, with males excreting higher 
amounts of the metabolite than females.  
  Urinary concentrations of DHBMA (561.2 ± 531.5 ng/ml in control female 
workers and 716.1 ± 830.7 ng/ml in occupationally exposed females) were 20-30 times 
greater than MHBMA in the same samples (Table 4.2). Although DHBMA 
concentrations were higher in the female BD exposed workers as compared to the control 
group, the difference was not statistically significant (p > 0.05). Mean DHBMA 
concentrations in exposed males (3136.1 ± 2560.3 ng/ml) were significantly higher than 
in control males (1480.6 ± 968.5 ng/ml) (p = 0.01). Similar to our results for MHBMA, 
urinary DHBMA concentrations in males were higher than in females for both the 
controls (p < 0.001) and the occupationally exposed group (p = 0.001).  
  Mean THBMA concentrations in control and BD exposed females were 24.2 ± 
16.6 ng/ml and 47.4 ± 70.9 ng/ml, respectively (Table 4.2). The corresponding values in 
 150 
 
males were 57.1 ± 33.5 ng/ml (control males) and 139.3 ± 104.7 ng/ml (BD exposed 
males). No significant difference was seen between THBMA concentrations between 
exposed and control groups in females. However, in males, the urinary THBMA 
concentrations were significantly higher in exposed group as compared to the controls (p 
= 0.001). Furthermore, THBMA concentrations in males were higher than females in 
control (p < 0.001) as well as the exposed group (p < 0.01).   
  Metabolic ratio calculated as MHBMA/(MHBMA+DHBMA+THBMA) can be 
used as an indicator of fraction of BD undergoing bioactivation via the CYP450 pathway. 
As shown in Table 4.2, the metabolic ratio was significantly higher in BD exposed group 
than in control group in both females and males (p < 0.005). However, there were no 
gender differences in the BD metabolic ratio. Overall, urinary concentrations of all three 
BD urinary metabolites were present in significantly higher concentrations in urine of 
exposed workers as compared to controls. 
4.3.4 Correlation studies 
  Multiple regression analyses were conducted to reveal any associations of urinary 
biomarkers with gender, BD exposure concentration, cigarette pack years, and current 
smoking status. Among the four factors, significant correlation was found between BD 
urinary metabolites (MHBMA, DHBMA and THBMA) and BD exposure (p < 0.005). 
Additionally, MHBMA and DHBMA concentrations were associated with current 
smoking status (p < 0.05). Linear regression analyses were conducted to further 
understand the association between BD mercapturic acids concentrations/metabolic ratio 
and BD exposure. We found that urinary MHBMA concentrations and metabolic ratio in 
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individual workers significantly correlated with BD exposure (Figure 4.4). Additionally, 
DHBMA and THBMA concentrations were significantly associated with BD exposure, 
suggesting that occupational exposure to BD leads to the increased formation of EB, 
HMVK and EBD, which are excreted in urine as MHBMA, DHBMA and THBMA. 
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Figure 4.4 Associations between urinary MHBMA/metabolic ratio and BD exposure 
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  Pearson correlation coefficients were computed to determine the correlation 
between BD mercapturic acids (MHBMA, DHBMA and THBMA), BD-hemoglobin 
adducts (THB-Val, pyr-Val) and hprt mutation frequencies (Table 4.3, Figure 4.5). 
Significant correlation was found between MHBMA and DHBMA (r = 0.742, p < 0.001), 
MHBMA and THBMA (r = 0.419, p < 0.001) (Table 4.3, Figure 4.5), and DHBMA and 
THBMA (r=0.594, p<0.001) (Table 4.3). These results are consistent with the fact that all 
three metabolites originate from BD exposure. MHBMA and DHBMA concentrations 
were also significantly correlated with both THB-Val and pyr-Val concentrations (Table 
4.3). As predicted, THBMA was strongly associated with THB-Val (Table 4.3), since 
both originate from EB-diol (Scheme 1.1 and Scheme 1.2). In contrast, the correlation 
between THBMA and pyr-Val was not significant (p=0.07), probably because THBMA 
originates from EB-diol, while pyr-Val in formed from DEB (Scheme 1.1 and Scheme 
1.2, Table 4.3). The Pearson correlation coefficient for all these associations were 
between 0.45-0.75, with a p-value <0.001. These observations reveal a correlation 
between and among the three BD-mercapturic acids and also between BD-mercapturic 
acids and BD-DNA adducts. In contrast, no correlation was found between BD-urinary 
mercapturic acids and hprt mutation frequencies (Table 4.3). 
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Figure 4.5 Associations between MHBMA and DHBMA/THBMA 
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Table 4.3 Association between and among all BD biomarkers determined by Pearson 
correlation analysis (p-values) 
 MHBMA DHBMA THBMA THB-Val pyr-Val 
hprt mutation 
Frequency 
MHBMA NA <0.001 <0.001 0.007 <0.001 None 
DHBMA <0.001 NA <0.001 <0.001 <0.001 None 
THBMA <0.001 <0.001 NA <0.001 0.07 None 
 
NA: Not Applicable 
None: No significant association observed 
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4.3.5 Ethnic differences in BD metabolism (Multi-ethnic Study # 1) 
 In our first multi-ethnic study, MHBMA and DHBMA concentrations were 
determined in urine of smokers belonging to European American, Native Hawaiian and 
Japanese American ethnic groups (N=200 group). Urinary MHBMA and DHBMA 
concentrations (g/ml) were normalized to creatinine. Additionally, the BD metabolic 
ratios (MHBMA/MHBMA+DHBMA) were also determined. Mean urinary MHBMA 
concentrations in European American, Native Hawaiian and Japanese American smokers 
were 6.7, 5.3 and 4.4 ng/mg creatinine, respectively (Table 4.4). MHBMA concentrations 
differed significantly by race/ethnicity (p = 0.0002). This ethnic difference was observed 
in both sexes (males: p = 0.006 and females: p = 0.03). Mean DHBMA concentrations in 
European American, Native Hawaiian and Japanese American smokers were 552.8, 488.5 
and 506.9 ng/mg creatinine (Table 4.4). No differences in DHBMA were observed 
among the three different ethnic groups in either sex (p > 0.05).  
  The mean values of BD metabolic ratio in samples from European American, 
Native Hawaiian and Japanese American smokers were 0.012, 0.011 and 0.009, 
respectively. Similar to MHBMA, the metabolic ratio also differed by race/ethnicity (p = 
0.005) (Table 4.4). However, when stratified by sex, the metabolic ratios were only 
significantly different among the three ethnic groups in females (p < 0.05). The observed 
differences were not due to differences in age or smoking status as all the means were 
adjusted to age, BMI, nicotine equivalents. 
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Table 4.4 Geometric means of MHBMA, DHBMA and metabolic ratio, stratified by 
race/ethnicity and sex (Multi-ethnic study # 1) 
  
MHBMA 
(ng/mg Cr) 
DHBMA (ng/mg Cr) metabolic ratio 
 
N 
geometric means 
(95% CI)* 
geometric means 
(95% CI)* 
geometric means 
(95% CI)* 
All** 
       
  Japanese Americans 196 4.4 (3.8-5.1) 506.9 (462.1-556.0) 0.009 (0.007-0.010) 
  Native Hawaiian 193 5.3 (4.6-6.2) 488.5 (444.7-536.7) 0.011 (0.009-0.012) 
  European Americans 195 6.7 (5.8-7.8) 552.8 (504.3-606.0) 0.012 (0.011-0.014) 
  p-value
†
 
  
0.0002 
 
0.17 
 
0.005 
Men 
       
Japanese Americans 96 4.4 (3.6-5.4) 456.9 (392.2-532.4) 0.01 (0.008-0.012) 
Native Hawaiian 93 5.1 (4.2-6.3) 471.6 (402.4-552.7) 0.011 (0.009-0.013) 
European Americans 95 6.9 (5.7-8.4) 525.5 (451.1-612.3) 0.013 (0.011-0.016) 
p-value
†
 
  
0.006 
 
0.41 
 
0.14 
Females 
       
Japanese Americans 100 4.4 (3.6-5.4) 561.1 (503.8-625.0) 0.008 (0.006-0.009) 
Native Hawaiian 100 5.4 (4.4-6.7) 509.4 (457.5-567.3) 0.01 (0.009-0.013) 
European Americans 100 6.6 (5.4-8.2) 579.2 (520.7-644.2) 0.011 (0.009-0.014) 
p-value
†
 
  
0.03 
 
0.23 
 
0.03 
*Means are adjusted for age at urine collection, BMI (natural log), nicotine equivalents 
(natural log) 
**Also adjusted for sex 
†
P-value is comparing the difference across the three race/ethnicities 
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4.3.6 Ethnic differences in BD metabolism (Multi-ethnic Study # 2) 
In the second multiethnic study, MHBMA and DHBMA concentrations were 
determined in urine of smokers belonging to African American and European American 
ethnicity (N = 450 per group). Urinary MHBMA and DHBMA concentrations were 
normalized to creatinine, and the metabolic ratio was also determined.  Among 900 
subjects, 107 samples were removed either because of unusually low nicotine 
equivalents, lack of co-variate data (QC samples) or due to genotype filters. The 
differences between the two ethnic groups were determined by Wilcoxon parametric test. 
As shown in Table 4.5, the median MHBMA concentrations in European Americans 
(11.2 ng/mg creatinine) were significantly higher (p = 0.0003) than in African American 
smokers (8.9 ng/mg creatinine). DHBMA concentrations and metabolic ratios were also 
higher in the European American smokers, but the difference is not statistically 
significant. 
  Preliminary GWAS showed a strong association between MHBMA and 22 single 
nucleotide polymorphisms (SNPs) on chromosome 22. The genes that might be 
responsible for the differences in MHBMA among the ethnic groups are GSTT1, GSTT2, 
D-dopachrome decarboxylase (DDT) and macrophage migration inhibitory factor (MIF). 
Similar results were observed with metabolic ratio which correlated with 19 SNPs on 
chromosome 22, potentially with genes GSTT2, DDT and MIF. However, there were no 
associations between DHBMA and any genetic polymorphisms. These results are 
preliminary and further investigation needs to be performed. 
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Table 4.5 Median MHBMA, DHBMA concentrations and metabolic ratio, stratified by 
race/ethnicity (Multi-ethnic study #2) 
 MHBMA (ng/mg Cr) DHBMA  (ng/mg Cr) Metabolic Ratio 
European American 
(N=435) 
11.2 547.3 0.019 
African American 
(N=358) 
8.9 513.4 0.018 
p-value 0.0003 0.08 0.10 
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4.4 Discussion 
  The availability of sensitive, robust, and high throughput methodologies for 
monitoring human exposure to butadiene (BD) is essential in human risk assessment and 
molecular epidemiology studies. Although multiple HPLC-ESI-MS/MS methods have 
been previously described for quantification of BD-mercapturic acids in humans  (Table 
1.5) (33;96;97;99;102;105;107), many of these methods required at least 0.5 ml of urine, 
and thus are not applicable to studies where the sample volume is limited.   
  Roethig et al. analyzed MHBMA and DHBMA in urine of 3,585 smokers and 
1,077 non-smokers (105). Unfortunately, the details of sample preparation were not 
available for that study (105). MHBMA and DHBMA were determined separately with 
two different HPLC-MS/MS methods (105) that employed 0.5 ml and 0.2 ml of urine, 
respectively. The LOQ of the method was 0.1 ng/ml for MHBMA and 10.1 ng/ml for 
DHBMA (Table 1.5) (105). The mean MHBMA concentrations in smokers and non-
smokers were 3.61 and 0.3 µg/24 hr, respectively. The corresponding DHBMA 
concentrations were 556 and 391 µg/24 hr, respectively (105). 
  Ding et al. reported an HPLC-MS/MS method for simultaneous determination of 
six mercapturic acid metabolites of volatile organic compounds including MHBMA and 
DHBMA in 100 µl of human urine (104). The sample preparation involved dilution of 
urine and direct injection onto HPLC-ESI-MS/MS. The LOD of the method for MHBMA 
was 0.05 ng/ml (Table 1.5) (104). However, MHBMA concentration in urine of non-
smokers analyzed by this technique were unusually high (up to 73.2 ng/ml), and no 
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statistical significant differences were observed in the MHBMA concentrations 
(normalized to creatinine) between smokers and non-smokers (104). 
  Most recently, Sterz et al. developed a sensitive UPLC-HILIC-MS/MS method 
for the quantification of both regioisomers of MHBMA (1-MHBMA and 2-MHBMA) in 
100 µL of human urine (110) by hydrophilic interaction chromatography (HILIC). The 
LOQ values for 1-MHBMA and 2-MHBMA were reported 0.15 and 0.72 ng/ml, 
respectively (Table 1.5) (110). However, DHBMA was not quantified in that study. 
Furthermore, when we attempted to employ HILIC methodology for BD-mercapturic 
acids in our laboratory, severe shifts in HPLC retention times were observed (results not 
shown), suggesting that this method is not suitable for high throughput analysis.  
  In the present study, we have developed a novel HPLC-ESI
-
-MS/MS method for 
simultaneous quantification of two BD-mercapturic acids, MHBMA and DHBMA, in 
human urine. Some highlights of the current method are that it measures both metabolites 
simultaneously, requires only 200 µl of urine, and sample preparation is performed in a 
high throughput format by 96 well plate SPE. The current method has greater or 
comparable sensitivity than previously reported methods (Table 1.5) 
(33;96;97;99;102;105;107). The LOD and LOQ of our HPLC-ESI
-
-MS/MS method for 
MHBMA are 0.2 and 0.5 ng/ml, respectively, while the corresponding values for 
DHBMA are 5 and 10 ng/ml. Additionally, our method is highly accurate and 
reproducible (Table 4.1). 
  As an example of the method’s applicability to human studies, MHBMA and 
DHBMA concentrations were determined in urine samples from workers at a BD and 
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SBR plant (40 controls and 32 exposed) available from an earlier study (85). We found 
that urinary MHBMA concentrations in occupationally exposed workers were 
significantly higher as compared to controls (Table 4.2). DHBMA concentrations were 
also increased with BD exposure, but the difference was only statistically significant in 
males (Table 4.2). These results are consistent with earlier findings by Albertini (85). In 
addition to MHBMA and DHBMA, we quantified the third BD-mercapturic acid recently 
discovered in our laboratory (THBMA, Scheme 1.1), which is a novel biomarker of BD 
formed from EBD. As observed for MHBMA and DHBMA, THBMA concentrations 
were increased in exposed group as compared to controls (Table 4.2).  
  Our results (Table 4.2) suggest that males excrete higher concentrations of 
MHBMA, DHBMA and THBMA in their urine than females. This is only partially 
explained by the fact that females are exposed to relatively lower BD concentrations 
(0.32 mg/m
3
) as compared to males (0.68 mg/m
3
), because gender differences for 
MHBMA remained after metabolite concentrations were normalized to BD exposure 
concentrations (Table 4.2). This suggests that females form significantly lower MHBMA 
per unit BD than males (p < 0.05). In contrast, DHBMA and THBMA concentrations per 
unit of BD were not significantly different among the two genders (Table 4.2). The 
metabolic ratio (MHBMA/(MHBMA+DHBMA+THBMA) was  higher in males, but the 
difference is not statistically significant (Table 4.2). These results suggest that the relative 
utilization of detoxification pathways (conjugation vs. hydrolysis) is similar in both males 
and females. All three urinary BD-mercapturic acids (MHBMA, DHBMA, and THBMA) 
were strongly associated with BD exposure (Figure 4.4) (p < 0.001) Furthermore, 
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MHBMA, DHBMA, and their metabolic ratio correlated with the smoking status, 
consistent with previous study (96;105). Additionally, strong correlations were found 
between MHBMA and other biomarkers of BD exposure, e.g. DHBMA, THBMA, THB-
Val and pyr-Val (Figure 4.5, Table 4.3) (84;89;99). Since this is the first time THBMA 
was quantified in urine of occupationally exposed workers, it was an important finding 
that THBMA concentrations correlated with MHBMA, DHBMA, and THB-Val (Table 
4.3, Figure 4.5). Overall, there were strong associations between and among each of BD 
biomarkers suggesting that all of them reflect BD exposure. In contrast, there was no 
association between any of the BD mercapturic acids and hprt mutation frequency in the 
same individuals (Table 4.3).  
  In the first multi-ethnic study that included European American, Japanese, and 
Hawaiian smokers, significant differences in MHBMA concentrations and metabolic 
ratio were observed among the three ethnic groups (Table 4.4). Importantly, Japanese 
Americans, who have the lowest lung cancer risk among the there groups (14), also 
excrete the lowest amounts of MHBMA and have low metabolic ratio. However, the 
highest concentrations of MHBMA and metabolic ratio were observed in European 
American smokers who are in the intermediate risk group (14). These differences in 
MHBMA and metabolic ratio might be due to differences in frequency of genetic 
polymorphisms in the genes encoding the BD metabolizing enzymes. For example, the 
frequency of the CYP2E1 DraI variant allele was 6.6%, 33.3% and 15.4% in Caucasians, 
Japanese and Hawaiians, respectively (219). The frequency of the CYP2E1 RsaI allele 
was 2.0%, 25.6% and 16.2% in Caucasians, Japanese and Hawaiians, respectively (219). 
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Correlations between genetic polymorphisms and BD urinary metabolites will provide 
further insights into differences in BD metabolism. 
  In the second multi-ethnic study, we found significant differences in MHBMA 
concentrations between the European American and African American smokers, with the 
highest concentrations found in the former group (Table 4.5). Preliminary GWAS 
analysis revealed a strong association between MHBMA and 22 SNPs on chromosome 
22. This chromosome houses the GSTT1 gene, which along with GSTM1 is involved in 
the detoxification of EB (precursor to MHBMA) (220). No ethnic/racial differences in 
DHBMA concentrations were observed in both the studies. This is not surprising given 
the fact that DHBMA is present endogenously in very high concentrations in non-
smokers (33). 
  In conclusion, we report a robust, sensitive, high throughput HPLC-ESI
-
-MS/MS 
method for quantification of MHBMA and DHBMA in human urine. The applicability of 
the new method was demonstrated in urine samples from workers employed at a BD-
SBR production facility. We found that urinary BD-mercapturic acids concentrations 
were strongly associated with BD exposure. We also observed that MHBMA 
concentrations (adjusted per unit of BD exposure) were significantly higher in males as 
compared to females, suggesting that there might be gender differences in metabolism of 
BD in humans. The novel method was successfully applied to two large multiethnic 
cohort studies, leading to identification of significant ethnic/racial differences in 
metabolism of BD. Future studies will focus on identifying any correlations between 
genetic polymorphisms and BD urinary metabolites. 
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V. TRANSLESION SYNTHESIS ACROSS 1,N6-(2-HYDROXY-3-HYDROXY 
METHYLPROPAN-1,3-DIYL)-2′-DEOXYADENOSINE (1,N6-γ-HMHP-dA) 
ADDUCTS BY HUMAN AND ARCHEBACTERIAL DNA POLYMERASES 
Reprinted with permission from: Srikanth Kotapati, Leena Maddukuri, Susith Wickramaratne, 
Uthpala Seneviratne, Melissa Goggin, Matthew G Pence, Peter Villalta, F. Peter Guengerich, 
Lawrence Marnett and Natalia Y. Tretyakova. J Biol Chem. (2012) 287, 38800-38811. 
© 2012 The American Society for Biochemistry and Molecular Biology, Inc. 
5.1 Introduction 
Cellular DNA is constantly damaged by physical and chemical factors, including 
reactive oxygen species, lipid peroxidation products, UV light, environmental pollutants, 
and dietary carcinogens (221). If not repaired, the resulting DNA adducts can block the 
progression of replicative DNA polymerases along the damaged strand (122;222). In this 
case, a specialized group of polymerases, translesion synthesis polymerases (TLS), are 
recruited to the damaged site and can carry out DNA polymerization across the lesion 
(Figure 1.2) (223;224). Five TLS DNA polymerases are primarily involved in translesion 
synthesis in humans: hPol η, hPol ι, hPol κ, Rev1 from the Y family and hPol ζ from the 
B family of polymerases  (121;225;226). The archebacterial translesion DNA polymerase 
from Sulfolobus solfataricus P2 (Dpo4) has been widely used as a model TLS 
polymerase for kinetic and structural studies of DNA lesions due its ready availability 
and its functional similarity to human hPol η (164;227). This damage tolerance 
mechanism allows the cell to overcome replication blocks induced by bulky lesions such 
as UV-induced thymine dimers, facilitating cell survival. However, TLS polymerases are 
less catalytically efficient than replicative DNA polymerases and have a relatively low 
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fidelity due to an increased size and flexibility of their active sites 
(120;123;124;127;228).  
An important DNA lesion that occurs upon exposure to the human carcinogen 
1,3-butadiene (BD) is 1,N
6
-(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-2′-
deoxyadenosine (1,N
6
-γ-HMHP-dA) and its isomer 1,N6-(1-hydroxymethyl-2-
hydroxypropan-1,3-diyl)-2′-deoxyadenosine (1,N6-α-HMHP-dA) (Scheme 5.1) (48). BD 
is an important industrial chemical widely used in the production of synthetic rubber, 
resins, and polymers; as well as an environmental contaminant present in cigarette 
smoke, automobile exhaust, and urban air (26). BD is metabolically activated to 1,2,3,4-
diepoxybutane (DEB), which can alkylate adenine residues of DNA to give 1,N
6
-HMHP-
dA (48). HPLC-ESI
+
-MS/MS analysis of DEB-treated calf thymus DNA revealed a 
concentration-dependent formation of 1,N
6
-α-HMHP-dA and 1,N6-γ-HMHP-dA adducts 
(48). Under physiological conditions, the two lesions interconvert via a Dimroth 
rearrangement-like mechanism (48). Both isomers of 1,N
6
- HMHP-dA have been 
detected in liver, lung, and kidney tissues of laboratory mice exposed to 6.25-625 ppm 
BD (67). Although these lesions are less abundant than guanine monoadducts and 
guanine-guanine cross-links of DEB, they are persistent in mouse tissues for at least 10 
days, suggesting that they may contribute to the biological effects of BD (185). 
Since both the N
6 
and the N-1 positions of adenine in 1,N
6
-HMHP-dA adducts are 
blocked by the HMHP exocycle, they can no longer be used to form complementary 
hydrogen bonds with dT. Structurally related 1,N
6
-ethenodeoxyadenosine (1,N
6 
-εdA) 
adducts are known to adopt the syn conformation about the glycosidic bond, allowing 
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them to mispair with protonated dC in the active site of human DNA polymerase ι (229). 
We therefore hypothesized that 1,N
6
-HMHP-dA adducts can similarly form Hoogsteen 
base pairs with dG and protonated dA, potentially leading to A→T and A→C 
transversions, respectively. Such mispairing could explain the mutational spectra 
observed upon treatment of cells and laboratory animals with BD and DEB (35;177;230). 
The main aim of the present study was to investigate the ability of human TLS 
polymerases to carry out DNA synthesis past site-specific (R,S) 1,N
6
-γ-HMHP-dA 
lesions. We have determined steady-state kinetic parameters for nucleotide insertion 
opposite the lesion and identified primer extension products following in vitro replication 
in the presence of polymerases κ , η , ι, and Dpo4. Our results indicate that hPol κ, hPol η, 
and Dpo4 are able to bypass (R,S) 1,N
6
-γ-HMHP-dA lesions and to extend the primer 
beyond the damaged site by incorporating either correct (T) or incorrect base (A or G ) 
opposite the adduct, along with introducing -1 and -2 frameshift mutations. In contrast, 
replicative hPol β is completely blocked by the lesion, and hPol ι inserts correct 
nucleotide, but is unable to extend past the lesion site. 
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Scheme 5.1 Formation of 1,N
6
-γ-HMHP-dA and 1,N6-α-HMHP-dA adducts from 1,2,3,4-
diepoxy butane (DEB) 
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5.2 Experimental Procedures 
Materials. Full-length recombinant hPol , hPol , and hPol  enzymes used for 
steady-state kinetic experiments were obtained from Enzymax (Lexington, KY). 
Recombinant human DNA Pol κ (amino acids 19-526), recombinant human DNA Pol ι 
(amino acids 1-420), and recombinant human Pol η (amino acids 1-437) employed in full 
length primer extension and mass spectrometry experiments were expressed and purified 
as described previously (231-233). Dpo4 polymerase was expressed and purified by 
Professor Michael Stone (Vanderbilt University) as per the previously published 
methodology (164). hPol β was purchased from Trevigen (Gaithersburg, MD). T4 
polynucleotide kinase and E.coli uracil DNA glycosylase (UDG) were obtained from 
New England Biolabs (Beverly, MA). [γ-32P]ATP was purchased from Perkin-Elmer Life 
Sciences (Boston, MA). The unlabeled dNTPs were obtained from Omega Bio-Tek 
(Norcross, GA). 40% 19:1 Acrylamide/Bis Solution was purchased from Bio-Rad 
laboratories (Hercules, CA). All the other chemicals and reagents were obtained from 
Sigma-Aldrich (St. Louis, MO) and Fisher Scientific (Pittsburgh, PA). Urea, Sigmacote, 
Tris, boric acid, ammonium acetate, formamide, bovine serum albumin (BSA), 
dithiothreitol (DTT), magnesium chloride, and N,N,N′,N′-tetramethylethylenediamine 
were purchased from Sigma Aldrich. Ammonium persulfate, acetonitrile and EDTA were 
obtained from Fisher Scientific. 
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Oligonucleotide synthesis. 18-mer oligodeoxynucleotide templates containing 
site- and stereospecific (R,S) 1,N
6
-γ-HMHP-dA lesions at the 5th position (5'-
TCATXGAATCCTTCCCCC-3') were synthesized by the post-oligomerization 
methodology developed in our laboratory (186). Briefly, 18-mer oligodeoxynucleotides 
containing site-specific 6-chloropurine at position X were coupled with (R,R)-N-Fmoc-1-
amino-2-hydroxy-3,4-epoxybutane to generate the corresponding oligomers containing 
site- and stereospecific (R,R)-N
6
-(2-hydroxy-3,4-epoxybut-1-yl) adenine (N
6
-HEB-dA) 
adducts. N
6
-HEB-dA-containing oligomers were isolated by HPLC and incubated in 
water at room temperature to allow the cyclization of (R,R)-N
6
-HEB-dA to (R,S) 1,N
6
-γ-
HMHP-dA (186). The corresponding unmodified 18-mer (5'-
TCATAGAATCCTTCCCCC-3') and 13-mer primers (5'-GGGGGAAGGATTC-3', 5'-
GGGGGAAGGAUTC-3') were purchased from Integrated DNA Technologies 
(Coralville, IA). All DNA strands were purified by HPLC, characterized by HPLC-ESI
-
- 
MS/MS, and quantified by UV spectrophotometry. 
Generation of Primer-template DNA Substrate for In Vitro Assays. The 13-
mer oligodeoxynucleotide primer (5'-GGGGGAAGGATTC-3') was 5'-end labeled in the 
presence of 32-P-ATP (>6000 Ci/mmol) and T4 polynucleotide kinase in 50 mM Na-
MOPS buffer (pH 7.5), 10 mM MgCl2, and 5 mM DTT for 1 h at 37 °C. Excess 
32
-P-
ATP was removed by gel filtration through Bio-spin 6 filters (Bio-Rad). The 
32
P –
endlabeled primer was annealed to an equimolar amount of 18-mer oligodeoxynucleotide 
templates containing either dA or 1,N
6
-γ-HMHP-dA (1:1 molar ratio) by heating at 95 °C 
for 3 min in the presence of 40 mM NaCl, followed by slow cooling overnight. 
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Reaction conditions for Enzyme Assays. Primer extension assays and steady 
state kinetics experiments were conducted for each of the five DNA polymerases (hPol β, 
hPol , hPol , hPol  and Dpo4). The assays were conducted at 37 °C in buffered 
solutions
 
containing 50 mM Na-MOPS (pH 7.5), 50 mM NaCl, 5 mM DTT,
 
100 µg/ml 
BSA, 10% glycerol (v/v) with 50 nM radiolabeled primer-template
 
complexes, and 5 nM 
of polymerase enzymes (except for Dpo4 which was used at 25 nM and hPol β, 2 units). 
The reactions were initiated by the addition of individual nucleotides or a mixture of all 
four dNTPs and MgCl2 (final concentration, 5 mM). The reactions
 
were stopped after pre-
selected time intervals by the addition
 
of 36 µL of stop solution (95% formamide (w/v),
 
10 mM EDTA, 0.03% bromophenol blue (w/v), 0.03% xylene cyanol (w/v)) to a 4 µl 
aliquot of the sample. 
Primer Extension Assays.
32
P-endlabeled primer/template complexes containing 
either unmodified dA or 1,N
6
-γ-HMHP-dA at position X of the template strand were 
incubated with DNA polymerases as described above in the presence of all four dNTPs 
(500 µM) for 0-60 minutes. The reaction products were separated on a 20% (w/v) 
denaturing polyacrylamide gel containing 7 M urea at a constant voltage (2500 V) for 3 
h. The radioactive products were visualized with a phosphorimager (Bio-Rad). 
Steady-state Kinetics Analyses. 
32
P-endlabeled primer/template complexes were 
incubated with TLS polymerases in the presence of increasing concentrations of 
individual dNTPs (0-800 µM) for 0-60 minutes. The resulting oligodeoxynucleotide 
products were separated by gel electrophoresis as described above and visualized with a 
phosphorimager. DNA amounts in each band were quantified with Quantity One image 
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software (Bio-Rad), and the steady-state kinetic values were determined by plotting 
product formation versus dNTP concentration by nonlinear regression analysis (one-site 
hyperbolic fits in GraphPad Prism). 
HPLC-ESI-MS/MS analysis of primer extension products from DNA 
polymerase reactions. Oligodeoxynucleotide 18-mers (5'-TCATXGAATCCTTCCCCC-
3', where X = dA or (R,S) 1,N
6
-γ-HMHP-dA) were annealed to the 13-mer primer (5'-
GGGGGAAGGAUTC-3') (100 pmol each) in 20 µl 50 mM NaCl to form template-
primer complexes. The resulting partial duplexes were incubated with individual DNA 
polymerases (hPol κ, 40 pmol; hPol η, 40 pmol; or Dpo4, 100 pmol) in 50 mM Tris-HCl 
(pH 7.8) buffer containing 5% glycerol, 5 mM DTT, 5 mM MgCl2, 100 µg/ml BSA at 37 
°C for 4-6 hours. Primer extension reactions were initiated by the addition of all four 
dNTPs (1 mM each) in a final reaction volume of 75 µl. The reactions were terminated 
by removing excess dNTPs by size exclusion on a Bio-Spin 6 column (Bio-Rad). Tris-
HCl, DTT and EDTA were added to the filtrate to restore their concentrations to 50 mM, 
5 mM, and 1 mM, respectively.  
In order to facilitate MS/MS analyses, oligodeoxynucleotide products were 
cleaved into smaller fragments by incubation with uracil DNA glycosylase (UDG, 6 
units, 37
 
°C for 6 hours), followed by heating with 0.25 M piperidine at 95
 
°C for 1 hour 
(176). The final solution was dried under vacuum, and the residue was reconstituted in 25 
µl of water. 14-mer oligonucleotide (5'p-CTTCACGAGCCCCC-3'; 40 pmol) was added 
as an internal standard for mass spectrometry. The injection volume for mass 
spectrometric analysis was 8 µl. Primer extension products following reactions catalyzed 
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by hPol β (10 units) and hPol ι (80 pmol) were not cleaved with UDG/piperidine since 
only short extension products were observed that could be directly sequenced by MS/MS.  
HPLC-ESI
-
-MS/MS analysis was conducted on an Eksigent HPLC system 
(Eksigent, Dublin, CA) interfaced to a Thermo LTQ Orbitrap Velos mass spectrometer 
(Thermo Fisher Scientific, Waltham, MA). The instrument was operated in the negative 
ion ESI MS/MS mode. Polymerase extension products were separated with an Agilent 
Zorbax SB 300 C18 (0.5 x 150 mm, 5 µm) column using a gradient of 15 mM 
ammonium acetate (Buffer A) and acetonitrile (Buffer B). The column was eluted at a 
flow rate of 15 µl/min. The solvent composition was linearly changed from 1 to 10 % B 
in 18 min, further to 75% B in 2 min, held at 75% B for 3 min, and brought back to 1% B 
in 2 min and held at 1% B for 10 min. Under these conditions, all DNA 
oligodeoxynucleotides, including extension products, eluted between 10 and 13 minutes.  
Electrospray ionization conditions were as follows: ESI source voltage, 3.5 kV; 
source current, 6.7 µA; auxiliary gas flow rate setting, 0; sweep gas flow rate setting, 0; 
sheath gas flow setting, 30; capillary temperature, 275 °C; and S-lens RF level, 50%. The 
most abundant ions from the ESI
-
-FTMS spectra were selected and subjected to collision-
induced dissociation (CID) analysis on the linear ion trap. The MS/MS conditions were 
as follows: normalized collision energy, 35%; activation Q, 0.250; activation time, 10 ms; 
product ion scan range, m/z 300-2000. The amount of each extension product was 
calculated by comparing peak areas corresponding to each product in extracted ion 
chromatograms with the peak area of the internal standard. Expected CID fragmentation 
patterns of oligonucleotides were obtained with the Mongo Oligo mass calculator v2.06 
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available from the Mass Spectrometry Group of Medicinal Chemistry at the University of 
Utah (http://library.med.utah.edu/masspec/ mongo.htm). 
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Scheme 5.2 Sequences of DNA substrates with (R,S) 1,N
6
-γ-HMHP-dA adduct employed 
in primer extension assays 
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5.3 Results 
5.3.1 Primer extension studies in the presence of all four dNTPs 
Our initial studies investigated the ability of DNA polymerases to bypass 1,N
6
-γ-
HMHP-dA lesions in the presence of all four dNTPs. 1,N
6
-γ-HMHP-dA was site-
specifically incorporated into a 18-mer template (5'-TCATXGAATCCT TCCCCC-3', 
where X = 1,N
6
-γ-HMHP-dA), which was annealed to a 13-mer primer (5'-
GGGGGAAGGATTC-3'). In the resulting duplex (Scheme 5.2), the primer terminus is 
positioned immediately prior to the lesion site. The template-primer complexes were 
subjected to in vitro replication in the presence of hPol β, η, κ, ι, and Dpo4. Control 
experiments with template containing only native nucleotides (X = dA) confirmed a 
complete primer extension by hPol β, hPol κ, hPol η, and Dpo4, to form an 18-mer 
product (Left panels in Figures 5.1A and 5.2). In addition, some 19-mer products have 
also been observed with Dpo4 (Figure 5.2C, left panel), which could be attributed to 
template independent nucleotide incorporation (blunt end addition) as observed 
previously (160;234). hPol ι formed primarily a 16-mer product (Figure 5.1B) due to its 
low processivity as compared to other Y family polymerases (235-238) 
The presence of 1,N
6
-γ-HMHP-dA at position X led to a complete blockage of 
primer extension by hPol β, while hPol ι inserted a single nucleotide, but was unable to 
extend past the lesion site (right panels in Figure 5.1). In contrast, hPol η and hPol κ were 
able to extend the primer to the terminus, forming the expected 18-mer products (right 
panels in Figure 5.2). The efficiency of primer extension was markedly reduced in the 
presence of 1,N
6
-γ-HMHP-dA as compared to unmodified dA, as evident by the presence 
 177 
 
of incomplete extension products (15-mers, 16-mers, and 17-mers). No primer extension 
was observed in Dpo4 reactions with 1,N
6
-γ-HMHP-dA-containing DNA template until 
the enzyme:DNA ratio was increased to 1:2.  
To determine whether the incomplete extension products generated by hPol ι 
(which is stalled after the insertion of dTMP opposite the 1,N
6
-γ-HMHP-dA adduct, 
Figure 5.1B) can be extended by hPol η or κ, 32P-endlabeled primer/template complexes 
were first incubated in the presence of hPol ι, resulting in the extension of primer by one 
base to form a 14-mer product. Upon subsequent addition of hPol κ to the above reaction 
mixture, the 14-mer product was completely extended to form the expected 18-mer 
product (Figure 5.3). Similar results were obtained in the presence of hPol η (data not 
shown). This provides preliminary evidence for possible co-operativity of TLS 
polymerases during the replication of 1,N
6
-γ-HMHP-dA-containing DNA, with hPol ι 
adding one nucleotide across the damaged base, polymerase switching, and hPol η or κ 
completing the bypass synthesis. 
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Figure 5.1 Primer extension opposite dA or 1,N6-γ-HMHP-dA adduct by hPol β and 
hPol ι  
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Figure 5.2 Primer extension opposite dA or 1,N
6
-γ-HMHP-dA adduct by hPol η, hpol κ 
and Dpo4
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Figure 5.3 Cooperativity of human TLS polymerases ι and κ during the bypass of 1,N6-γ-
HMHP-dA adduct 
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5.3.2 Steady state kinetic analysis of dNTP incorporation opposite 1,N
6
-γ-HMHP-dA 
adducts 
Single nucleotide insertion assays were conducted in order to compare the rates of 
incorporation of each nucleotide opposite 1,N
6
-γ-HMHP-dA lesion by individual TLS 
DNA polymerases. Template-primer complexes containing 1,N
6
-γ-HMHP-dA or 
unmodified dA (control) were incubated with polymerase enzymes in the presence of 
each of the four individual dNTPs. Our pilot experiments have revealed that hPol η, hPol 
κ and Dpo4 incorporate dTMP, dAMP, and dGMP, but not dCMP, opposite the 1,N6-γ-
HMHP-dA lesion (Figure 5.4). hPol ι preferentially inserted dTMP opposite the lesion. 
Subsequently, the rates of incorporation of dAMP, dGMP, and dTMP opposite 1,N
6
-γ-
HMHP-dA by hPol η, hPol κ, and Dpo4 were determined in kinetic experiments. No 
kinetic analysis was possible for hPol β, since it was completely blocked by 1,N6-γ-
HMHP-dA (Figure 5.1). In the case of hPol ι, the kinetic experiments were limited to 
dTMP, since no incorporation of other nucleotides was observed. The insertion rate for 
each nucleotide was calculated by plotting reaction velocity against dNTP concentration. 
The kinetic results are summarized in Table 5.1, where the catalytic specificity constant 
(kcat/Km) provides a measure of catalytic efficiency for each dNTP insertion, while the 
misinsertion frequency (f) reflects the probability of insertion of an incorrect dNTP as 
compared to that of correct one (dTTP) . 
Our kinetic data indicate that hPol η, hPol κ, and hPol ι polymerization rates for 
template-primer complexes containing 1,N
6
-γ-HMHP-dA were 3-8 fold slower than for 
the control templates containing unmodified dA (Table 5.1). In the case of Dpo4, the 
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efficiency of incorporation of correct base (dTMP) opposite 1,N
6
-γ-HMHP-dA was 600 
fold lower than dT incorporation opposite unmodified dA. The preference order for the 
insertion of individual dNTPs opposite the 1,N
6
-γ-HMHP-dA adduct by hPol η was T > G 
> A, with approximately 1.5-fold preference for incorporation of dTMP as compared to 
dGMP and dAMP (Table 5.1). A similar specificity (T > G > A) was observed for hPol κ, 
which was 1.5-fold more likely to incorporate dTMP rather than dGMP opposite the 
lesion and 5-fold more likely to insert dTMP rather than dAMP (Table 5.1). The 
preference order for Dpo4 was T > A > G, and this polymerase was 2- fold more likely to 
incorporate dTMP rather than dAMP and 3-fold more likely to incorporate dTMP rather 
than dGMP (Table 5.1).  
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Figure 5.4 Single nucleotide insertion by hPol η (A) and hPol k (B) opposite unmodified 
dA (control) and 1,N
6
-γ-HMHP-dA 
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Table 5.1 Steady-state kinetic parameters for single nucleotide incorporation opposite dA 
and 1,N
6
-γ-HMHP-dA adduct 
Polymerase Template incoming 
nucleotide 
kcat (min
-1
) Km (µM) kcat/Km  
(µM
-1
 min
-1
) 
f 
hPol κ dA dTTP  0.3 ± 0.01 0.8 ± 0.1 0.38 1 
dATP  0.06 ± 0.005 20 ± 4.6 0.003 0.008 
dGTP  0.27 ± 0.01 73 ± 10.4 0.004 0.01 
1,N
6
-γ-
HMHP-dA 
dTTP  0.3 ± 0.02 4.0 ± 1.0 0.07 1 
dATP  0.2 ± 0.004 13 ± 3.5  0.01 0.2 
dGTP  1.8 ± 0.008 35 ± 7.4 0.05 0.7 
hPol η dA dTTP  1.6 ± 0.1 3.2 ± 0.9  0.5 1 
dATP  0.04 ± 0.002 5.6 ± 2.3 0.007 0.01 
dGTP  0.09 ± 0.02 35 ± 25 0.002 0.004 
1,N
6
-γ-
HMHP-dA 
dTTP  0.6 ± 0.03 4.4 ± 1.2 0.14 1 
dATP  0.7 ± 0.03 9.2  ± 2.2 0.08 0.57 
dGTP  0.9 ± 0.04 10 ± 2.0 0.09 0.65 
Dpo4 dA dTTP  0.6 ± 0.03 2.8 ± 0.4 0.21 1 
dATP  0.05 ± 0.005 471 ± 112 0.00016 0.0004 
1,N
6
-γ-
HMHP-dA 
dTTP  0.35 ± 0.04 979 ± 194 0.00035 1 
dATP  0.14 ± 0.05 884 ± 272 0.00016 0.45 
dGTP  0.07 ± 0.004 596 ± 77 0.00011 0.31 
hPol ι dA dTTP 1.6  0.2 21  7 0.08 1 
1,N
6
-γ-
HMHP-dA 
dTTP 0.06  0.004 4.6  1.5 0.01 1 
* f is misinsertion frequency  
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5.3.3 LC-MS/MS Analysis of primer extension products 
A mass spectrometry based strategy was employed to confirm the identities of 
nucleotides incorporated opposite 1,N
6
-γ-HMHP-dA adduct by various DNA 
polymerases and to detect any insertion/deletion events. Synthetic template-primer 
complexes were incubated with individual polymerases in the presence of all four dNTPs, 
and the primer extension products were sequenced by capillary HPLC-ESI
-
-MS/MS using 
an LTQ Orbitrap Velos instrument. Due to the high sensitivity of this method, 100 pmol 
of DNA was sufficient to obtain sequence information for the extension products.  
Parallel reactions were conducted with unmodified and 1,N
6
-γ-HMHP-dA 
containing template-primer complexes (Scheme 5.2, bottom). To facilitate MS analysis of 
the products, one of the thymine residues within the primer was substituted for uridine 
(5'-GGGGGAAGGAUTC-3') to allow for selective cleavage of the extension products 
with UDG/hot piperidine. This generates oligonucleotides (5-, 6- or 7-mers) that are short 
enough to be readily sequenced by HPLC-ESI-MS/MS(164). However, the extension 
products from hPol β and hPol ι-catalyzed reactions were not cleaved since these 
polymerases generated short products by adding 0-1 nucleotides (Figure 5.1).  
Each primer extension reaction mixture was analyzed twice. First, samples were 
analyzed by full scan HPLC-ESI
-
-FTMS to detect the molecular ions corresponding to 
the expected extension products (Figure 5.5). In subsequent analysis, MS/MS spectra of 
these target ions were obtained (Figure 5.6). Tandem mass spectra of the observed 
oligodeoxynucleotides (Figures 5.7 and 5.8) were compared to the predicted CID spectra 
of each extension product to determine their nucleobase sequence. 
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Figure 5.5 HPLC-ESI
-
-MS/MS analysis of in vitro replication opposite 1,N
6
-γ-HMHP-
dA-adduct containing template by hPol κ 
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Figure 5.6 Extracted ion chromatograms of primer extension products opposite 1,N
6
-γ-
HMHP-dA- adduct template by hPol κ 
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Figure 5.7 MS/MS spectra of full length primer extension products observed following in 
vitro replication of 1,N
6
-γ-HMHP-dA-containing template by hPol κ 
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Figure 5.8 MS/MS spectra of -1 and -2 deletion products observed following in vitro 
replication of 1,N
6
-γ-HMHP-dA-containing template by hPol κ 
 
 
 
 
 
 
 
 
 190 
 
HPLC-ESI
-
-MS/MS analysis of the hPol β reactions with unmodified template-
primer complex and all four dNTPs revealed the presence of the fully extended primer 
(5'-GGGGGAAGGAUTCTATGA-3'; m/z 1406.23; [M-4H]
4-
) as the major product (> 
95%) (not shown). This is consistent with our previous observation (left panel in Figure 
5.1A) that in the absence of the lesion, the primer is completely extended by hPol β. In 
contrast, the corresponding reaction mixtures from hPol β extension of 1,N6-γ-HMHP-dA 
containing template:primer complexes contained mainly the unextended primer (5'-
GGGGGAAGGAUTC-3'; m/z 1015.17; [M-4H]
4-
) (results not shown). These results 
indicate that primer extension by human Pol β is completely blocked by the 1,N6-γ-
HMHP-dA lesion, in accordance with our previous observation from the gel 
electrophoresis analysis (right panel in Figure 5.1A).  
HPLC-ESI
-
-MS/MS analysis of the primer extension products produced upon 
incubation of 1,N
6
-γ-HMHP-dA containing template:primer complexes with hPol κ has 
revealed six major peaks at m/z: 777.6, 929.6, 942.1, 1086.2, 1090.7, 1098.7 which 
correspond to the doubly charged ions of 5'-pTC__TGA-3', 5'-pTCT_TGA-3', 5'-
pTCG_TGA-3', 5'-pTCTATGA-3', 5'-pTCAATGA-3', and 5'-pTCGATGA-3', 
respectively (Scheme 5.3A, Figure 5.6). CID spectra of each extension product were 
obtained in order to determine their exact nucleobase sequence (Figures 5.7 and 5.8). 
This sequence information cannot be obtained from molecular weight only. For instance, 
the molecular weight of the doubly charged ions at m/z 1086.2 (M = 2175.4) is consistent 
with an oligonucleotide product containing three Ts, two As, one C, and one G. 
Extension products 5'p-TCTATGA-3' (insertion of T opposite the lesion and A opposite 
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the next base) and 5'-p TCATTGA-3' (insertion of A opposite the lesion and T opposite 
the next base) are indistinguishable by gel electrophoresis or MW. By comparing the CID 
spectra obtained from MS/MS analysis with the predicted CID fragments (a-B and w 
ions, Figure 5.7C, Table 5.2), the sequence of the product was determined as 5'p-
TCTATGA-3', with the correct base (T) inserted opposite the adduct. Detailed MS/MS 
analysis was conducted for each of the hPol κ extension products detected by HPLC-ESI-
-FTMS. According to HPLC-ESI
-
-FTMS peak areas, 18% of the extension products were 
error-free, with the incorporation of correct base (T) opposite the lesion (Scheme 5.3A). 
Approximately 21% and 25% of the extension products were formed by misincorporation 
of dAMP and dGMP opposite the lesion, respectively. In addition, three deletion products 
were detected. 5'-pTCG_TGA-3' (22%) was formed as a result of misinsertion of G 
opposite 1,N
6
-γ-HMHP-dA and deletion of the next base. 5'-pTCT_TGA-3' (13%) was 
formed upon incorporation of the correct base (T) opposite the lesion and skipping the 
next base. A minor -2 deletion product, 5'-pTC__TGA-3' (< 1%), was also detected, in 
which no base was incorporated opposite the lesion or the 3'-neighboring base. These 
results are summarized in Scheme 5.3A. Overall, our HPLC-ESI
-
-FTMS results for hPol 
κ are consistent with the gel electrophoresis data, but revealed several additional products 
generated upon deletion of one or two bases. 
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Scheme 5.3 Summary of primer extension products opposite X= (R,S) 1,N
6
-γ-HMHP-dA 
by hPol κ , hPol η and Dpo4 
 
(A) hPol κ 
 
 
 
(B) hPol η 
 
(C) Dpo4 
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Table 5.2 Expected CID fragments of 5'-pTCTATGA-3' 
 
 
    n   ch      a-B        w         y       d-H2O 
 
    1   -1             330.217   250.237   303.189 
        -2                                 151.090 
    2   -1   481.274   659.427   579.447   592.374 
        -2   240.133   329.209   289.219   295.683 
        -3                                 196.786 
    3   -1   770.459   963.624   883.644   896.571 
        -2   384.725   481.308   441.318   447.781 
        -3   256.147   320.536   293.876   298.185 
        -4                                 223.386 
    4   -1  1074.656  1276.834  1196.854  1209.781 
        -2   536.824   637.913   597.923   604.386 
        -3   357.546   424.939   398.279   402.588 
        -4   267.908   318.452   298.457   301.689 
        -5                                 241.149 
    5   -1  1387.866  1581.031  1501.051  1513.978 
        -2   693.429   790.011   750.021   756.485 
        -3   461.950   526.338   499.678   503.987 
        -4   346.210   394.501   374.506   377.738 
        -5   276.766   315.399   299.403   301.989 
        -6                                 251.489 
    6   -1  1692.063  1870.216  1790.236  1843.188 
        -2   845.527   934.604   894.614   921.090 
        -3   563.349   622.733   596.073   613.724 
        -4   422.259   466.798   446.803   460.041 
        -5   337.606   373.236   357.240   367.831 
        -6   281.170   310.862   297.532   306.358 
        -7                                 262.448 
 
 
*Fragments found in the CID spectrum are shown in bold 
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HPLC-ESI
-
-MS/MS analysis of the primer extension products from hPol η - 
catalyzed reactions revealed the same six major products as observed with hPol κ (5'-
pTC__TGA-3', 5'-pTCT_TGA-3', 5'-pTCG_TGA-3', 5'-pTCTATGA-3', 5'-pTCAATGA-
3', and 5'-pTCGATGA-3'), but their relative contributions were entirely different 
(Scheme 5.3B). Error free replication past the adduct (5'-p TCTATGA-3') accounted for 
over 80% of the total products. The relative yields of 5'-pTCGATGA-3' and 5'-p 
TCAATGA-3' corresponding to the incorporation of incorrect bases, G and A, opposite 
the lesion, accounted for < 10%, while single deletion products, 5'-pTCG_TGA-3' and 5'-
pTCT_TGA-3', accounted for < 5%. The double deletion product (5'-pTC__TGA-3') was 
also detected, with the relative yield of < 1%. These results are summarized in Scheme 
5.3B. Taken together, these results indicate that hPol η makes fewer errors than does hPol 
κ upon replicating 1,N6-γ-HMHP-dA containing DNA. 
HPLC-ESI-FTMS analysis of hPol ι extension products of 1,N6-γ-HMHP-dA 
containing 18-mer oligonucleotide template:primer complexes revealed the formation of 
a single product with an m/z of 1091.20 (not shown). CID fragmentation of m/z 1091.20 
confirmed that the product was 5'-GGGGGAAGGAUTCT-3', which is formed upon 
incorporation of the correct base (T) opposite the lesion, but no further extension by the 
enzyme (results not shown). As discussed above, UDG/piperidine cleavage was not 
employed for hPol ι generated products due to their relatively short length, enabling their 
direct sequencing by MS/MS. These results confirm that human hPol ι is able to insert the 
correct base (T) opposite 1,N
6
-γ-HMHP-dA, but is unable to extend the primer beyond 
the damaged site. This result is consistent with our gel electrophoresis results (see above). 
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HPLC-ESI
-
-MS/MS analysis of the Dpo4 primer extension mixtures has revealed 
the presence of five major DNA peaks at m/z 929.6, 934.2, 1086.2, 1090.7, and 1098.7 
(Scheme 5.3C). The nucleobase sequences of these products were determined by MS/MS 
as described above. We found that the major products were 5'-pTCTATGA-3' (59%) and 
5'-pTCAATGA-3' (30%), corresponding to error-free replication and the misinsertion of 
A opposite the lesion, respectively. A low abundance product, 5'-pTCGATGA-3' (4%) 
formed by the misinsertion of G, was also observed. Analogous to our results for hPol κ, 
a single nucleotide deletion product 5'-pTCT_TGA-3' (5%) was found. A novel 
frameshift deletion product, 5'-pTCA_TGA-3' (2%), was formed by misinsertion of A 
opposite the adduct, followed by skipping of the neighboring 3' base. These results are 
summarized in Scheme 5.3C. 
5.4 Discussion 
 
1,2,3,4-Diepoxybutane (DEB) is a key carcinogenic metabolite of 1,3-butadiene 
(BD), an important industrial and environmental chemical present in urban air and in 
cigarette smoke. DEB is considered the ultimate carcinogenic metabolite of BD due to its 
potent genotoxicity (26). Studies in the hprt gene have revealed that DEB induces a large 
number of A → T mutations and deletions, along with smaller numbers of A→G and 
A→C base substitutions (230;239). Furthermore, exposure of rat2 laci transgenic cells 
and human TK6 lymphoblasts to DEB induced an increased frequency of A → T 
transversions and partial deletions (Table 1.4) (35).  
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Despite significant efforts, specific DNA adducts responsible for DEB-induced 
genetic changes have not been previously identified.  DEB-mediated DNA alkylation 
gives rise to a complex mixture of nucleobase adducts including 2,3,4-trihydroxybut-1-yl 
(THB) monoadducts, 2,3-dihydroxy-butane-1,4-yl DNA-DNA cross-links, DNA-protein 
lesions, and exocyclic dG and dA adducts (177-179;181;193). Polymerase bypass studies 
of synthetic DNA templates containing N
6
-THB-adenine monoadducts revealed 
essentially error-free replication, producing very low levels of A  G and A  C base 
substitutions (< 0.3%) (177). N
2
-THB-dG lesions completely blocked DNA replication 
(178). The N1-THB-dI lesions originating from deamination of the corresponding N1-dA 
adducts induced high numbers of A  G transitions (179). Similar studies conducted 
with putative N
2
-guanine and N
6
-adenine intrastrand DNA-DNA cross-links have 
revealed that bis-N
2
G-BD crosslinks are not bypassed by DNA polymerases, while bis-
N
6
A-BD lesions induce A  G base substitutions at the 3'-base (179;181). It should be 
noted that N1-THB-dI, bis-N
6
A-BD, and bis-N
2
G-BD have not been detected in tissues of 
BD-treated animals and may not be relevant in vivo. In summary, studies to date have not 
uncovered the origins of A  T transversions that predominate in DEB-treated cells and 
tissues. 
Previous studies in our laboratory have revealed that DEB can sequentially react 
with the N1 and the N
6
 positions of adenine in DNA to form 1,N
6
- α-HMHP-dA adducts 
(Scheme 5.1) (48). 1,N
6
-α-HMHP-dA can undergo a slow, reversible Dimroth-like 
rearrangement in water at room temperature to 1,N
6
-γ-HMHP-dA adducts (48). The 
concentrations of both exocyclic 1,N
6
-HMHP-dA adducts increased linearly when calf 
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thymus DNA was treated in vitro with increasing concentrations of DEB (50 to 1000 μM) 
(48). Furthermore, 1,N
6
-HMHP-dA adducts were formed in a dose-dependent manner in 
liver, kidney, and lung DNA of B6C3F1 mice exposed to BD by inhalation (67). 
Importantly, these lesions persisted in vivo, with an estimated half-life of > 40 days (185). 
Based on their stability and their chemical structure that resembles known promutagenic 
lesions such as 1,N
6
-etheno-dA and 1,N
6
-ethano-dA, 1,N
6
-HMHP-dA adducts have been 
proposed to contribute to the mutagenicity of BD (185).  
In the present study, in vitro polymerase bypass experiments were conducted 
employing synthetic DNA templates containing site specific 1,N
6
-γ-HMHP-dA adducts. 
Human lesion bypass polymerases hPol β, hPol η, hPol κ, hPol ι and archebacterial DNA 
polymerase Dpo4 were investigated, since these polymerases are known to conduct DNA 
replication past a variety of DNA lesions. For example, hPol η is capable of bypassing 8-
oxoguanine, O
6
-methylguanine and cis-syn TT dimer (120), while hPol κ efficiently 
bypasses bulky N
2
-guanine adducts (121;162). Additionally, hPol ι has been proven to 
conduct translesion synthesis across several DNA lesions including N
2
-ethylguanine 
(235). 1,N
2
-etheno guanine and M1dG lesions are bypassed by archebacterial polymerase 
Dpo4 (164;240). 
Primer extension experiments combined with gel electrophoresis and HPLC-
MS/MS analyses of the products revealed that hPol η, hPol κ, and Dpo4 were able to 
bypass the lesion and to extend the primer completely to the terminus (Figures 5.1, 5.2, 
and 5.6). In contrast, hPol β was completely blocked by the lesion, while hPol ι 
incorporated the correct nucleotide (dTMP) opposite the lesion, but was unable to extend 
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the primer further (Figure 5.1B). However, incomplete primer extension products 
generated by hPol ι can be completed either by hPol η or hPol κ (Figure 5.3). Similar co-
operativity experiments conducted for N
2
-ethylguanine adducts revealed that hPol η can 
successfully complete the polymerization started by hPol α (241). 
Steady state kinetic analysis of the incorporation of single nucleotide opposite the 
lesion was completed for human Pol η, Pol κ, Pol ι and Dpo4 to determine the specificity 
constants (kcat/Km) and to obtain the misinsertion frequencies (f). The kcat/Km values for 
the incorporation of correct nucleotide (dTMP) opposite 1,N
6
-γ-HMHP-dA by hPol η and 
hPol κ were 0.14 and 0.07 µM-1 min-1, respectively, which is comparable to 
corresponding values for dTMP insertion opposite structurally analogous 1,N
6
-εdA 
lesions (0.004 and 0.001 µM
-1
 min
-1
, respectively) (165). The efficiency of incorporation 
of dTMP opposite the lesion by hPol η and hPol κ was 3-8 fold lower than those for the 
control template containing unmodified dA (Table 5.1). An even greater decrease (600-
fold) was observed for archebacterial DNA polymerase Dpo4. Similar decreases in the 
efficiency of Dpo4 upon replication of damaged templates have been previously reported 
for the incorporation of dCTP opposite guanine adducts 7,8-dihydro-8-
oxodeoxyguanosine (169), O
6
-methylguanine (173) and 1,N
2
-ethenoguanine (164).  
In addition to the correct base (dTMP), hPol η, κ, and Dpo4 also inserted incorrect 
bases (dGMP and dAMP) opposite 1,N
6
-γ-HMHP-dA lesions.  The misinsertion 
frequency was between 0.2-0.7, depending on specific polymerase (Table 5.1). For 
example, the frequency of dAMP incorporation opposite 1,N
6
-γ-HMHP-dA by hPol κ 
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was 0.7 (Table 5.1). If observed in vivo, such mis-incorporation is expected to cause 
A→T transversion mutations.  
An important limitation of gel electrophoresis experiments is that they cannot 
determine the nucleotide sequence of the primer extension products, potentially yielding 
misleading or incomplete results. Zang et al. have developed a robust methodology for 
the analysis of primer extension products by HPLC-ESI-MS/MS (164). In their approach, 
a uracil residue is introduced into the primer, and the extension products are cleaved with 
UDG/hot piperidine to facilitate their sequencing by tandem mass spectrometry. This 
methodology has been previously applied in polymerase bypass studies of several DNA 
lesions (160;162;169;173;176). We adopted a similar methodology to sequence the in 
vitro replication products of 1,N
6
-γ-HMHP-dA containing templates by HPLC-ESI-
MS/MS (Figures 5.5-5.7, Schemes 5.3-5.5). To enhance HPLC-ESI
-
-MS/MS detection 
sensitivity, a capillary HPLC column was employed instead of the conventional 1.0-2.0 
mm i.d. columns used previously (160;162;169;173;176). By this modified HPLC-ESI
-
-
MS/MS methodology, it was possible to characterize primer extension products with only 
100 pmol of modified oligonucleotide. In comparison, the previous analytical methods 
required 1-4 nmol of modified oligonucleotide and large amounts of recombinant 
polymerases (160;162;169;173;176). The observed CID spectra of the primer extension 
products were in good agreement with the predicted CID spectra (Figures 5.7, 5.8 and 
Table 5.2). 
HPLC-MS/MS sequencing has revealed that among the three polymerases that are 
able to conduct DNA synthesis past 1,N
6
-γ-HMHP-dA (hPol η, hPol κ, and Dpo4), primer 
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extension by hPol κ was the most error-prone. hPol κ displayed a greater preference for 
the incorporation of incorrect nucleotide dGMP opposite the lesion (Scheme 5.3A) as 
compared to the correct nucleotide dTMP. Only 18% of the total extension products 
formed corresponded to error-free replication products. In addition, -1 frameshift 
products accounted for approximately 35% of the total hPol κ extension products 
(Scheme 5.3A and Figure 5.8). In these cases, dGMP or dTMP were incorporated 
opposite the lesion, and the next base was skipped, followed by correct primer extension 
all the way to the terminus (Scheme 5.3A). On the other hand, in vitro replication past 
1,N
6
-γ-HMHP-dA by hPol η and Dpo4 was less error-prone, with a higher production of 
error-free extension products that accounted for more than 60% of the products and a 
lower percentage of single nucleotide deletion products (<10%) (Schemes 5.4 and 5.5). 
For both hPol η and Dpo4, misincorporation of dGMP opposite the lesion accounted for 
less than 10% of total products. However, Dpo4 reaction mixtures also contained 
significant amounts of the extension product corresponding to the incorporation of dAMP 
opposite the lesion (30%). In addition, small amounts of -2 frame shift deletion products 
were observed in primer extensions catalyzed by Pol κ and η, but not Dpo4.  
Taken together, our gel electrophoresis and tandem mass spectrometry results 
indicate that human TLS polymerases η, κ and Dpo4 are able to bypass DEB-induced 
1,N
6
-γ-HMHP-dA lesions and to extend the primer to the terminus, but they are 
potentially error-prone. In addition to correct nucleotide (dTMP), these bypass 
polymerases incorporate dAMP and dGMP opposite the lesion and produce -1 and -2 
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deletion products (Schemes 5.3-5.5). In contrast, hPol ι is unable to extend beyond the 
1,N
6
-γ-HMHP-dA lesion, and hPol β is completely blocked at the modification site.  
A possible model for the insertion of dA, dT, dG opposite 1,N
6
-γ-HMHP-dA is 
shown in Scheme 5.4. 1,N
6
-γ-HMHP-dA adduct can exist in two tautomeric froms. The 
N1-C6 immonium ion  tautomer can be envisioned to adopt a syn confirmation and form 
a stable Hoogsteen base pair with dT or dG. The C6-N
6
 imino tautomer could form a 
Hoogsteen base pair with protonated dA. The ability of 1,N
6
-γ-HMHP-dA adduct to adopt 
a syn confirmation and mispair with dG and protonated dA is not unprecedented. For 
example, 1,N
6
-etheno-dA adducts have been shown to adopt the syn confirmation in the 
active site of hPol ι, forming a Hoogsteen base pair with dT or protonated dC (229). 
Taken together, our results provide a possible mechanism for the induction of A→T and 
A→C transversions and frame shift mutations by DEB and its metabolic precursor, 1,3-
butadiene. 
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Scheme 5.4 Models for the correct insertion of dT and misinsertion of dG and dA 
opposite 1,N
6
-γ-HMHP-dA 
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VI. TRANSLESION SYNTHESIS ACROSS 1,3-BUTADIENE-INDUCED N6-
DEOXYADENOSINE ADDUCTS BY HUMAN DNA POLYMERASES 
6.1 Introduction 
While the exact mechanisms of smoking-induced lung cancer remain to be established 
(7), DNA adducts induced by electrophilic metabolites of tobacco carcinogens are 
thought to induce critical genetic changes required for cancer initiation (242). If not 
repaired, some tobacco carcinogen-DNA adducts can block DNA replication by normal 
replicative DNA polymerases (120;122;243). A specialized group of polymerases called 
translesion synthesis (TLS) polymerases are capable of accommodating damaged DNA 
bases in their open and flexible active sites, allowing for replication to continue in the 
presence of nucleobase damage and preventing toxicity (120;122;123;243). hPol η, hpol 
ι, hpol κ, Rev1 belonging to the Y family and Pol ζ from the B family of polymerases 
have the ability to carry out translesion DNA synthesis in humans (120-122;225;226). 
However, TLS polymerases have relatively low fidelity and carry out the replication 
process with high error rates (120;128;130), potentially contributing to mutations and 
cancer (7;242;244;245). 
  1,3-butadiene (BD) is a high volume industrial chemical used in the production of 
rubber and plastics (16). Exposure of general population to BD is widespread because of 
its presence in cigarette smoke, forest fires, and automobile exhaust (16;26). Based on 
inhalation studies in laboratory rodents and epidemiological evidence of an increased risk 
of leukemia in workers occupationally exposed to BD, BD is classified as a “known 
human carcinogen” by the National Toxicology Program (26). BD is metabolically 
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activated by CYP450 2E1 to form 3,4-epoxy-1-butene (EB) (27), which can be further 
oxidized to the highly mutagenic and genotoxic diepoxide,  1,2,3,4-diepoxybutane (DEB) 
(29). EB modifies the exocyclic amine groups of adenines in DNA to form N
6
-(2-
hydroxy-3-buten-1-yl)- 2′-deoxyadenosine (N6-HB-dA I) and its regioisomer N6-(1-
hydroxy-3-buten-2-yl)- 2′-deoxyadenosine (N6-HB-dA II) (42;59;182;246). DEB 
produces exocyclic deoxyadenosine lesions N
6
,N
6
-(2,3-dihydroxybutan-1,4-diyl)-2′-
deoxyadenosine (N
6
,N
6
-DHB-dA), N
6
-(2-hydroxy-3-hydroxymethylpropan-1,3-diyl)-2′-
deoxyadenosine (1,N
6
-γ HMHP-dA), and 1,N6-(1-hydroxymethyl-2-hydroxypropan-1,3-
diyl)-2′-deoxyadenosine (1,N6-α HMHP-dA) (48;67;185).  The mechanism of formation 
of N
6
-HB-dA I, N
6
-HB-dA II and N
6
,N
6
-DHB-dA from BD is illustrated in Scheme 6.1. 
  N
6
-HB-dA I and N
6
-HB-dA II (Scheme 6.1) have been detected in vitro (calf 
thymus DNA treated with EB)  (52;182;246) and in vivo (lung DNA of laboratory mice 
and rats exposed to BD by inhalation) (52;183). These adducts can be formed directly by 
alkylation of the N
6
 position of adenine or via Dimroth rearrangement of the 
corresponding N1-HB-dA lesions (42;246). N
6
,N
6
-DHB-dA adducts are yet to be 
observed in living cells, probably due to their relatively low abundance. 1,N
6
-HMHP-dA 
adducts were formed in vitro upon treatment of calf thymus DNA with DEB (48). 
Additionally, 1,N
6
-HMHP-dA adducts were also detected in DNA extracted from liver, 
lung and kidney tissues of mice exposed to BD by inhalation (67). Our recent study has 
revealed that polymerase bypass of 1,N
6
-γ-HMHP-dA adducts of DEB leads to A→T and 
A→C transversions and frameshift mutations (Chapter V) (247). However, the 
mispairing properties of N
6
-HB-dA I and N
6
,N
6
-DHB-dA lesions have not been 
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previously evaluated. We hypothesized that the presence of two alkyl groups at the 
exocyclic N
6
 position of adenine of N
6
,N
6
-DHB-dA interferes with Watson-Crick base 
pairing, leading to mutations  (48). In contrast, the presence of H-bond donor at the N
6
 
position of N
6
-HB-dA I may allow this lesion to form a correct base pair with dT. 
  The primary goal of the present study is to investigate the influence of N
6
-HB-dA 
I and N
6
,N
6
-DHB-dA adducts on DNA replication by human lesion bypass polymerases. 
Primer extension and steady-state kinetics studies for hPol β, hPol κ, hPol η and hPol ι 
were performed using synthetic DNA templates containing site-specific (S)-N
6
-HB-dA I 
or (R,R)-N
6
,N
6
-DHB-dA prepared in our laboratory. Our results reveal significant 
differences between the biological consequences of replication past N
6
-HB-dA I and 
N
6
,N
6
-DHB-dA lesions. While the N
6
-HB-dA was not mutagenic, N
6
,N
6
-DHB-dA adduct 
induced both point mutations and deletions, probably as a result of its inability to form 
the correct base pair with dT. 
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Scheme 6.1 Formation of N
6
-HB-dA and N
6
,N
6
-DHB-dA adducts from BD 
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6.2 Experimental Procedures 
Materials. Full-length recombinant human polymerase κ (hPol κ) used for gel 
electrophoresis experiments was purchased from Enzymax (Lexington, KY).  Human 
polymerase β was obtained from Trevigen (Gaithersburg, MD). Recombinant human 
DNA polymerases hPol  (amino acids 1-437), hPol ι (amino acids 1-420) and hPol κ 
(amino acids 19-526) were expressed and purified as per previously published 
methodologies (231-233). T4 polynucleotide kinase (T4-PNK) and E.coli uracil DNA 
glycosylase (UDG) were procured from New England Biolabs (Beverly, MA). [γ-
32
P]ATP was purchased from Perkin-Elmer Life Sciences (Boston, MA). Ammonium 
acetate, boric acid, bovine serum albumin (BSA), dithiothreitol (DTT), formamide, 
magnesium chloride, sigmacote, N,N,N′,N′-tetramethylethylenediamine, trizma base and 
urea were from Sigma Aldrich (St. Louis, MO), while ammonium persulfate, acetonitrile 
and EDTA were obtained from Fisher Scientific (Pittsburgh, PA). 40% 19:1 
Acrylamide/bis solution and Bio-spin columns were purchased from Bio-Rad laboratories 
(Hercules, CA). 
Oligonucleotides synthesis, labeling and annealing. Synthetic 18-mer 
oligodeoxynucleotides (5’-TCATXGAATCCTTCCCCC-3’) containing 6-chloropurine at 
position X were prepared by standard solid phase synthesis and coupled with (S)-N-
Fmoc-1-aminobut-3-en-2-ol (184) and (R,R)-pyrrolidine-3,4-diol (186) to yield the 
corresponding strands containing site- and stereospecific (S)-N
6
-HB-dA I and (R,R)-
N
6
,N
6
-DHB-dA adducts. Detailed methodologies for oligonucleotide synthesis have been 
previously published (184;186). The corresponding unmodified 18-mer template 
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containing native dA (5’-TCATAGAATCCTTCCCCC-3’), 13-mer primers (5’-
GGGGGAAGGATTC-3’ and 5’-GGGGGAAGGAUTC-3’) and 9-mer primer (5’-
GGGGGAAGG-3’) were purchased from Integrated DNA Technologies (Coralville, IA). 
All DNA oligodeoxynucleotides were purified by semi-preparative HPLC, characterized 
by HPLC-ESI
-
 MS/MS, and quantified by UV spectrophotometry (184;186). The 
structures of (S)-N
6
-HB-dA I, (R,R)-N
6
,N
6
-DHB-dA  adducts and the sequences of DNA 
oligomers used in this study are shown in Scheme 6.2. The 13-mer primer (5’-
GGGGGAAGGATTC-3’) and the 9-mer primer (5’-GGGGGAAGG-3’) were 
radiolabeled and subsequently annealed to the corresponding 18-mer templates as 
previously described (247) to obtain primer-template complexes for in vitro replication 
studies. 
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Scheme 6.2 Sequences of DNA substrates containing site specific (S)-N
6
-HB-dA and 
(R,R)-N
6
,N
6
-DHB-dA  lesions employed in primer extension assays 
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Primer Extension Assays. Primer extension studies were performed using the 
previously published methods (Section 5.2) (247), with a few modifications. Briefly, 
32
P-
endlabeled 13-mer primer-template duplexes (50 nM, shown in Scheme 6.2) were 
dissolved in a buffer containing 50 mM Tris-HCl (pH 7.8), 50 mM NaCl, 5 mM DTT,
 
100 µg/ml BSA, and 10% glycerol (v/v) and incubated at 37 
0
C in the presence of 
individual human DNA polymerases (hPol β, 12.5 nM; hPol η, 10 nM; hPol ι, 20 nM; 
hPol κ, 5 nM). The polymerase reactions were initiated by the addition of dNTP mix (500 
µM, all 4 dNTPs) in 5 mM MgCl2. Aliquots of the reaction mixture (4 µl) were taken at 
0, 5, 15, 30, 45 and 60 mins and quenched with 36 µl of stop solution (95% formamide 
(w/v),
 
10 mM EDTA, 0.03% bromophenol blue (w/v), 0.03% xylene cyanol (w/v)). 
Similar reactions were performed under running-start conditions with 
32
P-endlabeled 9-
mer primer/template duplexes (shown in Scheme 6.2) in the presence of higher enzyme 
concentrations (hPol β, 25 nM; hPol η, 25 nM; hPol κ, 12.5 nM). The primer extension 
products were resolved by gel electrophoresis using a 20% (w/v) denaturing 
polyacrylamide gel containing 7 M urea. The radioactive primer extension products were 
visualized on a GE Typhoon FLA 7000 phosphorimager.   
Steady-state Kinetics Analyses. The kinetics of incorporation of various 
nucleotides opposite (S)-N
6
-HB-dA I or (R,R)-N
6
,N
6
-DHB-dA was evaluated by 
conducting polymerization reactions in the presence of increasing concentrations of 
individual dNTPs (0-800 µM) for different time periods (0-180 min). The polymerase 
concentrations used were same as above, with the exception of hPol κ which was used at 
2.5 nM, 3.33 nM or 5 nM concentrations. The radioactive product bands visualized on a 
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GE Typhoon FLA7000 phosphorimager were quantified with ImageQuant software (GE 
HealthCare). Nonlinear regression analysis (one-site hyperbolic fits in GraphPad Prism) 
was employed to determine the steady-state kinetic parameters. 
HPLC-ESI-MS/MS analysis of primer extension products from DNA 
polymerase reactions. Uracil-containing 13-mer primer/template complexes (100 pmol) 
(shown in Scheme 6.2) were incubated with hPol η or hPol κ (40 pmol) in a buffer 
containing 50 mM Tris-HCl (pH 7.8), 5% glycerol, 5 mM DTT, 5 mM MgCl2, 100 µg/ml 
BSA and 1 mM each of the four dNTPs at 37 °C for 5 hours. At the end of incubation, 
excess dNTPs were removed with a size-exclusion chromatography column (Bio-Spin 6 
chromatography column; Bio-Rad).  The reaction mixture was restored to the 
concentrations of 50 mM Tris-HCl (pH 7.8), 5 mM DTT and 1 mM EDTA by the 
addition of appropriate buffers and subjected to UDG hydrolysis and piperidine treatment 
to reduce the size of primer extension products for sequencing by HPLC-ESI-MS/MS 
(247). The final reaction mixture was dried under vacuum and reconstituted in 25 µl of 
water containing 40 pmol of a 14-mer used as an internal standard (5’p-
CTTCACGAGCCCCC-3’). Primer extension products were resolved on a Agilent 
Zorbax SB 300 C18 (0.5 x 150 mm, 5µ) column on an Eksigent HPLC system (Eksigent, 
Dublin, CA) interfaced to a Thermo LTQ Orbitrap Velos mass spectrometer (Thermo 
Fisher Scientific, Waltham, MA) (247). The relative quantification and MS/MS 
sequencing of primer extension products were achieved in the ESI
-
 MS/MS mode as 
described previously in Section 5.2 (247). 
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6.3 Results 
6.3.1 Standing-start and Running-Start Primer extension studies with all  dNTPs 
Our initial experiments were conducted in the presence of all four 
deoxynucleotides in order to identify DNA polymerases capable of bypassing (S)-N
6
-HB-
dA I and (R,R)-N
6
,N
6
-DHB-dA adducts. Standing-start experiments were conducted with 
13-mer primer/18-mer template complexes, where the primer 3’ terminus is positioned 
one base prior to the unmodified dA (control), (S)-N
6
-HB-dA I, or (R,R)-N
6
,N
6
-DHB-dA 
on the template (X in Scheme 6.2). Under our experimental conditions, hPol β, hPol κ 
and hPol η completely extended 13-mer primers annealed to unmodified template 
(X=dA) to form the corresponding 18-mer products (Figures 6.1A, 6.2A, 6.2B; left 
panels) while primarily 16-mer (+1) products were formed in the reactions involving hPol 
ι (Figure 6.1B; left panel). hPol β, hPol κ and hPol η were able to bypass (S)-N6-HB-dA I 
lesion and completely extend the primer to the terminus to yield 18-mer products 
(Figures 6.1A, 6.2A, 6.2B; second panels), while hPol ι formed 16-mer products (Figure 
6.1B; second panel). The observation of incomplete primer extension products (15, 16, 
and 17-mers) in reaction mixtures involving (S)-N
6
-HB-dA I-containing template 
suggests that the efficiency of DNA synthesis was reduced in the presence of the lesion.  
In contrast, standing-start primer extension studies with (R,R)-N
6
,N
6
-DHB-dA 
template revealed no primer extension in the presence of hPol β at enzyme:DNA ratio of 
1:4 (Figure 6.1A; third panel) and an insignificant amount of primer extension (<2%) at 
enzyme:DNA ratio of 1:2 (Figure 6.1A; fourth panel), suggesting that translesion 
synthesis by hPol β is blocked by (R,R)-N6,N6-DHB-dA. hPol ι was able to incorporate a 
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single base opposite (R,R)-N
6
,N
6
-DHB-dA, but did not extend the primer any further, 
even at enzyme:DNA concentration of 1:1 (Figure 6.1B; third and fourth panels). Primer 
extension by hPol κ was stalled after single nucleotide incorporation opposite (R,R)-
N
6
,N
6
-DHB-dA to produce 14-mer products (Figure 6.2A; third panel). When the hPol 
κ:DNA ratio was changed from 1:10 to 1:2, significant amounts of 18-mer products were 
formed (Figure 6.2A; fourth panel). Similarly, hPol η was able to bypass (R,R)-N6,N6-
DHB-dA to form 18-mer products, but only when the polymerase concentration was 
increased significantly (hPol η:DNA ratio of 1:2) (Figure 6.2B; third and fourth panels). 
Overall, DNA synthesis past (R,R)-N
6
,N
6
-DHB-dA by all human polymerases studied 
was inefficient.  
Similar experiments were conducted under running-start conditions with a 9-mer 
primer/18-mer template duplex (Figure 6.3). We found that hPol β, hPol η, and hPol κ 
were able to bypass (S)-N
6
-HB-dA I and extend the primer completely to the terminus 
(Figures 6.3A-B, middle panel). In contrast, the presence of (R,R)-N
6
,N
6
-DHB-dA in the 
template has lead to stalling of  replication by hPol β at the site of damage and the 
formation of primarily 13-mer products (Figure 6.3A, right panel). In the presence of 
polymerases hPol η (data not shown) and hPol κ, primer extension past (R,R)-N6,N6-
DHB-dA primarily yielded 13-mer, 14-mer products and a small amount of 18-mer 
products (Figure 6.3B, right panel). These results are consistent with our standing-start 
results (Figure 6.2), confirming that (R,R)-N
6
,N
6
-DHB-dA can be bypassed by hPol η and 
hPol κ, albeit inefficiently.  
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Figure 6.1 Primer extension (standing start) opposite dA, (S)-N
6
-HB-dA or (R,R)-N
6
,N
6
-
DHB-dA adduct by hPol β  and hPol ι 
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Figure 6.2 Primer extension (standing start) opposite dA, (S)-N
6
-HB-dA or (R,R)-N
6
,N
6
-
DHB-dA adduct by hPol κ and hPol η 
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Figure 6.3 Primer extension (running start) opposite dA, (S)-N
6
-HB-dA and (R,R)-N
6
,N
6
-
DHB-dA adduct by hPol β and hPol κ. 
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6.3.2 Co-operativity and synergistic effects of TLS polymerases during replication 
past (R,R)-N
6
,N
6
-DHB-dA 
To determine whether TLS polymerases can work cooperatively to bypass (R,R)-
N
6
,N
6
-DHB-dA adducts, additional experiments were conducted with multiple enzymes. 
As shown in the right panel of Figure 6.1B, hPol ι incorporates a single nucleotide 
opposite (R,R)-N
6
,N
6
-DHB-dA, with no further primer extension. When the incomplete 
extension products from hPol ι reaction were incubated with hPol η, full extension to 18-
mer products was observed (Figure 6.4). Similar results were obtained when hPol ι and 
hPol η were added simultaneously (Figure 6.5). As a negative control, parallel reactions 
were performed with hPol ι or hPol η separately and these were combined following 
protein inactivation. We found that the amount of 18-mer full extension products 
following dual enzyme incubation (12%) was significantly higher than in control 
reactions (2%) (Figure 6.5, compare lanes DHB-dA (iota+eta 1:1, 60 min) and Additive 
lane A4). While these observations provide preliminary evidence that hPol ι and hPol η 
can act synergistically to bypass (R,R)-N
6
,N
6
-DHB-dA lesions, further studies are needed 
incorporating additional protein factors such as proliferating cell nuclear antigen 
(PCNA), which can facilitate polymerase switching.  
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Figure 6.4 Cooperativity of human TLS polymerases ι and η during the bypass of (R,R)-
N
6
,N
6
-DHB-dA lesion  
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Figure 6.5 Synergistic effect of combination of TLS polymerases ι and η during the 
bypass of (R,R)-N
6
,N
6
-DHB-dA lesion  
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6.3.3 Steady-state kinetic analysis of incorporation of individual dNTPs opposite the 
lesions 
To determine which nucleotides are incorporated opposite (R,R)-N
6
,N
6
-DHB-dA 
and (S)-N
6
-HB-dA I by human DNA polymerases, single nucleotide insertion 
experiments were conducted in the presence of dAMP, dCMP, dGMP, or dTMP. We 
found that all four nucleotides were incorporated opposite (S)-N
6
-HB-dA I and (R,R)-
N
6
,N
6
-DHB-dA I by hPol η and hPol κ, although with different efficiency. In contrast, 
hPol ι incorporated only the correct base (dTMP) opposite both lesions, and hPol β 
incorporated dTMP opposite (S)-N
6
-HB-dA, but was unable to insert any base opposite 
(R,R)-N
6
,N
6
-DHB-dA.  
Additional single nucleotide insertion experiments were performed in the 
presence of increasing concentrations of each of individual dNTPs (0-800 µM) for 
specified time periods (0-180 min) in order to obtain steady-state kinetic parameters (kcat  
and Km ) for nucleotide incorporation. The resulting data were used to calculate the 
catalytic specificity constants (kcat/Km) and the misinsertion frequencies for nucleotide 
insertion (f) for each polymerase. The kcat/Km values can be used as a measure of insertion 
efficiency.  
We found that hPol β was 19-fold less efficient at incorporating the correct base 
(dTMP) opposite (S)-N
6
-HB-dA I as compared to unmodified dA (Table 6.1). No kinetic 
analysis was possible for dTMP incorporation opposite (R,R)-N
6
,N
6
-DHB-dA by this 
polymerase, as the product formation was not quantifiable. In the case of hPol ι, dTMP 
incorporation opposite (S)-N
6
-HB-dA I and (R,R)-N
6
,N
6
-DHB-dA was 5- and 33- fold 
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less efficient than opposite native dA (positive control), respectively. As shown in Table 
6.1, the kcat values for these reactions were similar; but the Km values were markedly 
increased in the presence of lesions (Table 6.1).  
As expected, human pol κ incorporated primarily dTMP opposite unmodified dA, 
while dAMP and dGMP were incorporated 50-400 fold less efficiently (Table 6.1). For 
templates containing (S)-N
6
-HB-dA I, hPol κ catalyzed the addition of the correct 
nucleobase (dTMP), although the efficiency of dTMP incorporation was 3 fold less than 
that opposite unmodified dA (positive control). The other three bases were incorporated 
100 fold less efficiently (Table 6.1), suggesting that this adduct retains the ability to 
preferentially form Watson-Crick base pair with dT. In contrast, all four nucleotides were 
added opposite (R,R)-N
6
,N
6
-DHB-dA (T > C > A > G), with only ~1.5 more efficient 
dTMP insertion as compared to the other three bases (Table 6.1). dTMP incorporation 
opposite (R,R)-N
6
,N
6
-DHB-dA by hPol κ was ~450 fold less efficient than opposite dA 
(Table 6.1), indicating that hPol κ was less tolerant of (R,R)-N6,N6-DHB-dA 
modification.  
Human TLS polymerase hPol η preferentially incorporated dTMP opposite 
unmodified dA (positive control) and (S)-N
6
-HB-dA I adducts (Table 6.1).  The 
efficiency of dTMP incorporation opposite (S)-N
6
-HB-dA was 50 fold higher than that of 
dAMP or dCMP and ~200 fold higher than dGMP insertion (Table 6.1). The preference 
order of nucleotide insertion by hPol η opposite (R,R)-N6,N6-DHB-dA was G > T = A = 
C, with ~1.6 fold higher efficiency for dGMP insertion as compared to the other three 
bases. kcat/Km values for insertion of all four dNTPs opposite (R,R)-N
6
,N
6
-DHB-dA were 
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similar for both hPol η and hPol κ (Table 6.1). The efficiency of dTMP incorporation 
opposite (R,R)-N
6
,N
6
-DHB-dA by hPol η was ~800 fold less as compared to unmodified 
dA, indicative of a low tolerance of TLS polymerases for this lesion (Table 6.1). Overall, 
these results indicate that translesion synthesis by TLS polymerases is essentially error-
free for (S)-N
6
-HB-dA I and is highly error-prone for (R,R)-N
6
,N
6
-DHB-dA. Furthermore, 
(R,R)-N
6
,N
6
-DHB-dA bypass by all TLS polymerases studied was quite inefficient, 
suggesting that it blocks DNA replication.  
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Table 6.1 Steady-state kinetic parameters for single nucleotide incorporation opposite dA, (S)-N
6
-HB-dA and (R,R)-N
6
,N
6
-DHB-dA  
Polymerase Template dNTP kcat (min
-1
) Km (µM) kcat/Km (µM
-1
 min
-1
) f 
Fold decrease 
efficiency 
hPol κ 
Da 
T 5.72 ± 0.57 5.5 ± 1.8 1.04 1 1 
A 0.87 ± 0.05 354.6 ± 44.9 2.4 X 10
-3
 2.4 X 10
-3
 433 
G 4.27 ± 0.70 197.0 ± 18.1 0.02 0.02 52 
N
6
-HB-dA 
T 5.16 ± 0.46 13.7 ± 2.5 0.38 1 3 
A 0.83 ± 0.02 153.0 ± 11.5 5.4  X 10
-3
 0.01 193 
G 0.97 ± 0.08 180.1 ± 34.6 5.4  X 10
-3
 0.01 193 
C 0.08 ± 0.01 15.3 ± 7.6 5.5  X 10
-3
 0.01 189 
N
6
,N
6
-DHB-dA 
T 0.35 ± 0.04 152.8 ± 37.0 2.3  X 10
-3
 1 452 
A 0.35 ± 0.03 285.7 ± 67.4 1.2  X 10
-3
 0.53 867 
G 0.45 ± 0.06 454.6 ± 118.4 1.0  X 10
-3
 0.43 1040 
C 0.29 ± 0.03 169.5 ± 37.7 1.7  X 10
-3
 0.76 612 
hPol η 
 
dA 
T 2.38 ± 0.19 1.8 ± 0.5 1.32 1 1 
A 0.60 ± 0.02 51.3 ± 7.0 0.01 8.8 X 10
-3
 132 
G 0.52 ± 0.07 85.3 ± 27.3 6.0  X 10
-3
 4.6 X 10
-3
 220 
N
6
-HB-dA 
T 2.60 ± 0.19 30.9 ± 7.4 0.08 1 16 
A 0.15 ± 0.02 111.6 ± 31.3 1.4  X 10
-3
 0.02 943 
G 0.07 ± 0.01 176.9 ± 35.6 0.4  X 10
-3
 4.6 X 10
-3
 3300 
C 0.25 ± 0.02 177.8 ± 30.2 1.4  X 10
-3
 0.02 943 
N
6
,N
6
-DHB-dA 
T 0.13 ± 0.02 78.6 ± 16.8 1.7  X 10
-3
 1 776 
A 0.12 ± 0.01 72.0 ± 14.2 1.6  X 10
-3
 0.98 825 
G 0.31 ± 0.02 114.7 ± 18.7 2.7  X 10
-3
 1.64 489 
C 0.25 ± 0.02 140.2 ± 32.5 1.8  X 10
-3
 1.06 733 
hPol ι 
dA T 1.01 ± 0.03 21.1 ±1.8 0.05 1 1 
N
6
-HB-dA T 0.88 ± 0.06 83.0 ± 13.2 0.01 1 5 
N
6
,N
6
-DHB-dA T 0.74 ± 0.08 480.6 ± 116.7 1.5  X 10
-3
 1 33 
hPol β 
dA T 2.59 ± 0.51 27.9 ± 7.1 0.09 1 1 
N
6
-HB-dA T 2.44 ± 0.40 510.6 ± 139.9 4.8  X 10
-3
 1 19 
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6.3.4 LC-MS/MS analysis of primer extension products formed by hPol η and hPol κ 
In order to confirm the results of primer extension and steady-state kinetic 
experiments conducted by gel electrophoresis and to uncover additional genetic changes 
not detectable by gel electrophoresis, the products of hPols κ and η mediated  translesion 
synthesis past (S)-N
6
-HB-dA I and (R,R)-N
6
,N
6
-DHB-dA were sequenced by HPLC-ESI-
MS/MS. The capillary HPLC-ESI
-
-MS/MS methodology previously reported by our 
laboratory was employed (247). In brief, the primer employed for primer extension is 
constructed to contain a uracil residue 3 bases upstream from the lesion site. Following in 
vitro replication, the extended primer is cleaved with UDG/piperidine treatment to yield 
5-, 6- or 7-mer products that can be readily sequenced by tandem mass spectrometry 
(247). The relative abundance of each primer extension product is calculated by 
comparing their HPLC-MS peak areas to that of an internal standard, while the product 
identity is established by MS/MS sequencing as described previously (247).  
 Primer extension reactions of (S)-N
6
-HB-dA I template by hPol κ contained 
oligonucleotide fragments with m/z values of 825.1, 1078.7, 1086.2, 1090.7. MS/MS 
spectra have revealed that these products correspond to 5’-p TCTTATGA-3’, 5’-p 
TCCATGA-3’, 5’-p TCTATGA-3’ and 5’-p TCAATGA-3’, respectively. The error-free 
extension product 5’-p TCTATGA-3’ accounted for 82.5% of the total (Scheme 6.3). The 
relative contributions of other minor extension products 5’-p TCTTATGA-3’, 5’-p 
TCCATGA-3’, and 5’-p TCAATGA-3’ were 6, 3, and 8.5%, respectively (Scheme 6.3).  
HPLC-ESI-MS/MS sequencing of primer extension products originating from 
hPol κ catalyzed replication of (R,R)-N6,N6-DHB-dA containing template resulted in a 
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complex mixture of products, including those at m/z 777.6, 922.1, 934.1, 942.1, 1078.7, 
1086.2, 1090.7 and 1098.7, which correspond to 5’-p TC__TGA-3’, 5’-p TCC_TGA-3’, 
5’-p TCA_TGA-3’, 5’-p TCG_TGA-3’, 5’-p TCCATGA-3’, 5’-p TCTATGA-3’, 5’-p 
TCAATGA-3’ and 5’-p TCGATGA-3’, respectively. HPLC-ESI-MS extracted ion 
chromatograms of these primer extension products are shown in Figure 6.6. The product 
of error-free extension, 5’-p TCTATGA-3’ accounted for only 37% of total extension 
products. The product formed by misinsertion of A opposite the lesion (5’-p TCAATGA-
3’) accounted for 20% of the products (Scheme 6.3). Approximately 30% and 10% of 
total extension products corresponded to -1 and -2 deletions.  5’-p TCA_TGA-3’ and 5’-p 
TC__TGA-3’ were the major deletion products, corresponding to 18 and 9% of total 
products, respectively (Scheme 3). Complete results of primer extension products for 
both lesions in the presence of hPol κ are summarized in Scheme 6.3. 
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Figure 6.6 Extracted ion chromatograms of primer extension products opposite (R,R)-
N
6
,N
6
-DHB-dA adduct template by hPol κ 
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Scheme 6.3 Summary of primer extension products opposite (S)-N
6
-HB-dA and (R,R)-
N
6
,N
6
-DHB-dA by hPol κ  
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Parallel reactions were conducted for hPol η. We found that in vitro replication of 
(S)-N
6
-HB-dA I containing template resulted in two main products:  5’-p TCTATGA-3’ 
(92%) and 5’-p TCCATGA-3’ (8%) (Scheme 6.4). In contrast, hPol η catalyzed bypass 
of (R,R)-N
6
,N
6
-DHB-dA generated the same 7 products which were also detected in the 
hPol κ reaction (Scheme 6.3).  However, the relative contributions of these primer 
extension products were significantly different as compared to hPol κ reaction. The major 
product (5’-p TCCATGA-3’) was formed by misinsertion of C opposite (R,R)-N6,N6-
DHB-dA (46%) (Scheme 6.4). Only 19% of the products were error-free (5’-p 
TCTATGA-3’). Similar to hPol κ reaction, 20% of primer extension products were 
identified as 5’-p TCAATGA-3’. Deletion products accounted for 15% of total products 
(Scheme 6.4). 
 The exact nucleotide sequence of each extension product was determined from 
their MS/MS spectra. Good sequence coverage of a-B and w ions was obtained to 
accurately identify the sequence of primer extension products. For example, MS/MS 
spectra of the product with m/z 1078.7 yielded ions at m/z 1059.3, 1276.3 (Figure 6.7B) 
which corresponds to a4-B4 ion and w4 ion of 5’-p TCCATGA-3’, respectively. MS/MS 
spectra of the major primer extension products (5’-p TCTATGA-3’, 5’-p TCAATGA-3’, 
5’-p TCCATGA-3’ and 5’-p TCA_TGA-3’) are shown in Figure 6.7.  Overall, the 
HPLC-ESI-MS/MS results (Schemes 6.3, 6.4) confirmed that polymerase bypass of (S)-
N
6
-HB-dA I is mainly error-free, while (R,R)-N
6
,N
6
-DHB-dA adducts are highly error-
prone, resulting in A→G transitions, A→T transversions, A→C transversions, and 
deletions. 
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Scheme 6.4 Summary of primer extension products opposite (S)-N
6
-HB-dA and (R,R)-
N
6
,N
6
-DHB-dA by hPol η 
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Figure 6.7 MS/MS spectra of the major products formed upon in vitro primer extension 
opposite (R,R)-N
6
,N
6
-DHB-dA by hPol κ and hPol η 
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6.4 Discussion 
EB and DEB are carcinogenic metabolites formed upon cytochrome P450-
mediated metabolic activation of BD (16;248). Studies in human lymphoblastoid TK6 
cells have revealed that EB and DEB induce mutations at the hprt and tk loci, with DEB 
being ~100 fold more mutagenic than EB (34). EB treatment of Rat2 laci transgenic cells 
and human TK6 lymphoblasts resulted in an increased frequency of A → T transversions 
(35). Additionally, A→C transversions were also observed in Rat2 laci transgenic cells 
(35). EB induced A→T transversions and deletions in the lung of B6C3F1 laci transgenic 
female mice, while DEB induced A→T transversions and deletions at hprt locus in 
human TK6 lymphoblasts (35;239). A high frequency of A→T and A→G mutations was 
observed in the bone marrow and spleen of B6C3F1 laci transgenic female mice exposed 
to BD (35).  
It has been previously reported that bis-N
6
A-BD and N1-(1-hydroxy-3-buten-2-yl) 
deoxyinosine lesions induced A→G mutations (179). In contrast, the identity of 
deoxyadenosine adducts responsible for A→T transversions has remained unknown. In 
vitro translesion synthesis experiments involving DEB-induced (R,S)-1,N
6
-γ HMHP-dA 
adducts (Chapter V) showed that these adducts induced A→T, A→C transversions (247). 
Another DEB-induced exocyclic dA lesion detected in our earlier study is N
6
,N
6
-DHB-
dA (48). Since in this adduct the exocyclic N
6
 position of dA is blocked by pyrrolidine-
3,4-diol moiety, it cannot participate in standard Watson-Crick hydrogen bonding with 
dT, thereby leading to potential mispairing. Similarly, the identity of EB-derived dA 
adducts that induce A→T transversions has not been established. EB can alkylate DNA 
 232 
 
to form regioisomeric N
6
-HB-dA I and N
6
-HB-dA II adducts in vitro and in vivo 
(42;52;182;183;246), but previous in vitro and in vivo replication studies have been 
limited to N
6
-HB-dA II (177). The mutagenic potential of N
6
-HB-dA I has not been 
previously evaluated. In the present study, we conducted in vitro translesion synthesis 
studies on synthetic DNA templates containing (S)-N
6
-HB-dA I and (R,R)-N
6
,N
6
-DHB-
dA in the presence of human DNA polymerases β, η, ι and κ.  
 Standing-start and running-start primer extension studies showed that (S)-N
6
-HB-
dA I can be efficiently bypassed by human DNA polymerases β, η, ι and κ (Figures 6.1, 
6.2, 6.3). Similar to our previous primer extension studies with (R,S)-1,N
6
-γ HMHP-dA 
adduct (247), (R,R)-N
6
,N
6
-DHB-dA also blocked DNA synthesis by hPol β (Figures 
6.1A, 6.3A). hPol ι was able to insert a base opposite the lesion but didn’t extend the 
primer further (Figure 6.1B). Standing-start primer extension studies of  (R,R)-N
6
,N
6
-
DHB-dA in the presence of hPols κ and η required 2.5 times higher enzyme concentration 
as compared to positive control or (S)-N
6
-HB-dA I for the formation of fully extended 18-
mer products (Figure 6.2). For running-start primer extension studies in the presence of 
hPol κ (Figure 6.3B) and hPol η, significant amounts of 18-mer were detected, but the 
major products were 13- and 14-mers. Furthermore, steady-state kinetics confirmed that 
the incorporation of dTMP opposite (R,R)-N
6
,N
6
-DHB-dA adduct by hPols η and κ is 
~400-800 fold less efficient than opposite native dA (Table 6.1). Taken together these 
results suggested that the (R,R)-N
6
,N
6
-DHB-dA lesions significantly reduce the rate of 
DNA synthesis (Figure 6.3B). Similar decreases in efficiency (up to 1000-fold) were also 
reported for the incorporation of dTMP opposite 1,N
6
-ethenodeoxyadenosine by hPol κ 
 233 
 
(165). hPol ι inserted dTMP opposite (R,R)-N6,N6-DHB-dA with higher efficiency than 
hPols η and κ (Table 6.1), although it did not catalyze primer extension to the terminus. 
The presence of (S)-N
6
-HB-dA I lesion also decreased the catalytic efficiency of 
nucleotide insertion but only by 3-16 fold similar to (R,S)-1,N
6
-γ HMHP-dA lesions. All 
four bases were incorporated with similar frequencies opposite (R,R)-N
6
,N
6
-DHB-dA by 
hPols η and hPol κ (Table 6.1) indicating that this lesion is highly mutagenic. In 
comparison, incorrect bases (A and G) were incorporated with similar frequencies 
opposite (R,S)-1,N
6
-γ HMHP-dA lesions along with the correct base T (247). However, T 
was the most preferred base incorporated opposite (S)-N
6
-HB-dA I indicating that these 
adducts are non-mutagenic.   
The mutagenic ability of the lesions were further investigated by conducting 
primer extension studies and sequencing the primer extension products by a sensitive 
HPLC-ESI
-
-MS/MS method previously employed by our laboratory (247). HPLC-
MS/MS primer extension studies opposite (S)-N
6
-HB-dA I in the presence of hPols η and 
κ showed that the major product was 5’-p TCTATGA-3’ resulting from error-free 
replication (Schemes 6.3 and 6.4). HPLC-MS/MS results for (S)-N
6
-HB-dA were in 
agreement with gel electrophoresis experiments (Table 6.1), indicating that the primer 
extension is mostly error-free. In vitro translesion synthesis experiments with N
6
-HB-dA 
II, the regioisomer of N
6
-HB-dA I (Scheme 6.1) have also showed that E.Coli 
polymerases were able to bypass the lesion efficiently. Additionally, T was the preferred 
base inserted opposite the N
6
-HB-dA II (177). In vivo studies further confirmed that N
6
-
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HB-dA II lesion was non-mutagenic. Similarly, our data with N
6
-HB-dA I also indicate 
that this lesion is non-mutagenic. 
HPLC-MS/MS sequencing of the extension products generated upon in vitro 
replication of (R,R)-N
6
,N
6
-DHB-dA-containing template by hPols η and κ were identified 
as 5’-p TCCATGA-3’, 5’-p TCTATGA-3’, 5’-p TCAATGA-3’ and 5’-p TCGATGA-3’ 
(Schemes 6.3 and 6.4). This confirmed our steady-state kinetic results that all four bases 
can be incorporated opposite (R,R)-N
6
,N
6
-DHB-dA. These events, if happen in vivo, 
would result in A→G, A→T and A→C mutations. Additionally significant amounts of -1 
and -2 deletion products were observed in primer extension reactions opposite (R,R)-
N
6
,N
6
-DHB-dA indicating that this adduct induces deletion mutations. In our earlier study 
with (R,S)-1,N
6
-γ HMHP-dA (another DEB induced exocyclic dA adduct), we found that 
the adduct induces A→T, A→C mutations and deletions (247). These results indicate that 
(R,R)-N
6
,N
6
-DHB-dA along with previously identified (R,S)-1,N
6
-γ HMHP-dA are the 
BD induced deoxyadenosine adducts responsible for the induction of A→T, A→C, 
A→G mutations and deletion events. 
 In summary, our gel electrophoresis and HPLC-MS/MS primer extension studies 
indicate that the human DNA polymerases β, η, κ and ι are able to bypass (S)-N6-HB-dA 
I, while only hPols κ and η can bypass (R,R)-N6,N6-DHB-dA adducts. The efficiency of 
incorporation of the correct nucleotide dTMP opposite BD-dA exocyclic lesions was (S)-
N
6
-HB-dA I ~ (R,S)1,N
6
-γ HMHP-dA >> (R,R)-N6,N6-DHB-dA. Among the three 
adducts, (S)-N
6
-HB-dA I is primarily non-mutagenic, probably because for this 
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monoadduct, there is still one N
6
-hydrogen available for correct hydrogen bonding with 
dT (Scheme 6.5). (R,R)-N
6
,N
6
-DHB-dA is more mutagenic than (R,S)-1,N
6
-γ HMHP-dA 
since all the four bases were incorporated opposite (R,R)-N
6
,N
6
-DHB-dA and the 
majority of the primer extension products were error-prone. Our results indicate that 
(R,R)-N
6
,N
6
-DHB-dA can primarily induce A→G, A→T mutations, deletions, and some 
A→C transversions, while (S)-N6-HB-dA I is non-mutagenic and is unlikely to be 
responsible for the monoepoxide’s mutagenic ability. While exact mechanism of 
mispairing of (R,R)-N
6
,N
6
-DHB-dA with all four bases requires additional NMR and 
crystallographic studies, we hypothesized that it might adopt a syn conformation around 
the glycosidic bond (Scheme 6.5) similar to (R,S)-1,N
6
-γ HMHP-dA. Structural studies 
are currently in progress to investigate this extreme mutagenicity of (R,R)-N
6
,N
6
-DHB-
dA.  
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Scheme 6.5 Proposed models for base pairing of (S)-N
6
-HB-dA and (R,R)-N
6
,N
6
-DHB-
dA with dT 
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VII. SUMMARY AND CONCLUSIONS 
Lung cancer is the major type of cancer in the US, with an estimated mortality of 159,480 
in 2013 (2). Approximately 87% of these lung cancer deaths can be directly attributed to 
cigarette smoking (2). The risk of lung cancer is significantly different among different 
ethnic and racial groups (9;14). African American and Native Hawaiian smokers have a 
higher risk of lung cancer as compared to European American, Latin American and 
Japanese American smokers (Table 1.2) (14). Although it has been hypothesized that 
these inter-ethnic differences in lung cancer risk are due to differences in carcinogen 
metabolism among the different ethnic groups (9;14), very few studies have investigated 
such a possibility (249). Among 70 other carcinogens present in cigarette smoke, 1,3-
butadiene (BD) has a very high cancer risk index (25) and hence we chose to investigate 
whether there are ethnic differences in metabolism of BD.  
BD is metabolically activated by CYP2E1 and CYP2A6 to form electrophilic 
metabolites, EB, HMVK, EBD, and DEB which can undergo detoxification by hydrolysis 
(via epoxide hydrolase) or glutathione conjugation (Scheme 1.1) (27-30;189). The 
glutathione conjugates of EB, HMVK, EBD, and DEB can be further metabolically 
converted into mercapturic acids, MHBMA, DHBMA, THBMA and bis-BDMA, 
respectively, and excreted in urine  (Scheme 1.1) (31;93). If not detoxified, EB, EBD and 
DEB can alkylate nucleophilic sites of DNA to form covalent nucleobase adducts 
including mono adducts (52;59), exocyclic adducts (48;67), and DNA-DNA cross links 
(46;64;68). These DNA adducts, if not repaired, can induce mutations in critical genes, 
ultimately leading to lung cancer (7). Urinary metabolites can be used as biomarkers of 
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carcinogen activation and detoxification in vivo (209) and hence we hypothesized that 
differences in BD metabolism in the different ethnic/racial groups will be reflected in 
differences in the levels of the four urinary metabolites of BD, MHBMA, DHBMA, 
THBMA and bis-BDMA.  
Among the BD-urinary metabolites, only MHBMA and DHBMA have been 
previously quantified in urine of rats and humans exposed to BD (33;96;99;110). 
Although THBMA is formed from the most abundant BD-epoxide EBD, this metabolite 
has not been previously detected in humans, e.g. smokers and occupationally exposed 
workers. DEB, the most genotoxic BD-epoxide can potentially react with two glutathione 
molecules to form bis-glutathione conjugates in vitro (94). We hypothesized that these 
bis-glutathione conjugates can be further modified to bis-mercapturic acids and excreted 
in urine as bis-BDMA. If detected in vivo, this urinary metabolite can be used as a 
specific biomarker of DEB. Hence, the initial goals of this thesis were to develop HPLC-
ESI
-
-MS/MS methods for the quantification of novel urinary metabolites of BD, THBMA 
and bis-BDMA in vivo and evaluate their potential as biomarkers of BD exposure and 
bioactivation. 
A sensitive and specific stable isotope dilution HPLC-ESI
-
-MS/MS method was 
developed for the quantification of THBMA in human urine (Chapter II). We applied this 
method for THBMA quantification in urine samples from smokers (N = 27) and 
nonsmokers (N = 19). Significant amounts of THBMA were detected in both smokers 
and non-smokers (Figure 2.6). Urinary THBMA concentrations in smokers (21.6 ± 10.2 
ng/mg creatinine) were significantly higher than in non-smokers (13.7 ± 7.9 ng/mg 
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creatinine) (p < 0.01) (Figure 2.6). The presence of endogenous THBMA in samples from 
non-smokers might be due to environmental exposure to BD or because of an alternate 
endogenous source yet to be identified. Additionally, we also found that the THBMA 
levels decreased by ~45% after smoking cessation (Figure 2.7). Because higher levels of 
THBMA were present in smokers as compared to non-smokers and THBMA levels 
decreased after smoking cessation, we concluded that a significant amount of THBMA is 
directly formed from BD present in cigarette smoke. However, since THBMA is also 
present in urine of non-smokers, it might not be the best biomarker of smoking-mediated 
exposure to BD. 
 The second goal of this thesis was the development of a sensitive HPLC-ESI
-
-
MS/MS method for quantification of bis-BDMA in urine of rats exposed to BD, humans 
occupationally exposed to BD, and smokers. Significant amounts of bis-BDMA were 
detected in the urine of F344 rats exposed to 62.5 ppm or 200 ppm BD, while no bis-
BDMA was detected in urine of rats exposed to filtered air (Figures 3.4 and 3.5). 
However, the urinary concentrations of bis-BDMA in occupationally exposed workers 
and smokers were below the LOD of our method (0.1 ng/ml) (Figure 3.7) confirming 
earlier reports of the inefficient formation of DEB in humans (26;89). Additionally, the 
urinary concentrations of MHBMA, DHBMA and THBMA were also determined in rat 
and human urine samples. In rats, the relative contribution of individual urinary 
metabolites to total BD-mercapturic acids was DHBMA (47%)>THBMA 
(37%)>MHBMA (15%)>bis-BDMA (1%) (Figure 3.6A). However, in humans the 
metabolites were DHBMA (93%)>THBMA (5%)>MHBMA (2%)>bis-BDMA (<0.1%) 
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(Figure 3.6B). These results reveal significant interspecies differences in metabolism of 
BD between rats and humans. However, it should also be noted that the high percentage 
of DHBMA in humans might be due to the presence of an endogenous source. 
Furthermore, we observed gender differences in BD metabolism, with female rats 
excreting higher concentrations of bis-BDMA as compared to males (Figure 3.5 A). 
Since bis-BDMA was not detected in humans, it cannot be used as a biomarker in 
smokers to study the interethnic differences in lung cancer risk. 
 Our third goal was to develop a robust, high throughput HPLC-ESI
-
-MS/MS 
method for quantification of MHBMA and DHBMA in human urine and apply the 
method for quantification of these metabolites in urine of smokers belonging to different 
ethnic groups. The levels of MHBMA decreased by >90% upon smoking cessation, 
therefore this metabolite can be considered as a specific biomarker of exposure to BD in 
cigarette smoke (33). DHBMA, on the other hand is present in urine of both smokers and 
non-smokers, and the urinary DHBMA levels remain constant even after smoking 
cessation (33). Metabolic ratio (MHBMA/MHBMA+DHBMA) has been widely used as 
an indicator of relative contribution of detoxification pathways (glutathione conjugation 
vs. epoxide hydrolysis) and hence can be used to study any inter-ethnic differences in BD 
metabolism (85).  Although, a number of HPLC-MS/MS methods for quantification of 
MHBMA and DHBMA in humans have been reported in literature (Table 1.5), none of 
the methods employ a 96 well plate SPE method amenable for multiple sample 
processing in large studies. Additionally, most of the methods use a relatively large 
volume of urine (>0.5 ml) which was not available for our studies (Table 1.5). We 
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developed and validated an Oasis HLB 96 well plate SPE method and a sensitive HPLC-
ESI
-
-MS/MS method (LOQ: MHBMA, 0.5 ng/ml; DHBMA, 10 ng/ml) (Table 4.1). 
 This new method was employed to quantify BD-urinary mercapturic acids in 
workers employed at a BD and SBR manufacturing facility in Czech Republic (85). We 
found significantly higher amounts of MHBMA and DHBMA in urine of workers 
exposed to BD as compared to controls (Figure 4.1, Table 4.2). Additionally, we also 
found significantly higher amounts of THBMA in exposed workers as compared to 
controls (Figure 4.2, Table 4.2). In the exposed group, male workers excreted 
significantly higher amounts of MHBMA, DHBMA and THBMA as compared to 
controls (Table 4.2). These differences were observed probably because males were 
exposed to significantly higher concentrations of BD as compared to females (Table 4.2). 
Indeed, when the urinary concentrations were normalized to per unit dose of BD, only 
MHBMA formation was found to be significantly higher in males as compared to 
females (Table 4.2). We also found that there were no differences in 
MHBMA/MHBMA+DHBMA metabolic ratio between males and females (Table 4.2) 
suggesting that there are no gender differences in relative usage of BD detoxification 
pathways. A strong association was observed between BD exposure and urinary BD-
mercapturic acids (Figure 4.4). Correlation studies also revealed a strong association 
between and among the three BD-urinary mercapturic acids (Figure 4.5, Table 4.3). 
Significant correlations were also found between each of BD-urinary mercapturic acids 
and BD-hemoglobin adducts (HB-Val and pyr-Val) (Figure 4.5, Table 4.3). 
 242 
 
 The new method was further applied to quantify MHBMA and DHBMA in urine 
of smokers of Native Hawaiian, Japanese American and European American descent 
(N=200 per group). We found that the mean urinary MHBMA concentrations (adjusted 
for age, sex and log nicotine equivalents) significantly differed among the three ethnic 
groups (p=0.0002) with the highest MHBMA amounts observed in European Americans 
(6.7 ng/mg creatinine), followed by Native Hawaiians (5.3 ng/mg creatinine) and the 
lowest in Japanese American smokers (4.3 ng/mg creatinine) (Table 4.4). However, it 
should be noted that the lung cancer risk is highest in Native Hawaiian smokers, 
intermediate in European American smokers and least in Japanese American smokers.  
Significant ethnic differences were observed in the MHBMA/MHBMA+DHBMA 
metabolic ratio (p = 0.0037) but not for DHBMA (p=0.15) (Table 4.4). These results 
provided preliminary evidence for the presence of inter-ethnic differences in BD 
metabolism. A larger study involving smokers from two ethnic groups, European-
Americans (N=450) and African-Americans (N=450) was also completed. We found 
median MHBMA levels in European–American smokers (11.2 ng/mg creatinine) were 
significantly higher than in African-American smokers (8.9 ng/mg creatinine) (Table 
4.5). In contrast, no significant ethnic differences were observed for urinary DHBMA 
concentration and metabolic ratio between the ethnic groups (Table 4.5). Additionally, 
genome-wide association study (GWAS) analysis revealed significant associations 
between single-nucleotide polymorphisms (SNPs) in chromosome 22 (22564172bp – 
22735492 bp, nearby genes GSTT1, GSTT2, DDT and MIF) and MHBMA. GSTT1 is 
the major enzyme involved in the detoxification of EB (precursor to MHBMA). Overall, 
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the results from the two studies confirm our earlier hypothesis that there are significant 
differences in metabolism of BD among different ethnic groups (Tables 4.4 and 4.5). 
However, additional correlation analysis between genetic polymorphisms and urinary 
metabolites will need to be completed to identify specific genetic polymorphisms 
responsible for these differences. These results indicate that because of different 
frequency of genetic polymorphisms in carcinogen metabolizing genes among ethnic 
groups, there are measurable ethnic differences in metabolic activation and deactivation 
of carcinogens, ultimately leading to differences in susceptibility to lung cancer.  
 Among the four urinary BD metabolites investigated in this work, MHBMA is the 
most specific biomarker of BD. A strong association was found between MHBMA and 
BD exposure (Figure 4.4). Additionally, MHBMA concentrations were significantly 
different among the ethnic groups in two multi-ethnic cohort studies (Tables 4.4 and 4.5). 
In contrast, no significant ethnic differences were observed with DHBMA. Furthermore, 
DHBMA and THBMA were detected in significant amounts in non-smokers, probably 
due to their endogenous formation in humans.  bis-BDMA would be an ideal biomarker 
of BD bioactivation to DEB, but unfortunately bis-BDMA concentrations in human urine 
were below the LOD of our method and hence cannot be used for human studies. 
The second part of the thesis focuses on investigating the mutagenic ability of 
three BD-dA adducts (Scheme 1.4). The investigations of deoxyadenosine adducts are of 
special importance because BD, EB, and DEB induce a large number of A→T mutations 
and deletions (35). Although polymerase bypass of some BD-dA lesions has been studied 
previously (Chart 1.3) (177-181), the identity of specific lesions responsible for A→T 
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mutations remained to be determined. We have focused on three BD-dA adducts 
(Scheme 1.4) which have been observed in vitro (N
6
-HB-dA, N
6
,N
6
-DHB-dA, 1,N
6
-
HMHP-dA) and in vivo (N
6
-HB-dA and 1,N
6
-HMHP-dA) (48;52;67). 1,N
6
-HMHP-dA 
lesions have been shown to persist in tissues of laboratory mice following exposure to 
BD (185). Since N
6
,N
6
-DHB-dA and 1,N
6
-HMHP-dA are exocyclic lesions that cannot 
form Watson-Crick pairs and are likely to block replicative DNA polymerases, we 
hypothesized that they are subject to bypass by translesion synthesis (TLS) polymerases, 
potentially leading to mutations because of the relatively low fidelity of these enzymes 
(120;121;130). In vitro replication studies were conducted with synthetic 18-mer 
template strands generated by the post-oligomerization strategy developed in our 
laboratory (186). Each template strand contained site-specific (S)-N
6
-HB-dA, (R,R)-
N
6
,N
6
-DHB-dA and (R,S)- 1,N
6
-γ-HMHP-dA adducts (Schemes 5.2 and 6.2). Following 
annealing to a 13-mer primer with 3’ terminus one base before the lesion (standing start 
conditions), primer extension was conducted in the presence of human polymerases β, η, 
ι, and κ . 
We found that among the three lesions, (S)-N
6
-HB-dA adducts was the least 
mutagenic and easiest to bypass. Human polymerases β, η, ι, and κ were able to bypass 
the lesion and extend the primer to the terminus (18-mer, except for hPol ι which formed 
a 16-mer) (Figures 6.1, 6.2). Steady-state kinetic experiments showed that T was the 
preferred base of incorporation opposite (S)-N
6
-HB-dA (Table 6.1). Additionally, 
sequencing of primer extension products using HPLC-ESI
-
-MS/MS confirmed that 
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primer extension opposite (S)-N
6
-HB-dA was error-free, as the correct product (5’p-
TCTATGA-3’) accounted for > 80% of all products (Schemes 6.3 and 6.4).  
In contrast, exocyclic 1,N
6
-γ-HMHP-dA and N6,N6-DHB-dA adducts blocked 
replication and induced polymerase errors. Primer extension studies past (R,S)- 1,N
6
-γ-
HMHP-dA using gel electrophoresis showed that primer extension by hPol β was 
completely blocked by (R,S)- 1,N
6
-γ-HMHP-dA (Figure 5.1 A). hPol ι was able to 
incorporate a base but could not extend the primer beyond that (Figure 5.1 B). Steady-
state kinetic experiments confirmed that the presence of the lesion decreased the 
polymerization rates as indicated by low kcat/Km ratios for nucleotide incorporation 
opposite the lesions (Table 5.1). Importantly, A and G were incorporated with a high 
frequency opposite 1,N
6
-γ-HMHP-dA. Further analysis of primer extension products by 
HPLC-ESI
-
-MS/MS (164) revealed that nucleotide incorporation opposite (R,S)- 1,N
6
-γ-
HMHP-dA by hPol κ was highly mutagenic, producing only 18% of error-free product 
(5’p-TCTATGA-3’) (Scheme 5.3A).  The rest of the primer extensions products 
correspond to misincorporation of A, G opposite the lesion and -1, -2 deletion products 
(Schemes 5.3, 5.4 and 5.5, Chapter V). These results are consistent with the ability of 
DEB to induce A →T transversions and frameshift mutations (35). 
Similar to (R,S)- 1,N
6
-γ-HMHP-dA lesions, (R,R)-N6,N6-DHB-dA lesions also 
blocked replication by non-TLS polymerase hPol β (Figure 6.1 A). hPol ι was able to 
incorporate only a base opposite (R,R)-N
6
,N
6
-DHB-dA lesion to form a 14-mer primer 
but was unable to extend further (Figure 6.1 B). hPols η and κ were unable to extend the 
primer at low enzyme:DNA concentration ratios, but were able to extend the primer 
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completely to the terminus at higher concentration ratios (Figure 6.2). Steady-state 
kinetic experiments revealed that all four bases were incorporated almost with identical 
frequencies opposite (R,R)-N
6
,N
6
-DHB-dA lesions by hPols η and κ (Table 6.1). 
Additionally, the kcat/Km for incorporation of nucleotide incorporation opposite this lesion 
was only ~ 0.002, reflecting a decreased tolerance of TLS polymerases for this lesion 
(Table 6.1). Primer extension studies with HPLC-MS/MS showed that >60% of the 
primer extension products opposite this lesion were error-prone (Schemes 6.3 and 6.4). 
Our results indicate that (R,R)-N
6
,N
6
-DHB-dA can induce A→G, A→T, A→C and 
deletion mutations (Schemes 6.3 and 6.4).  
 In summary, studies described in this thesis have identified two novel urinary 
metabolites of BD, THBMA and bis-BDMA (Scheme 1.1), which were subsequently 
detected in urine of BD-exposed laboratory animals (THBMA and bis-BDMA) and 
humans exposed to BD via smoking and/or occupational exposure (THBMA) (Figures 
2.5, 3.4 and 4.2). Additionally, a high throughput, ultra-sensitive HPLC-ESI
-
-MS/MS 
method was developed and successfully employed for the quantification of MHBMA and 
DHBMA in smokers belonging to different ethnic groups in two separate multi-ethnic 
cohort studies (Chapter IV). Significant ethnic differences in urinary concentrations of 
MHBMA were observed, with European American smokers excreting the highest levels, 
followed by African Americans and Native Hawaiians, and Japanese group excreting the 
lowest amounts of BD metabolites (Tables 4.4 and 4.5). To our knowledge, this study 
provides the first definitive evidence for ethnic differences in BD metabolism, which may 
contribute to the observed differences in lung cancer risk. Furthermore, we investigated 
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the mutagenic potential of three BD-dA adducts, (S)-N
6
-HB-dA, (R,R)-N
6
,N
6
-DHB-dA 
and (R,S)- 1,N
6
-γ-HMHP-dA. We found that while (S)-N6-HB-dA lesions were non-
mutagenic, (R,R)-N
6
,N
6
-DHB-dA and (R,S)- 1,N
6
-γ-HMHP-dA produced high levels of 
base substitutions and frameshift mutations (Schemes 5.3, 5.4, 6.3, and 6.4) providing a 
likely mechanism for the induction of A→T transversions and deletion mutations in cells 
and animals exposed to BD and DEB. 
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VIII. FUTURE WORK 
8.1 Quantification of bis-BDMA in rats and humans exposed to low concentrations 
of BD 
As described in Chapter III, DEB-specific urinary biomarker bis-BDMA was 
detected in the urine of rats exposed to high doses of BD (62.5 ppm or 200 ppm) (Figure 
3.4) but not in occupationally exposed workers (~1 ppm BD exposure) (Figure 3.7). 
Since humans are generally exposed to much lower doses of BD, it would be important to 
study the formation of bis-BDMA in urine of laboratory rats and mice exposed to 0.5, 1 
or 1.5 ppm BD.  Boysen et al. have detected the formation of DEB-specific hemoglobin 
adducts (pyr-Val) (89) in both control and exposed workers, therefore it is likely that bis-
BDMA is formed in humans, albeit at much lower concentrations. Our current HPLC-
ESI
-
-MS/MS method with an LOD of 1 ng/ml was not sufficient to detect bis-BDMA in 
human urine. We attempted to develop a more sensitive capillary HPLC-ESI
-
-MS/MS 
method with a Zorbax SB-C18 (0.5 X 100 mm, 5µ) column with an LOD of 0.1 ng/ml, 
but could not detect any bis-BDMA in exposed workers or smokers (Figure 3.7B).  
 To increase HPLC-ESI
-
-MS/MS method sensitivity, the use of alternate SPE 
methods (e.g. Strata X-A) should be explored. Our preliminary studies suggest that this 
would improve SPE recovery for bis-BDMA, as well as decrease the interferences that 
cause ion suppression. Alternatively, use of accurate mass LTQ Orbitrap mass 
spectrometry might help decrease the baseline noise and further improve the sensitivity. 
The use of NanoLC LC-ESI
-
-MS/MS will further improve sensitivity but the presence of 
high salts and interferences from urine matrix might be the deterrents. An offline HPLC 
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clean-up or consecutive SPE clean-ups (C18 and ion-exchange) followed by analysis by 
NanoLC LC-ESI
-
-MS/MS might be an interesting methodology to explore. 
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8.2 DHB-Lysine as a novel urinary biomarker of DEB formation from BD 
 
Since bis-BDMA, specific biomarker of DEB formation form BD, could not be 
detected in the urine of occupationally exposed workers or smokers (Figure 3.7), alternate 
DEB-specific biomarkers could be explored. DEB is known to react with N-terminal 
valine of hemoglobin to form exocyclic pyr-Val adducts (Scheme 1.2) (89). We 
hypothesize that DEB can similarly alkylate side chain of amino acids (e.g. lysine) to 
form N,N-2,3-dihydroxybutan-1,4-diyl-lysine adducts (DHB-Lysine). These would be 
excreted in urine following proteolytic degradation of the affected proteins as small 
modified peptides or adducted Lysine. We attempted to synthesize authentic DHB-Lysine 
by reacting tBoc-Lysine with equimolar amounts of DEB in the presence of triethylamine 
and glacial acetic acid at 50 
°
C for 7 days (Scheme 8.1) (250). The formation of tBoc-
DHB-Lysine (m/z 333) was confirmed by infusion into ion trap MS and the reaction 
mixture was fractionated by semi-preparative HPLC. The purified tBoc-DHB-Lysine was 
deprotected with 10% TFA, and DHB-Lysine was isolated by semi-preparative HPLC. 
The identity of the product was established by tandem mass spectrometry (Figure 8.1).  
 HPLC-ESI-MS/MS method development for DHB-Lysine in human urine is 
challenging because the extreme polarity of this modified amino acid. Initial attempts 
were made to increase the retention of this analyte on reverse phase HPLC in the 
presence of ion pairing agents such as perfluoroheptanoic acid. These methods need to be 
optimized further and applied to urine samples of laboratory rats exposed to BD by 
inhalation and occupationally exposed workers to investigate the formation of DHB-
Lysine in vivo. 
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Scheme 8.1 Synthesis of DHB-Lysine 
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Figure 8.1 MS/MS spectrum of DHB-Lysine 
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8.3 Development of an HPLC-MS/MS method for simultaneous quantification of 
MHBMA, DHBMA and THBMA 
 
In this thesis, an HPLC-MS/MS method for simultaneous quantification of 
MHBMA and DHBMA was developed (Chapter IV). THBMA was quantified by a 
separate HPLC-MS/MS method on a different HPLC column (Chapters II, IV). This was 
because the recoveries of THBMA with the Oasis HLB SPE method (used for MHBMA 
and DHBMA) are close to 0%. More recently, we have found that Isolute ENV+ 
cartridges offer >40% recoveries for all the three urinary metabolites of BD and can be 
used for simultaneous quantification of MHBMA, DHBMA and THBMA in human 
urine. Alternatively, Strata X-A columns also offer good recoveries of all the three 
analytes and need to be explored in the future. 
The ability of the Diphenyl HPLC column (Agilent) currently only used for 
MHBMA and DHBMA) to retain THBMA needs to be evaluated. Alternate columns that 
retain polar compounds such as Synergi Polar-RP can be tested. If a HPLC-MS/MS 
method for simultaneous quantification of MHBMA, DHBMA and THBMA can be 
developed, it will be highly efficient as it would save sample, sample processing time, 
and MS analysis time. Such a method would be highly beneficial for future multi-ethnic 
cohort studies or animal studies with large number of samples as it will provide important 
information on formation of THBMA along with MHBMA and DHBMA.  
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8.4 Identifying the DHBMA and THBMA concentrations directly related to BD 
exposure 
High concentrations of DHBMA and THBMA have been detected in the urine of non-
smokers (Chapter II) (33;206). It has been hypothesized that EB-diol, the common 
precursor to HMVK and EBD can be formed during the carbohydrate catabolism (87). 
The portion of EB-diol that is formed from direct exposure to BD and subsequent 
detoxification to DHBMA and THBMA has not been assessed before. To differentiate 
the endogenous DHBMA and THBMA formation from that formed from BD exposure, 
the following experiment can be performed. 
 F344 rats can be exposed with 62.5 ppm 
13
C2-1,3-butadiene for 2 weeks (6 h/day, 
5 days/week). At the end of the exposure period, urine samples would be collected and 
then the urinary concentrations of 
13
C2-DHBMA, 
13
C2-THBMA along with DHBMA and 
THBMA can be determined by the stable isotope dilution HPLC-ESI
-
-MS/MS methods 
described in Chapters II and IV. Comparison of 
13
C2-DHBMA, 
13
C2-THBMA with 
endogenous DHBMA and THBMA would provide information on the relative formation 
of these BD-mercapturic acids from BD exposure vs other endogenous sources. 
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8.5 Expanding multi-ethnic cohort study to different racial groups and correlation 
studies 
Our preliminary results from a small multi-ethnic study (200 smokers per group) 
confirmed that there are significant differences in the MHBMA concentrations among 
Native Hawaiian, Japanese American and European American smokers (Table 4.4 in 
Chapter IV). Unfortunately, no significant association studies between the genetic 
polymorphisms and MHBMA concentrations were possible because of the low frequency 
of polymorphisms in a study population of 600 smokers.  
In a larger multi-ethnic cohort study, we examined the differences in BD 
metabolism between African American and European American smokers (N=450 per 
group). We found that European American smokers excreted significantly higher 
concentrations of MHBMA as compared to African American smokers (Table 4.5 in 
Chapter IV).  It will be interesting to expand this larger study to other ethnic groups, e.g. 
Native Hawaiian, Japanese American, and Latin American smokers (N=450 per group) 
so that the total study population would be ~2500 smokers. That would provide an 
opportunity to conduct GWAS between genetic polymorphisms and urinary BD-
mercapturic acids to understand the genetic basis for differences in metabolism. 
Eventually, such a study could contribute to our understanding of the origins of ethnic 
differences in lung cancer risk. The proposed study design is summarized in Figure 8.2.  
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Figure 8.2 GWAS design for the multi-ethnic cohort study 
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8.6 Investigate the mutagenic ability of other BD-dA lesions and improve HPLC-
MS/MS primer extension methodology 
In the present thesis, the mutagenic ability of (R,R)-N
6
,N
6
-DHB-dA and (R,S)- 1,N
6
-γ-
HMHP-dA was evaluated (Chapters V and VI). It would be interesting to perform similar 
translesion synthesis studies for additional stereoisomers of the adducts, e.g. (S,S)-N
6
,N
6
-
DHB-dA and (R,R)- 1,N
6
-γ-HMHP-dA (Chart 8.1). The synthesis of oligonucleotide 
templates incorporating these adducts at site-specific positions has already been described 
by our group (186). Additionally, we previously reported that 1,N
6
-γ-HMHP-dA adducts 
undergo base-catalyzed Dimroth arrangement to form 1,N
6
-α-HMHP-dA (48). Since 
1,N
6
-γ-HMHP-dA adducts induce A→T mutations and deletions,  translesion synthesis 
studies opposite 1,N
6
-α-HMHP-dA adducts would be especially interesting. 
 Another potential area of improvement is the HPLC-MS/MS methodology for 
primer extension studies. In the present method, a 13 mer uracil containing primer is 
annealed to an 18 mer template containing the adduct, and the resulting primer-template 
complex is incubated in the presence of TLS polymerases and dNTPs. At the end of 
incubation, the primer is cleaved by UDG hydrolysis and piperidine treatment, and the 
primer extension products were directly injected onto the LC-MS. The disadvantage of 
the current method is the presence of interferences such as UDG and template which 
might result in suppression of primer extension products. Christov et al. have modified 
this methodology using a biotinylated primer/template duplex (Scheme 8.2) (176). After 
the extension reaction, the biotinylated primer was separated from the other components 
by streptavidin capture and further subjected to UDG hydrolysis and piperidine treatment 
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(Scheme 8.2).  This methodology offers superior clean-up of primer extension products 
and hence improves the detection of those primer extension products present at low 
levels. This methodology can be directly applied to translesion synthesis studies in our 
laboratory to further improve the sensitivity. 
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Chart 8.1 New BD-dA adducts of interest 
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Scheme 8.2 Improved method for HPLC-MS/MS primer extension studies 
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